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Summary 
Heart disease, as a consequence of cardiac injury, is a major cause of morbidity 
and mortality in the UK. Following cardiac insult, cardiac fibroblasts (CFs) 
proliferate in mass and undergo a phenotypic switch to become myofibroblasts 
(MFs). These cells have a contractile phenotype, by developing the expression of 
α-smooth muscle actin (αSMA), and secrete excessive volumes of extracellular 
matrix components, resulting in typical fibrosis seen after injury. This contributes 
to cardiac dysfunction and dramatically increases the proarrhythmic potential of 
the heart, by creating an anatomical structure for re-entry to occur. In the healthy 
heart, gap junctions (GJs), composed of connexin (Cx) proteins, are mainly 
present at the intercalated discs between neighbouring cardiac myocytes (CMs) 
and assist in rapid electrical conduction through the myocardium. Reduced and/or 
disorganised Cx43 (the main cardiac connexin) expression in CMs has been 
demonstrated in many cardiomyopathies. In contrast, in experimental models of 
myocardial infarction (MI), CFs have been demonstrated to have augmented Cx43 
levels in comparison to control CFs. As there is growing evidence that GJs can be 
formed between CMs and CFs, greater levels of Cx43 in CFs in disease could 
increase heterocellular coupling therefore augment the effect of CFs on CMs. 
Co-culture studies, mainly using cells from a neonatal origin, have suggested CFs 
can enhance the risk for arrhythmias involving paracrine mediators and direct cell-
to-cell interactions. However, more research is required determine the effect of 
adult CFs on adult CMs. Therefore, the primary aim of this thesis was to investigate 
the effect of rat adult CFs (RACFs) on the function of adult CMs in an in vitro 
co-culture model and in an in situ model following direct injection of CFs into the 
left ventricle. 
Initially, the development of a lentiviral (LV) vector which would allow 
overexpression of Cx43 in RACFs and was suitable for in vitro investigation as well 
as in situ imaging was investigated. The initial cloning strategy to develop a LV 
plasmid which would permit the expression of Cx43 and nuclear localised 
enhanced green fluorescent protein (eGFP) reporter under the control of an 
artificial hybrid αSMA reporter was unsuccessful. However, a functional adenoviral 
(Ad) vector overexpressing Cx43 was successfully produced and characterised.  
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Next, mediators that are known to be upregulated in disease and could  
consequently enhance Cx43 levels in CFs including angiotensin II (Ang II), 
transforming growth factor β1 (TGFβ1), tumor necrosis factor α (TNFα), 
interleukin (IL)-1β, IL-1α and IL-6 alone or in combination with the soluble IL-6 
receptor (sIL-6R) were investigated for the effect on Cx43 mRNA expression in 
RACFs. Among these: TGFβ1, IL-6 in combination with the sIL-6R, IL-1β and IL-1α 
significantly upregulated Cx43 mRNA expression. Both IL-1β and IL-1α induced a 
similar large increase in Cx43 mRNA, however due to indistinguishable actions, 
only IL-1β was investigated further. IL-1β was found to induce a morphological 
change and augment Cx43 protein levels where clear punctate Cx43 expression 
could be detected at cell contact points. This IL-1β-induced Cx43 upregulation 
was shown to involve activation of IL-1 receptor (IL-1R), nuclear factor-κB 
(NF-κB), p38 mitogen-activated protein kinase (MAPK) and MAPK/extracellular 
signal-regulated kinase (ERK) kinase (MEK) 1/2 as inhibition of these proteins with 
the recombinant human IL-1 receptor antagonist, SC-514, SB203580 and AZD6244 
respectively, partially prevented IL-1β-induced Cx43 upregulation. Furthermore, 
inhibition of c-Jun N-terminal kinase (JNK) with SP600125 was demonstrated to 
potentiate the IL-1β-mediated increase in Cx43, suggesting activation of JNK acts 
to suppress Cx43 upregulation.  
IL-1β has also been reported to inhibit TGFβ1-mediated CF activation to the MF 
phenotype. Therefore the effect of IL-1β and TGFβ1 alone or in combination on 
the mRNA levels of TGFβ1-regulated genes including connective tissue growth 
factor (CTGF), αSMA, plasminogen activator inhibitor-1 (PAI-1) and the 
transcriptional repressors, Snail and Slug were investigated. IL-1β was found to 
significantly reduce the mRNA expression of the MF makers CTGF and αSMA as well 
as partially inhibit TGFβ1-mediated significant or partial upregulation of these 
proteins.  
Next, an adult CM: CF co-culture model was established by seeding freshly isolated 
rat adult CM on a RACF monolayer and cultured overnight. Evidence for functional 
GJs between the cell types was demonstrated by the transfer of the fluorescent 
dye, calcein, from CMs to CFs over 20 h. Furthermore RACFs were found to shorten 
the contraction duration (CD) but not significantly alter the action potential 
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duration at 80 % repolarisation (APD80) of CMs in comparison to CMs cultured alone. 
Interestingly the effect on CD was dampened when the RACF monolayer was 
treated with IL-1β prior to CMs addition.   
Finally, a technically challenging model aimed at studying CM: CF interactions in 
situ was established. This involved the injection of RACFs which had been 
pre-transduced with a LV vector overexpressing eGFP (LVeGFP) into the left 
ventricular wall of the rat heart. Hearts directly injected with AdeGFP were used 
as a control so that eGFP could be detected in an optical mapping preparation 7 
days following injection. Indeed, eGFP signals were observed in both groups (RACF 
and AdeGFP injected hearts) and action potentials (APs) recorded over the 
epicardial surface of the heart during both dynamic and extrastimulus (S1S2) 
pacing protocols. Although this study contained small n-numbers, there was a 
potential prolongation of APD80 following the S2 impulse in the injection site in 
comparison to a similar myocardial area. Additionally, altered activation pattern 
around the injection site following of the S2 impulse at the shortest S1-S2 intervals 
was identified in one heart from each group. As these observations were present 
in both groups this may suggest damage to the myocardium during the injection 
procedure, however this requires further investigation.  
Overall, these studies provide further evidence that CFs are able to alter CM 
function in an in vitro adult co-culture model. Additionally, for the first time the 
altered phenotype of IL-1β-treated RACFs was shown to weaken the effect of 
RACFs on the CD of CMs. Finally, a model to investigate the effects of RACFs on 
CM electrical activity in situ has been established and will be valuable for future 
studies.  
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Chapter 1 General introduction 
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1.1 The heart  
The ultimate function of the heart is to pump oxygenated blood around the body. 
In order to complete this function the anatomy of the heart is expertly designed 
so that deoxygenated and oxygenated blood remain separated in the right and left 
side of the heart respectively. Each side consists of an atrium and ventricle which 
are separated by valves preventing premature blood flow from the atrium to the 
ventricle or back flow into the atrium during ventricular contraction. The left and 
right atria contract simultaneously followed by ventricular contraction. The right 
atrium receives deoxygenated blood from the body through the superior and 
inferior vena cava which, following atrial contraction, is pushed into the right 
ventricle. Blood then travels to the lungs following ventricular contraction through 
the pulmonary artery. Once oxygenated, blood returns to heart into the left 
atrium through the pulmonary veins, then on to the left ventricle which, following 
ventricular contraction, enters the aorta and vasculature to the rest of the body.  
1.2 Cellular composition of the heart 
The heart is a multicellular organ consisting of cardiac myocytes (CMs) and 
non-myocytes including; cardiac fibroblasts (CFs), vascular smooth muscle cells 
(VSMCs) and endothelial cells (ECs) (Banerjee et al. 2007). CMs are rod shaped 
muscle cells which constitute approximately 65-75 % of the cardiac volume 
(Ongstad and Kohl 2016). Fibroblasts are interspersed within the layers of CMs and 
are vital for maintenance of the cardiac structural network, mediating the 
synthesis and degradation of extracellular matrix (ECM) components (Ongstad and 
Kohl 2016). Finally, both VSMCs and ECs make up the vascular network of the 
heart, allowing blood supply to the myocardium. Discrepancy exists between 
studies exploring the contribution of cellular populations to the makeup of the 
myocardium. For instance, one study reported the murine heart to contain 
approximately 56 % CMs, 27 % CFs, 10 % VSMCs and 7 % ECs (Banerjee et al. 2007). 
In contrast, more recently Pinto et al. (2016) demonstrated that in the murine 
heart, ECs were the most abundant cell type constituting around 55 %, whereas 
CMs, CFs and VSMCs made up approximately 33 %, 13 % and 6 %, respectively (Pinto 
et al. 2016). These variations are likely to reflect differences in cell isolation 
techniques, use of cellular markers and detection methods. Despite this, 
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heterocellular crosstalk plays a vital role in cardiac function and following injury 
(Howard and Baudino 2014).  
1.2.1 Cellular markers of fibroblasts in the heart 
Fibroblasts are a difficult cell type to study due to their lack of specific cell 
markers. Fibroblast-specific protein 1 (FSP1), vimentin and discoidin domain 
receptor 2 (DDR2) have been used to identify CFs (Camelliti et al. 2005a;Santiago 
et al. 2010;Swaney et al. 2007); however their expression is not exclusive to 
fibroblasts. Untrue to its name, detection of FSP1, a cytoplasmic calcium (Ca2+) 
binding protein, has been reported in other cell types in the heart including 
VSMCs, ECs and hematopoietic cells (Kong et al. 2013). Vimentin is a type III 
intermediate filament protein present in fibroblasts, endothelial cells and 
mesenchymal cells (Fan et al. 2012). DDR2, considered to be a more specific 
fibroblast marker, is a receptor tyrosine kinase activated by fibrillar collagens, 
including collagen types I and III (Goldsmith et al. 2004;Xu et al. 2011a). It has 
been shown to play roles in fibroblast proliferation and migration through the ECM 
(Olaso et al. 2002). The expression of DDR2 was reported to be present in CFs but 
not in the other major cardiac cells including; CMs, VSMCs and ECs (Goldsmith et 
al. 2004). Conversely, others have detected DDR2 expression in VSMCs (Shyu et al. 
2008). Despite this, studies using vimentin or DDR2 antibodies to stain heart tissue 
have elegantly illustrated the presence of fibroblasts in the interstitial space 
between CMs (Camelliti et al. 2005a;Camelliti et al. 2005b;Goldsmith et al. 2004).  
1.3 Electrical conduction and cardiac contraction 
Coordinated cardiac contraction is required for the normal functioning of the 
heart. Electrical signals are generated by the hearts pacemaker cells in the 
sinoatrial node (SAN), which is located in the right atrium, and are transmitted 
through the atria causing atrial contraction. When signals reach the 
atrioventricular node (AVN), positioned in the right atrium at the intersection of 
the atria and ventricles, there is a slowing of conduction. This slowing is essential 
to allow time for the blood to pass from the atria to ventricles. The signals are 
then transmitted through the Bundle of His, bundle branches and Purkinje fibres, 
mediating uniform ventricular contraction (Figure 1-1). 
4 
 
Clinically, the electrical activity of the heart can be assessed by an 
electrocardiogram (ECG) (Figure 1-1). A healthly ECG will typically show three 
main aspects; the P wave, QRS complex and the T wave, each of which represents 
a different electrical event in the cardiac cycle. The T wave indicates atrial 
depolarisation, the QRS complex shows ventricular depolarisation and the P wave 
signals ventricular repolarisation (Becker 2006).  
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Figure 1-1 Electrical conduction through the cardiac cycle  
Electrical impulses originate in the sinoatrial node (SAN), and pass through both atria causing them 
to contract. When the electrical impulse reaches the atrioventricular node (AVN), the signal travels 
through the bundle of His, the bundle branches and down to the purkinje fibres where the ventricles 
then contract. A typical electrocardiogram (ECG) trace with P, QRS and T waves depicted is shown. 
(This figure, with modifications, was originally published in McArthur et al. 2015) 
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1.3.1 Cardiac action potential 
Although the shape of the ventricular action potential (AP) differs between species 
and within different areas of the heart, 5 phases (0-4) can be observed, each of 
which represents voltage changes in the membrane potential when a cell is 
activated by a cardiac impulse (Figure 1-2). This is created by a change in the 
permeability of different ion channels on the sarcolemma of the CM (Grant 2009). 
In the resting state (phase 4) the cell has very low permeability to sodium (Na+) 
and Ca2+ relative to potassium (K+), the three major ions involved in AP formation. 
This along with the action of ion pumps, establishes an electrochemical gradient 
whereby the extracellular concentration of Na+ and Ca2+ is greater than the 
intracellular concentration. Conversely, ion pumps maintain a high K+ 
concentration within the cells (Nattel and Carlsson 2006). During the AP upstroke 
(phase 0) the cell is rapidly depolarised from the resting membrane potential 
(RMP) which is approximately -90 mV to above 0 mV (Grant 2009). This rapid 
depolarisation, in response to stimulus, is a consequence of voltage-gated Na+ 
channels opening and creating a Na+ inward current (INa) in the cell which is then 
quickly inactivated. Depolarisation induces the opening of the L-type Ca2+ 
channels (LTCCs) to allow an inward Ca2+ current (ICaL) resulting in Ca2+ induced 
Ca2+ release (CICR) from the sarcoplasmic reticulum (SR) (section 1.3.2) (Kleber 
and Rudy 2004). The cell is then slightly repolarised by the fast activated outward 
K+ currents; transient-outward (Ito) and the ultra-rapid (IKur) inducing phase 1 of 
the AP. The plateau of the AP (phase 2) is caused by the balance of the inward 
Ca2+ and outward K+ currents (Nattel and Carlsson 2006). The rising rapid and slow 
outward delayed K+ currents (IKr and IKs respectively) during the plateau phase and 
following inactivation of the LTCCs induces the repolarisation of the cell back to 
the RMP (phase 3) (Kleber and Rudy 2004). The relationship between the AP, Ca2+ 
transient and contraction is shown in Figure 1-2.  
Immediately after AP firing, CMs are unexcitable until a midpoint in repolarisation, 
known as the effective refractory period (ERP). The ERP is a consequence of Na+ 
channel inactivation, and only when enough channels have recovered can another 
AP fire (King et al. 2013). This inactivity can prevent a premature stimulus eliciting 
an electrical impulse. The ERP is just short of the AP duration (APD), described as 
the time from the onset of phase 0 to full repolarisation back to the RMP (Burton 
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and Cobbe 2001). Experimentally, a percentage of the repolarisation is often used, 
for instance the APD at 90 % repolarisation (APD90), due to difficulties in accurate 
detection of 100 % repolarisation. Within the intact heart some degree of 
dispersion, difference between the longest and shortest repolarisation time, exists 
(Burton and Cobbe 2001). For instance APD was shorter at the apex and 
progressively longer towards the base in guinea pig hearts (Choi and Salama 2000). 
A mean left ventricular apex to base dispersion of 42 ms in healthy human hearts 
under physiological conditions has been also reported (Ramanathan et al. 2006). 
Dispersion is also seen through the myocardial wall, known as transmural 
dispersion. The presence of electrically distinct M cells in the midmyocardium, 
which have a more prolonged APD than sub-epicardial and sub-endocardial cells, 
are thought to be a major contributor to this (Antzelevitch 2010). Additionally, 
the activation pattern influences the APD or activation-recovery intervals (ARI), 
as demonstrated by generally greater APD/ARI closer to the activation site which 
gets progressively shorter further from the activation site (Franz et al. 
1987;Hanson et al. 2009;Myles et al. 2010;Yuan et al. 2001).  
1.3.2 Excitation-contraction coupling  
Excitation-contraction coupling (ECC) is the process whereby electrical signals 
lead to the contraction of CMs and ultimately the heart as a whole. Ca2+ is integral 
for contraction. When the CM is depolarised, voltage sensitive LTCCs open in 
response to the change in voltage and Ca2+ enters the cell (Figure 1-3) (Bers 2002). 
LTCCs are preliminary located on transverse tubules (T-tubules) as demonstrated 
by their close proximity with the ryanodine receptor (RyR) throughout the cell, 
not only at the cell surface (Scriven et al. 2000). An increase in intracellular Ca2+ 
concentration ([Ca2+]i) induces the opening of the RyRs which are located on the 
SR, a major intracellular Ca2+ store. This promotes CICR from the SR, resulting in 
a further increase in [Ca2+]i (Banerjee et al. 2007). High [Ca2+]i acts in a negative 
feedback loop to close LTCCs and the RyRs (Bers 2002).  
CM contraction requires the movement of the thin filament (actin) along the thick 
filament (myosin), which are arranged into many contractile units termed 
sarcomeres. Each sarcomere also contain regulatory proteins (troponin and 
tropomyosin [Tm]) and cytoskeletal proteins (titin and myosin binding protein C) 
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(Yin et al. 2015). Contraction is initiated when Ca2+ binds to the Ca2+-binding 
subunit of the troponin complex, cardiac troponin C (cTnC), inducing a 
conformational reorganisation of the other troponin subunits including the 
inhibitory cardiac troponin I (cTnI) and the Tm-binding cardiac troponin T (cTnT). 
This leads to the movement of Tm, revealing a myosin-binding site on actin. 
Consequently, a cross bridge between the myosin head and actin is established. 
Energy from ATP is then utilised by the myosin head to complete a power stroke, 
moving actin along the myosin filament (Yin et al. 2015). The myosin head then 
detaches from actin and the process is repeated, known as cross bridge cycling, 
producing further cell shortening. For relaxation to occur, Ca2+ must leave the 
cytosol leading to dissociation from cTnC. This is mediated through four main Ca2+ 
handling proteins including the sarcolemmal Na+/Ca2+ exchanger (NCX), 
sarcolemmal Ca2+-ATPase, mitochondrial Ca2+ uniport and the SR Ca2+-ATPase 
(SERCA) (Bers 2002). Both the mitochondrial Ca2+ uniport and SERCA mediate 
uptake of cytosolic Ca2+ into the mitochondria and the SR respectively for storage 
until the next stimulus (Bers 2002). SERCA is inactive when the inhibitory protein, 
phospholamban (PLN), is bound its dephosphorylated form. However upon 
phosphorylation of PLN, by mainly protein kinase A (PKA) or Ca2+/calmodulin 
(CaM)-dependent protein kinase II (CaMKII), PLN dissociates from SERCA allowing 
activation, hence Ca2+ uptake into the SR (Lou et al. 2012). Conversely, the NCX 
and the sarcolemmal Ca2+-ATPase are involved in the transfer of Ca2+ out of the 
cell by exchanging one Ca2+ ion inside the cell for three extracellular Na+ ions and 
using adenosine triphosphate (ATP) to actively extrude intracellular Ca2+, 
respectively (Bers 2002).    
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Figure 1-2 Ventricular cardiac myocyte action potential, calcium influx and contraction. 
The phases of the action potential and its relationship with intracellular calcium concentration and 
contraction in a rabbit cardiac myocyte are shown. Em; membrane potential. 
 
 
Figure 1-3 Cardiac myocyte calcium handling. 
Red and green arrows represent Ca2+ influx and efflux respectively. Ca2+; calcium, Na+; sodium, RyR; 
ryanodine receptor, SR; sarcoplasmic reticulum, SERCA; sarcoplasmic reticulum Ca2+-ATPase, 
NCX; sodium- calcium exchanger. 
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1.4 The intercalated disc 
Coordinated contraction of the heart relies on both mechanical and electrical 
coupling, in which the so called ‘intercalated discs’ (IDs) play an essential role. 
IDs are located at the long ends of CMs and are made up of three main junctions: 
adherens junctions (AJs), desmosomes and gap junctions (GJs) (Figure 1-4). Both 
AJs and desmosomes mediate mechanical coupling, whereas GJs allow electrical 
coupling (Noorman et al. 2009).  
1.4.1 Adherens junctions and desmosomes 
Mechanical junctions are essential for the maintenance of the structural integrity 
of the heart. AJs consist of the transmembrane protein cadherin, N-cadherin being 
the main form at IDs, and cytosolic catenins; including α, β, γ (plakoglobin) and 
p120 isoforms which allow interaction with actin filaments (Noorman et al. 2009). 
AJs are important in maintaining CM connections during contraction and assist in 
the transfer of contractile force between cells due to the indirect coupling of the 
intercellular actin cytoskeleton (Noorman et al. 2009).  
Conversely, desmosomes assist in structural support due to the interaction of 
cytosolic components with intermediate filaments. Desmosomes are made up of 
the two transmembrane demosomal cadherins; desmocollin and desmoglein as 
well as the cytosolic proteins; plakoglobin, plakophilin and desmoplakin. 
Desmoplakin is responsible for intermediate filament association (Noorman et al. 
2009).  
1.4.2 Gap junctions and cardiac connexins  
Electrical signals are transferred through the conduction system and on to CMs 
through GJs. GJs consist of numerous channels between cells allowing the passage 
of ions, second messengers and molecules up to 1 kDa (Zhou and Jiang 2014). This 
permits rapid signalling and co-ordinated cardiac contraction. GJs are 
predominately expressed at IDs however are also present at the lateral sides of 
CMs (Gutstein et al. 2001). Conduction is faster in the longitudinal in comparison 
to transverse direction (Valderrabano 2007), known as anisotropy which was first 
described in 1959 (SANO et al. 1959). 
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1.4.2.1 The structure of connexin channels 
GJ channels consist of two hemi-channels, one from each of the contiguous cells. 
The basic component of hemi-channels are connexin (Cx) proteins which  exist as 
four membrane spanning domains, two extracellular loops, an intracellular loop 
and cytosolic amino- and carboxyl-terminal (CT) tails (Figure 1-5) (Sohl et al. 
2005). Six connexin proteins constitute a hemi-channel, which then docks onto 
another hemi-channel from a participating cell to form a GJ channel (Sohl et al. 
2005) (Figure 1-5). In the heart, there are three main connexins; Cx40, Cx43 and 
Cx45 which are encoded by GJA5, GJA1 and GJA7 genes, respectively (Sohl and 
Willecke 2004). Hemi-channels can be composed of one connexin subtype or can 
be an arrangement of different connexins where they are then referred to as 
homomeric or heteromeric, respectively. The docking of two identical or 
dissimilar hemichannels are called homotypic or heterotypic GJ channels, 
respectively (Moreno 2004) (Figure 1-5).  
A GJ consists of a few to thousands of GJ channels clustered together to form 
junctional plaques (Sosinsky and Nicholson 2005). These plaques were first 
visualised in the 1960s using the heavy metal, lanthanum, which fills the 
extracellular spaces allowing regions of cell contact points that are 
interconnected to remain free from lanthanum (Revel and Karnovsky 1967). 
Structures evidently distinct from so called tight junctions, that lanthanum cannot 
penetrate, were identified as GJs (Sosinsky and Nicholson 2005).  
1.4.2.2 Distribution of connexin subtypes  
Although the distribution of connexin subtypes varies between species (van 
Kempen et al. 1995), Cx43 is the most widely expressed connexin throughout both 
the atria and ventricles (Vozzi et al. 1999). Cx40 is highly expressed in healthy 
atrial tissue and throughout the conduction system (Dupont et al. 2001;van Rijen 
et al. 2001;Vozzi et al. 1999), while Cx45 is most abundant in the AVN and also 
expressed in healthy myocardium (Frank et al. 2012;Kreuzberg et al. 2009;Vozzi 
et al. 1999).   
12 
 
 
Figure 1-4 Major components of the intercalated disc. 
The intercalated disc consists of three major junctions; gap junctions, desmosomes and adherens 
junctions. IC; intracellular, EC; extracellular, Ca2+; calcium.  
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Figure 1-5 Structure of connexin hemichannels and gap junction channels.  
Connexins can partner as homo-/heteromeric hemi-channels or homo-/heterotypic gap junction 
channels. Different connexins are represented in orange and pink. Each connexin protein has four 
membrane spanning domain with two extracellular loops, one intracellular loop and an intracellular 
amino-terminal (N+H3) and carboxyl-terminal (COO-) tail.  
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1.4.3 Importance of intercalated disc components  
Embryonic or neonatal lethality is common in homozygous knockout (KO) mouse 
models of ID proteins including; γ-catenin (Ruiz et al. 1996), desmoplakin (Garcia-
Gras et al. 2006) and Cx43 (Reaume et al. 1995). Additionally, a loss of function 
mutation in N-cadherin in mouse embryos results in death by day 10 of gestation 
(Radice et al. 1997). Interestingly, the disruption of the ID has been reported in 
an N-cadherin conditional knockout (CKO) mouse model (Kostetskii et al. 2005). 
Here, cardiac specific tamoxifen-induced deletion of N-cadherin resulted in 
additional loss of the AJ and demosomal components; α, β, γ and p120 catenins 
and desmoplakin (Kostetskii et al. 2005). Furthermore, Cx40 and Cx43 levels 
where reduced in the atrial and ventricular tissue, respectively (Li et al. 2005). 
Not surprisingly, sudden cardiac death (SCD) as a result of ventricular arrhythmias 
was observed between 1-2 months of tamoxifen treatment (Li et al. 2005). 
Additionally, Cx43 was shown to be reduced following adenoviral (Ad) mediated 
silencing of plakophilin 2 in neonatal rat CMs (Oxford et al. 2007) and in the human 
genetic conditions Naxos disease (Kaplan et al. 2004b) and Carvajal syndrome 
(Kaplan et al. 2004a) caused by mutations in plakoglobin and desmoplakin, 
respectively. Together this work suggests mechanical junctions assist in the 
formation of GJs. This is in agreement with the report that mechanical junctions 
are formed prior to GJ formation in a dedifferentiation adult rat CM culture model 
(Kostin et al. 1999) as well as in the postnatal development of the rat heart (Angst 
et al. 1997). Conversely, in human heart maturation GJ and AJ formation appears 
to occur simultaneously (Peters et al. 1994). However, due to the nature of limited 
stages in postnatal samples in this human study, AJ formation prior to GJ 
formation cannot be ruled out. 
Despite regulation of connexins by mechanical junction proteins, the 
cardiac-specific CKO of Cx43 in mice does not alter the expression or cellular 
localisation of AJ or desmosomal components (Gutstein et al. 2003); suggesting 
GJs are not involved in the formation of these mechanical junctions. Cx45 
homozygous KO mice die during embryogenesis from heart failure, suggesting a 
major role in heart development (Kumai et al. 2000).  Although Cx40-/- mice are 
viable, 50 % die in embryonic development and a further 16 % die shortly after 
birth (Kirchhoff et al. 2000). Viable Cx40-/- mice show abnormalities in conduction 
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with prolongation in ECG PR interval, QRS complex and the QT interval, potentially 
reflecting issues in the conduction system where Cx40 is known to be abundant 
(Simon et al. 1998).   
While a Cx43-/- genotype is lethal, studies using Cx43+/- mice have reported 
contradictory effects on cardiac electrical activity. For instance no alteration in 
ventricular conduction velocity (CV), as determined by optical mapping (OM), or 
ECG parameters in comparison to wild type (WT) controls were observed (Morley 
et al. 1999). Additionally, only small differences in ECG parameters were detected 
in these mice by others (Kirchhoff et al. 2000). Conversely, in other studies Cx43+/- 
mice had a slowed CV (Guerrero et al. 1997) as well as the development of lethal 
arrhythmias in a cardiac specific Cx43 CKO model (Gutstein et al. 2001). Despite 
this controversy, disorganised Cx43 expression is associated with disease and 
enhances the susceptibility for ventricular arrhythmias (Kostin et al. 2003;Poelzing 
and Rosenbaum 2004;Smith et al. 1991) (section 1.6.2.1), suggesting a 
fundamental role of Cx43 in normal cardiac conduction. 
1.5 Connexin channel regulation 
Connexins are well established to have a rapid turnover rate, which is around 1-3 h 
for Cx43 (Beardslee et al. 1998;Hunter et al. 2005;Laird et al. 1991;Saffitz et al. 
2000). This is mediated by a balance of synthesis and degradation, where both the 
proteasome and lysosome are implicated in the degradation of Cx43  (Laing et al. 
1997). As well as the levels of connexin at the cell surface, the composition of GJ 
channels can affect the channel properties including conductance, permeability 
and selectivity. Many factors are also known to contribute to the regulation of 
channels including voltage, pH, calcium and phosphorylation (Hood et al. 
2017;Peracchia 2004). Channels are known to exist in an open state where 
maximal conductance can be achieved, a residual or sub-conductance state where 
approximately 5-35 % conductance occurs depending on the connexins constituting 
the channel (Moreno et al. 2002) and a closed state where conductance is zero. 
The exact mechanism for channel inactivation and closure still remains to be fully 
elucidated however two main mechanisms may provide an explanation. The 
transition from open to residual state, also referred to as fast gating, may be 
explained by the ball-and-chain hypothesis where a region of the intracellular 
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domains, most likely the CT tail interacts with the channel pore ultimately 
reducing conductance (Moreno et al. 2002). Slow gating, also referred to as loop 
gating, of connexin channels is where the channel transitions from an open state 
to a fully closed state, has been suggested to be a result of conformational change 
involving the extracellular loops of connexin subunits (Bukauskas and Verselis 
2004).  
1.5.1 Voltage gating 
The gap junctional conductance (gj) influences the CV between cells, with a 
greater gj producing a faster CV (Shaw and Rudy 1997), and is therefore important 
to consider in the electrical conduction between cells. Gj is regulated by 
transjunctional voltage (Vj), which is defined as the difference in voltage between 
two cells participating in a GJ (Bukauskas et al. 2002). This can be examined 
experimentally by voltage clamping two contiguous cells with separate patch 
clamps. The voltage of each cell can then be modulated and gj monitored at 
varying Vj. Typically Cx40, Cx43 and Cx45 homomeric, homotypic channels have 
been reported to have maximal conductance when Vj is equal to zero. As the Vj 
deviates from zero in a positive or negative direction the conductance reduces in 
a sigmoidal fashion (Figure 1-6) (Barrio et al. 1997;Bukauskas et al. 
2002;Desplantez et al. 2011;Lin et al. 2003). Interestingly, conductance with 
varying Vj does not reach an absolute zero with maximal Vj; instead a residual 
state exists (Figure 1-6) (Moreno 2004). The voltage sensor for the residual state 
has been proposed to be located on the amino-terminal tail of connexin proteins 
(Verselis et al. 1994), and the CT tail has been suggested to be the effector 
(Moreno et al. 2002). Replacement of the charged amino acids at residues 12 and 
13 on the amino terminal tail of Cx40 and Cx43 to glycine and serine (uncharged 
amino acids) respectively has been shown to reduce voltage gating in response to 
changes in Vj. This effect is more pronounced in Cx43 mutant channels, whereby 
very little voltage gating occurs with changes in Vj (Gemel et al. 2006). Truncation 
of the CT tail of Cx43 has been shown to prevent the induction of the residual 
state, which is recovered when the Cx43 CT tail is co-expressed (Moreno et al. 
2002). Furthermore, the rate of transition between open and closed states in cells 
expressing this truncated form of the Cx43 CT tail is prolonged (Moreno et al. 
2002).  
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The inactivation kinetics of Vj in connexin GJs is thought to be too slow to 
influence AP propagation. The effect of an AP on the conductance and current 
through Cx43 GJs has been investigated in neuro2A neuroblastoma (N2A) cells 
transfected with Cx43 (Lin et al. 2003). Two adjoining cells were voltage patch 
clamped, a ventricular AP mimicked in one of the cells while the other was 
maintained at the diastolic resting potential and the properties of the connexin 
GJ channels examined. The junctional current was shown to follow a similar trend 
to the AP, in terms of upstroke, plateau and recovery. Conversely conductance 
was shown to have a rapid increase from 0 to 4.1 nS during the AP upstroke, 
followed by an initial rapid downstroke which slowed to a plateau of 1.6 nS. 
Conductance was shown to recover in phase 3 of the AP as the Vj proceeded 
towards zero (Lin et al. 2003).   
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Figure 1-6 Typical relationship between gap junctional conduction and transjunctional 
voltage. 
Maximal gap junctional conductance (gj) is typically observed when there is no difference in voltage 
between two of the participating cells; that is the transjunctional voltage is equal to zero. As the 
voltage is increased or decreased in one of the cells, transjunctional voltage becomes more positive 
or negative respectively, and the gj decreases symmetrically in both directions until the residual state 
of the channel is reached. 
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1.5.2 Chemical gating 
High [Ca2+]i and low intracellular pH (pHi) are known to regulate negatively 
regulate gj (Peracchia 2004). As both these conditions are known to occur 
following ischaemia, this may be a protective mechanism in disease to prevent 
the movement of damaging mediators to adjacent cells (Kalogeris et al. 2012). 
Gating by Ca2+ has been demonstrated in N2A cells in physiological Ca2+ solution 
following the addition of ionomycin, a reagent which acts to enhance [Ca2+]i, 
produced a 95 % reduction in Cx43 gj (Xu et al. 2012). In contrast, Cx40 gj was only 
reduced by <20 %, signifying Cx40 is less sensitive to [Ca2+]i. Interestingly, gj in 
mouse neonatal atrial and ventricular CMs declined by 73 % and 93 % respectively, 
suggesting less contribution of Cx43 in GJs in atrial cells in comparison to 
ventricular CMs (Xu et al. 2012). These effects of [Ca2+]i on gj has been reported 
to be mediated through the Ca2+ binding protein, CaM, where inhibitors of CaM 
have resulted in inhibition of Ca2+-dependent uncoupling (Lurtz and Louis 2007;Xu 
et al. 2012). Additionally, a CaM binding site has been identified on the 
intracellular loop of Cx43, supporting this interaction (Zhou et al. 2007).  
Similarly, as the pHi is reduced from physiological pH 7.4, uncoupling of connexin 
channels has been identified (Morley et al. 1996;Stergiopoulos et al. 1999). The 
CT tail of some connexin subtypes, such as Cx40 and Cx43, has been identified as 
an important mediator of this pHi-induced uncoupling (Stergiopoulos et al. 1999). 
For instance, in Xenopus oocytes overexpressing a truncated form of the Cx40 or 
Cx43 CT tail, there is little to no change in gj when the pHi is reduced 
(Stergiopoulos et al. 1999). Comparatively, when the CT tail is re-introduced into 
these cells the effect of pHi is restored, suggesting the CT tail acts in a ball-and-
chain mechanism or as an intermediate molecule to decrease channel activity 
(Morley et al. 1996;Stergiopoulos et al. 1999). This however is not the case for 
Cx45, where gj displays the same relationship with pHi in both WT and truncated 
forms (Stergiopoulos et al. 1999).  
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1.5.3 Regulation of connexin channels by phosphorylation 
Phosphorylation and dephosphorylation of the CT tail of connexin proteins play an 
essential role in the properties of the GJ channels, which can become 
dysregulated in disease (Hood et al. 2017). Cx43 primarily exists in a 
phosphorylated form in healthy hearts (Beardslee et al. 2000), where at least 19 
different phosphorylation sites have been identified (Solan and Lampe 2014). Many 
protein kinases including PKA, protein kinase C (PKC) and casein kinase 1 have 
been reported to phosphorylate Cx43 (Hood et al. 2017) which may differentially 
regulate GJ intercellular communication (GJIC). For instance an increase in PKA 
activity has been shown to enhance GJIC (Matsumura et al. 2006), while PKC has 
been demonstrated to reduce GJIC by phosphorylating the serine residue (Ser) 368 
(Lampe et al. 2000). Interestingly, phosphorylation of Ser368 has been reported 
to be enhanced in mouse hearts following ischaemia (Ek-Vitorin et al. 2006;Hund 
et al. 2007). Conversely, in an isolated rat heart model of ischaemia, complete 
dephosphorylation of this site within 30 min was shown, highlighting discrepancies 
between species and/or ischaemic models (Axelsen et al. 2006). Furthermore, 
dephosphorylation of numerous other sites including Ser306, Ser297 and Ser365 
have been associated with ischaemia, electrical uncoupling and slowed CV (Hood 
et al. 2017). Protein phosphatases (PP) including type 2A (PP2A) and type 1 (PP1) 
mediate this dephosphorylation resulting in reduced GJIC and enhanced 
vulnerability to arrhythmias (Ai and Pogwizd 2005;Beardslee et al. 2000;Boulaksil 
et al. 2016;Remo et al. 2011).  
1.6 The diseased heart 
Cardiovascular disease (CVD) is the leading cause of morbidity worldwide 
according to the World Health Organisation (WHO). In 2015, approximately 
17.7 million deaths occurred from CVD; around 7.4 million of these were 
attributed to coronary heart disease (CAD), a disease of the coronary arteries 
(WHO 2017). Narrowing or blockage of a blood vessel in the heart can lead to 
ischemia in a region of heart muscle ultimately causing a myocardial infarction 
(MI), defined as the death of CMs as a result of extended ischemia (Thygesen et 
al. 2012). The major cause of MI is atherosclerosis, where an accumulation of 
lipids, ECM and a variety of inflammatory cells within the inner lining of the 
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vascular wall form an atherosclerotic plaque (Hansson 2005). As the plaque 
develops, blood flow can be severely disrupted by remodelling of the plaque into 
the lumen, limiting downstream perfusion. Additionally, plaque rupture is 
common when the fibrosis cap is thinned or damaged which ultimately results in 
exposure of pro-thrombotic factors into the circulation leading to a coronary 
thrombosis and occlusion of the vessel (Hansson 2005). Following ischaemia, 
re-establishment of blood flow via thrombolytic therapy or primary percutaneous 
coronary intervention is mandatory to in order to limit the size of myocardial 
infarct (Yellon and Hausenloy 2007). Paradoxically, complex events associated 
with reperfusion can aggravate tissue damage, produce ventricular arrhythmias 
and consequently lead to cardiac dysfunction, commonly described as 
ischaemia/reperfusion (I/R) injury (Ferdinandy et al. 2007).  
CAD is not a prerequisite for MI; an imbalance between oxygen supply and demand 
due to an underlying condition such as coronary spasm, cardiac arrhythmia or high 
blood pressure (hypertension) can also result in a MI (Thygesen et al. 2012). The 
increased strain on the heart as a consequence of other areas of the cardiac 
muscle compensating for the impaired function of an ischemic region and or other 
contributing factors such as hypertension can result in progression towards heart 
failure (HF) (Burchfield et al. 2013). HF is defined as heart malfunction resulting 
in breathlessness, premature fatigue and/or oedema (Heineke and Molkentin 
2006). Not surprisingly, infarct size has been shown to predict mortality (Burns et 
al. 2002;Miller et al. 1995). One study reported a 7 % mortality rate when the 
infarct size was ≥12 % of the left ventricle (median infarct size), conversely there 
were no patients deaths where the infarct size was <12 % (Miller et al. 1995). 
1.6.1 Pathological cardiac remodelling  
It is well established that the heart remodels in response to pathological stimuli 
including MI, myocarditis and pressure or volume overload, for example 
hypertension and valvular regurgitation, respectively (Cohn et al. 2000). This 
process involves many molecular, cellular and ECM modifications (Cohn et al. 
2000). Following ischaemia, the remodelling process acts to replace dead 
myocytes with scar tissue. However, this can become maladaptive if 
inflammation, fibroblast activation and ECM degradation and production persist. 
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Ultimately these events can lead to pathological cardiac fibrosis, hypertrophy and 
the development of HF (Burchfield et al. 2013).  
1.6.1.1 Changes in ECM in cardiac remodelling 
The cardiac ECM is essential for maintaining the structural integrity of the heart. 
It is composed of both fibrous proteins; such as collagen, laminin and elastins, and 
non-structural proteins; including glycoproteins, proteoglycans and 
glycosaminoglycans. Collagens are produced primarily by fibroblasts as 
procollagen, where they are then cleaved in the extracellular space to collagen. 
Collagen type I in the most abundant collagen within the heart, although other 
subtypes including type III and IV exist. The levels of collagen are known to be up-
regulated in many animal models of cardiac disease including MI (Cleutjens et al. 
1995b), dilated cardiomyopathy (DCM) (Fedak et al. 2003) and pressure overload 
(Jalil et al. 1989). In a rat model of MI, procollagen type I and III mRNA, precursors 
of collagen type I and III, were shown to be upregulated 4 and 2 days post-MI in 
the infarcted left ventricle, respectively. Interestingly, procollagen mRNA was 
also shown to be upregulated in the right ventricle and ventricular septum, albeit 
to a lesser extent (Cleutjens et al. 1995b), suggesting remodelling of the whole 
heart in response to MI. A combination of increased collagen levels, a greater 
collagen type I to type III ratio and an increase in collagen crosslinking may 
contribute to myocardial stiffness (Badenhorst et al. 2003;Nishikawa et al. 
2001;Yamamoto et al. 2002;Zile et al. 2015). Myocardial stiffness can contribute 
to diastolic dysfunction (Chaturvedi et al. 2010) and is a good indicator of 
congestive heart failure patients (CHF) mortality (Watanabe et al. 2011), hence 
an important therapeutic target.  
Wall thinning and left ventricular dilatation, risks for cardiac rupture (Schuster 
and Bulkley 1979), occur soon after the onset of a MI (Olivetti et al. 1990). This 
involves the degradation of the existing ECM mediated by a balance between zinc-
containing matrix metalloproteinases (MMPs) and endogenous tissue inhibitors of 
MMPs (TIMPs). MMPs are a family of proteases which degrade the ECM components 
and can be subcategorised depending on the substrate specificity (Phatharajaree 
et al. 2007). These include collagenases (e.g MMP-1), gelatinases (MMP-2 and 
MMP-9) and stromelysins (MMP-3 and MMP-10), which typically degrade collagen, 
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gelatin and a range of ECM components respectively, although there are some 
exceptions (Phatharajaree et al. 2007). The activities of MMPs are known to be 
enhanced in animal models of numerous pathological cardiac conditions including 
DCM (Fedak et al. 2003) and MI (Cleutjens et al. 1995a). MMP1 activity has been 
reported to be significantly upregulated as early as 2 days post-MI (Cleutjens et 
al. 1995a), where a further increase to 6.5 fold above sham controls following 7 
days from the onset of MI. A return to control levels was reported 14 days post MI. 
This trend was similar for both MMP2 and MMP9 (Cleutjens et al. 1995a). KO of 
MMP2 or MMP9 in mice has been shown to be protective against myocardial rupture 
following MI (Hayashidani et al. 2003;Heymans et al. 1999;Matsumura et al. 2005), 
indicating a role for these enzymes in detrimental remodelling.  
The levels and/or activity of TIMPs are also known altered in cardiac remodelling. 
The protein levels of TIMP-1 and TIMP-3 have been reported to be significantly 
increased and decreased, respectively in DCM (Fedak et al. 2003). Interestingly, 
TIMP3-/- mice developed CM hypertrophy, contractile dysfunction and left 
ventricular dilatation with aging (Fedak et al. 2004), a phenotype which is typical 
of DCM. Hampered expression of TIMP-3 has also been shown in end-stage HF 
patients (Fedak et al. 2003). 
1.6.1.2 Cardiac fibrosis and fibroblast to myofibroblast differentiation 
Cardiac fibrosis manifests as excessive deposition of ECM components, mainly 
collagen, within the myocardium (Wang et al. 2015). It can occur to replace dead 
CMs such as following ischaemia, so called replacement fibrosis or within the 
interstitial space in areas other than the infarct (Czubryt 2012;Nguyen et al. 
2013). Interstitial fibrosis can also occur in cardiac injuries such as pressure or 
volume overload (de Meester de et al. 2015;Xia et al. 2009) and can develop into 
replacement fibrosis following necrosis of surrounding CMs (Travers et al. 2016). 
This can produce areas of patchy fibrosis, whereby surviving CM strands are 
located between dense scar tissue. Perivascular fibrosis seen in pressure overload 
animal models (Harada et al. 1998;Xia et al. 2009) is thought to reduce the supply 
of oxygen and nutrients to the myocardium.   
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A key cell in the development of fibrosis is the myofibroblast (MF). MFs are the 
activated form of the fibroblast, which express the contractile protein alpha 
smooth muscle actin (αSMA); the actin subtype present in smooth muscle cells 
(SMCs). However, although MFs express the actin subtype present in SMCs, the 
contraction in SMCs is rapid and short in duration whereas MF contraction is more 
prolonged and results in wound closure, suggesting different mechanisms between 
the cell types (Bochaton-Piallat et al. 2016). Indeed, in comparison to SMCs, 
increasing [Ca2+]i to activate myosin light chain kinase (MLCK), the kinase 
important for myosin light chain phosphorylation and contraction, was not 
sufficient to induce MF contraction. Rho/Rho kinase activity was shown to be 
essential for MF contraction (Parizi et al. 2000). Additionally, αSMA expression in 
MFs has been shown to positively correlate with enhanced contraction (Hinz et al. 
2001). MFs are absent in the healthy myocardium and only transdifferentiate from 
resident CFs or other cell types following cardiac insult (Kanisicak et al. 2016). 
The time course for the appearance of MFs in infarcted regions of the heart has 
been shown to differ between species. For instance in a in vivo mouse model of 
I/R, MF infiltration occurs rapidly within the first 72 h of reperfusion, where the 
numbers then progressively decline between 7 and 14 days (Dewald et al. 2004). 
In contrast MF infiltration in a canine I/R model is slower, where very little MFs 
were detected in the infarct at 72 h. However, substantial increases in MFs were 
reported after 7 days, which was negligible at 14 days reperfusion (Dewald et al. 
2004). Additionally, CFs isolated from animal models of cardiac injury including a 
rat transverse aortic constriction (TAC) model (Cartledge et al. 2015) and a canine 
CHF model (Dawson et al. 2012) have been shown to express αSMA, supporting 
CF-to-MF conversion in vivo in response to injury. 
Interestingly major contributors to cardiac fibrosis including angiotensin II (Ang 
II), endothelin-1 (ET-1) and transforming growth factor β (TGFβ1) (Li et al. 
2007;Rosenkranz et al. 2002;Widyantoro et al. 2010) have been demonstrated to 
induce CF-to-MF conversion (Bai et al. 2013;Bronnum et al. 2013;Nishida et al. 
2007). TGFβ is known to be up-regulated in pathological cardiac conditions such 
as following an MI (Deten et al. 2001;Dewald et al. 2004). As well as promoting 
αSMA expression, TGFβ1 increases the contraction of collagen gels and promotes 
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the production of collagen I and fibronectin by CFs (Chen et al. 2000;Lijnen et al. 
2003).  
TGFβ1-mediated MF transdifferentiation has been reported to occur through 
Smad3 signalling, a protein classically activated by TGFβ1 (Dobaczewski et al. 
2010;Hu et al. 2003). Although Smad3-/- mice had an increased number of MFs in 
the infarct following MI, collagen deposition was significantly reduced in 
comparison to WT hearts (Dobaczewski et al. 2010). Furthermore, in vitro analysis 
of Smad3-/- CFs showed impaired TGFβ1-induced αSMA expression,  collagen gel 
contraction and mRNA increases in fibronectin, collagen I and III and the 
profibrotic protein, connective tissue growth factor (CTGF). Migration of these 
cells towards 1 % serum was also diminished (Dobaczewski et al. 2010). Together 
this study demonstrates that Smad3 is required to produce functional MFs, hence 
could be a therapeutic target. 
Despite the known pro-fibrotic effects of TGFβ1 in cardiac injury, TGFβ1 is also 
known to promote cardioprotective effects in in vitro and in vivo models of I/R 
injury (Dandapat et al. 2008;Yang et al. 1999). This has been attributed to reduced 
CM apoptosis potentially due to reduced reactive oxidative species (ROS) 
production (Dandapat et al. 2008). This anti-apoptotic effect on CMs is also 
translated to CFs in vitro, where CF apoptosis induced by I/R was reduced 
following TGFβ1 treatment (Vivar et al. 2013). Inhibitors of both canonical and 
non-canonical TGFβ1 signalling pathways including; extracellular signal-regulated 
kinase (ERK)1/2, Akt and Smad3, were shown to prevent this anti-apoptotic effect 
on CFs (Vivar et al. 2013).  
Cardiac fibrosis is also prominent in Ang II animal infusion models (Li et al. 
2007;Sopel et al. 2011;Wang et al. 2015), which is again thought to be due to the 
actions on CFs. Losartan, the angiotensin receptor type 1 (AT1) antagonist, has 
also been shown to reduce fibrosis in many animal models of cardiac injury (Lim 
et al. 2001;Yamamoto et al. 2005) and in patients with hypertensive heart disease 
(Diez et al. 2002). The transcription factor, Ets-1, has been recently been reported 
to promote Ang II-mediated increases in plasminogen activator inhibitor-1 (PAI-1) 
and CTGF expression in CFs (Hao et al. 2015). Both PAI-1 and CTGF have been 
linked to the production of fibrosis (Daniels et al. 2009;Takeshita et al. 2004), 
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although the role of PAI-1 is controversial (Takeshita et al. 2004;Xu et al. 2010). 
Additionally, Ets-1-/- mice do not exhibit enlarged hearts in response to Ang II 
infusion, indicating a role for Ets-1 in Ang II-induced hypertrophy (Zhan et al. 
2005). Furthermore, rat adult CFs (RACFs) stimulated with Ang II resulted in 
production/mRNA expression of collagen I and III, which was diminished by the 
NADPH oxidase blocker, apocynin (Bai et al. 2013;Lijnen et al. 2006), suggesting 
Ang II-mediated ROS production in turn induces collagen production by RACFs. 
Apocynin was also shown to inhibit Ang II-mediated CF-to-MF transdifferentiation 
(Bai et al. 2013). Interestingly, Ang II increases the production of TGFβ1 by CFs 
(Campbell and Katwa 1997;Lee et al. 1995) which is prevented by Losartan 
(Campbell and Katwa 1997). Additionally, in human atrial myocardial samples, 
Ang II was demonstrated to significantly increase mRNA levels of TGFβ1 but have 
no effect on collagen I (Kupfahl et al. 2000). Conversely, TGFβ1 stimulation 
promoted an increase in mRNA levels of collagen I and III, but not fibronectin. 
Similar results were found in isolated human atrial CFs (Kupfahl et al. 2000) 
suggesting Ang II promotes fibrosis through increasing the release of TGFβ1.  
ET-1 (Nishida et al. 2007) and platelet-derived growth factor-D (PDGF-D) (Zhao et 
al. 2013) have also been shown to induce CF activation. PDGF-D mediated MF 
transdifferentiation has been shown to be mediated through the production of 
TGFβ1 (Zhao et al. 2013). Recently, miRNAs have also been implicated in 
transition of CFs to MFs including miR-125b (Bie et al. 2016;Nagpal et al. 2016), 
miR-145 (Wang et al. 2014c) and miR-154 (Sun et al. 2016). Interestingly the miR-
143/145 cluster has been suggested to be important in mediating the contractile 
phenotype of SMCs (Boettger et al. 2009).  
The expression of αSMA in fibroblasts is well established to occur naturally in 
culture, as demonstrated by the progressive increase in expression from passage 
0 to 2 (Santiago et al. 2010) or over 7 days in culture (Cartledge et al. 2015). 
Although αSMA expression is typically used to identify the MF phenotype, cultured 
CFs have been suggested to be dissimilar in phenotype from those resident in vivo 
(Cartledge et al. 2015;Dawson et al. 2012). Dawson et al. (2012) compared atrial 
CFs from CHF and control dogs and while there was marked differences at the 
time of isolation these variances were abolished after 48 h in culture. 
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Furthermore, the effect of mediators produced by cultured CFs were shown to 
reduce the amplitude of the CM Ca2+ transient, whereas it was enhanced by freshly 
isolated CFs (Cartledge et al. 2015). Together these studies suggest alterations in 
CF phenotype as a consequence of culture. Evidence for the similarity between 
cultured CFs and MFs from pressure overload hearts was shown in the same study 
by Cartledge et al. (2015) where MFs also produced a reduction in the CM Ca2+ 
transient. Ideally, experimental investigation of healthy CFs would be completed 
within 48 hrs from initial isolation. Unfortunately this is not practical in most 
investigations due to the length of studies and the quantity of cells required for a 
particular experiment. 
1.6.1.3 Origin of myofibroblasts 
The origin of cardiac MFs in disease has been a controversial topic. Some proposed 
origins include resident CFs (Kanisicak et al. 2016), ECs subsequent to endothelial-
to-mesenchymal transition (EndMT) (Zeisberg et al. 2007) and bone 
marrow-derived cells (van Amerongen et al. 2008). Genetic lineage tracing has 
been indispensable in these studies. For instance to study EndMT, Zeisberg et al. 
(2007) crossed transgenic mice expressing Cre recombinase under the control of 
the endothelial promoter, Tie1, (Tie1Cre mice) with mice expressing the 
ubiquitous promoter, ROSA (R26R), driving the expression of LacZ only when Cre 
recombinase is present in the cell due to a stop codon floxed between two loxP 
sites upstream of LacZ (R26RstoplacZ mice) (Zeisberg et al. 2007). Hence in 
Tie1Cre;R26RstoplacZ double transgenic mice, only endothelial cells should 
express LacZ regardless of any phenotypic changes as a result of injury. Here it 
was shown that following aortic banding, LacZ was co-localised with FSP1 
expression, suggesting EndMT had occurred in response to banding (Zeisberg et al. 
2007). Conversely, Kanisicak et al. (2016) demonstrated little to no contribution 
of ECs to the MF population following MI and suggested resident CFs to be the 
major MF source (Kanisicak et al. 2016). However as with all these studies, lack 
of cell specific markers for CFs/MFs and/or issues with promoter specificity makes 
it difficult to confidently confirm MF origins. 
Use of the periostin promoter has become an interesting tool for the investigation 
of MFs, which was able to identify virtually all MFs in the heart (Kanisicak et al. 
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2016). Periostin is a 90 kDa secreted matricellular protein that can interact with 
other ECM components and has roles in cell adhesion (Snider et al. 2009). The 
expression of periostin is undetectable in the healthy heart however becomes 
substantial following injury (Kanisicak et al. 2016;Oka et al. 2007). Additionally, 
mice deficient in periostin have reduced fibrosis, impaired MF activation and 
enhanced mortality mainly due to cardiac rupture in MI and TAC injury models 
(Oka et al. 2007;Shimazaki et al. 2008), demonstrating the importance of periostin 
in essential cardiac repair.  
1.6.1.4 Cardiac hypertrophy 
In response to many cardiac injuries, and generally increased workload, the 
cellular size of CMs increases, termed hypertrophy (Heineke and Molkentin 2006). 
Two main forms of hypertrophy tend to occur following injury known as eccentric 
and concentric hypertrophy (Figure 1-7), which typically result from volume and 
pressure overload respectively (Grossman and Paulus 2013). In eccentric 
hypertrophy there is a normal ratio of left ventricular wall thickness to radius 
(h/R) with elongation of CMs due to the addition of sarcomeres to already existing 
myofibrils. Conversely, the h/R ratio is high in concentric hypertrophy, where CMs 
maintain a similar length but expand in width due to addition of new myofibrils. 
This initially acts to compensate for the increase in pressure by reducing systolic 
left ventricular wall stress as a result of increased left ventricular wall thickness 
and is therefore thought of as an adaptive mechanism (Grossman and Paulus 2013). 
However, with time this can develop into systolic dysfunction due to fibrosis and 
myocyte degeneration (Hein et al. 2003). Aortic stenosis patients with a severely 
reduced left ventricular ejection fraction (LVEF) of <30 % had a 32 fold greater 
myocyte generation than control (Hein et al. 2003). Due to changes brought about 
by the development of eccentric and concentric hypertrophy, signals as a result 
of one type of hypertrophy can lead to the progression towards the other (Figure 
1-7) (Grossman and Paulus 2013).  
A range of factors have been shown to initiate cardiac hypertrophy including 
myocardial stretch, neurohormonal activation and other paracrine/autocrine 
mediators (Sutton and Sharpe 2000). Interestingly, the pro-hypertrophic stimuli, 
noradrenaline, ET-1 and Ang II, act through G-protein coupled receptors of the 
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Gαq/α11 subtype (Heineke and Molkentin 2006). Mice overexpressing the Gαq protein 
have been shown to develop hypertrophy leading to HF (D'Angelo et al. 
1997;Mende et al. 1998). Additionally, Gαq/α11 activation results in enhanced IP3 
levels and activation of MAPK signalling pathways, both of which have been 
implicated in the development of hypertrophy (Bueno et al. 2000;Nakayama et al. 
2010). Furthermore, Ang II and noradrenaline induced hypertrophy have been 
shown to involve other pro-hypertrophic stimuli including TGFβ1 and ET-1 
respectively (Moser et al. 2002;Schultz et al. 2002), illustrating indirect actions of 
these mediators.  
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Figure 1-7 Eccentric and concentric hypertrophy. 
Schematic demonstrating the process of eccentric and concentric hypertrophy by volume and 
pressure overload respectively. The increased diastolic wall stress as a result of enhanced diastolic 
pressure following volume overload can induce the addition of new sarcomeres to myofibrils and 
chamber enlargement. However this increases systolic wall stress which can prompt the parallel 
addition of new myofibrils (black dashed arrow) also observed in pressure overload in response to 
increased systolic pressure. Consequently, the left ventricular wall thickens not only leading to 
concentric hypertrophy but can also contribute to eccentric hypertrophy (blue arrow). Dashed red 
arrows represent negative feedback. LVH; left ventricular hypertrophy, σ; wall stress (Reproduced 
with permission from Grossman and Paulus 2013) 
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1.6.2 Electrical remodelling and cardiac arrhythmias 
Ventricular arrhythmias, defined as abnormal cardiac conduction, are a major 
cause of SCD (Roberts-Thomson et al. 2011). Due to the vast range of cardiac 
disease causes and severity, myocardial electrical consequences vary immensely. 
Cardiac fibrosis creates a vulnerable substrate which can create unidirectional 
conduction block and establish a re-entry loop of electrical activity (Nguyen et al. 
2013) (Figure 1-8). Consequently, re-entry increases the rate of ventricular 
contraction, known as ventricular tachycardia (VT). Further wave breaks can lead 
to ventricular fibrillation (VF), where the ventricles quiver and the heart cannot 
efficiently pump blood around the body, which is often fatal (Jalife 2000). 
Interstitial fibrosis results in slowing of CV by promoting GJ uncoupling due to 
separation between CMs. Severe interstitial or patchy fibrosis has great 
arrhythmogenic potential, due to the live strands of CMs between areas of dense 
scar through which electrical signals cannot pass (Nguyen et al. 2013). Slowing of 
CV combined with the electrical signals travelling in a zig zag pattern through the 
CMs strands increases the risk of the slowed electrical signal looping back on itself 
and activating CMs which are not in the ERP, hence promoting re-entry (Figure 
1-8) (Nguyen et al. 2013). Ectopic activity, such as following an early after 
depolarisation (EAD), defined as abnormal depolarisations during phases 2 or 3 of 
the AP, is required to trigger re-entry or worse, VF (Morita et al. 2011). EADs can 
occur when the repolarisation is impaired by a decrease in outward currents, an 
increase in inward currents or a combination of both. The ICaL is the main current 
responsible for the upstroke of an EAD, although the NCX current (INCX), which also 
produces an net inward current by exchanging one Ca2+ ion for three Na+ ions, may 
play a role following increased [Ca2+]i induced by ICaL (Weiss et al. 2010). Oxidative 
stress has been shown to induce EADs both in isolated CMs and in the intact heart 
(Morita et al. 2011;Song et al. 2006;Xie et al. 2009). EADs are associated with 
prolongation of the APD (Song et al. 2006) which is well established to occur in 
isolated CMs from failing human hearts (Beuckelmann et al. 1992;Piacentino et al. 
2003) and from animal model hearts of HF (Kaab et al. 1996). A reduction in 
repolarisation currents, such as the Ito, inward rectifier K+ current (IK1) and IKs, 
have been detected in HF, suggesting a potential contributing factor to APD 
prolongation (Beuckelmann et al. 1993;Kaab et al. 1996;Li et al. 2004). 
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Spatial and temporal dispersion in APD has also been linked to the development 
of cardiac arrhythmias due to heterogeneity of the ERP in myocardial areas or 
between cardiac beats respectively (Frommeyer et al. 2017;Rosenbaum et al. 
1994). Temporal dispersion in APD is described as APD alternans, where a long APD 
is followed by a short APD. Areas of the myocardium can either follow the same 
pattern; for instance long-short APD or vary spatially where areas of long-short 
APD are adjacent to areas following a short-long APD pattern, termed concordant 
or discordant alternans respectively (Burton and Cobbe 2001;Sato et al. 2006). 
The latter is somewhat more proarrhythmic by enhancing the risk of unidirectional 
block due to heterogeneity in ERPs (Sato et al. 2006). As the ECG T wave 
represents repolarisation, beat-to-beat variations in the T wave amplitude, shape 
or timing can be used to identify alternans (Narayan 2006). T wave alternans have 
been associated with the initiation of ventricular arrhythmias and mortality in man 
(Gold et al. 2000;Rosenbaum et al. 1994). 
1.6.2.1 Connexin expression in the diseased heart 
As well as fibrosis inducing CM uncoupling, Cx43 expression is known to be reduced 
in many cardiac pathologies including dilated, ischaemic and inflammatory 
cardiomyopathies (Kostin et al. 2003;Smith et al. 1991). In these conditions areas 
bordering the infarct displayed disorganised Cx43 expression, where movement of 
Cx43 from the IDs to the lateral surfaces of CMs was observed (Kostin et al. 
2003;Smith et al. 1991). Similar lateralisation of Cx43 has also been demonstrated 
in rat and canine MI models (Matsushita et al. 1999;Peters et al. 1997). 
Consequently, reduced Cx43 expression at the ID would promote uncoupling and 
slow CV. Indeed, the uncoupling agent, carbenoxolone, slowed CV in the isolated 
rabbit heart (de Groot et al. 2003) and in the human heart in vivo (Kojodjojo et 
al. 2006). Additionally, mice with CM-specific Cx43 knockout had a slowed CV in 
both the longitudinal and transverse directions and developed ventricular 
arrhythmias leading to SCD within 2 months of birth (Gutstein et al. 2001). 
Together these studies provide evidence that organised GJ expression is essential 
for the normal electrical conduction of the myocardium.  
33 
 
 
Figure 1-8 Establishment of a re-entry circuit. 
Electrical activity outside the normal sinus rhythm (red star) acts as a trigger for re-entry. This impulse 
outside the scar conducts normally (red arrows) until it reaches the myocyte strands located between 
dense scar. Unidirectional block occurs at the interface between the normal tissue and upper 
myocyte strand due to this area being within the ERP. However the lower myocyte strand which has 
a shorter ERP conducts the impulse albeit at a slower rate (green dashed arrows). This slowed 
impulse travels around the dense scar to the upper myocyte strand where the impulse can exit and 
reactivate the normal cardiac tissue as well as the lower myocyte strand creating a re-entry circuit 
(purple arrow). ERP; effective refractory period.  
1. Ectopic activity with unidirectional conduction block  
Dense scar
ERP
Dense scar
Entry site
Exit site
2. First beat of re-entry
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1.6.3 Impaired excitation-contraction coupling 
Alterations in Ca2+ transport into the cytoplasm and rate of removal can impact 
the initiation, intensity and duration of CM contraction (Lou et al. 2012). Abnormal 
Ca2+ handling is well established to occur in human HF, with an increase in the 
resting [Ca2+]i  and reductions in the Ca2+ transient amplitude, rate of Ca2+ removal, 
Ca2+ SR store and contractility (Beuckelmann et al. 1992;Kubo et al. 
2001;Piacentino et al. 2003). In human HF the expression and/or the activity of 
numerous proteins involved in controlling [Ca2+]i throughout contraction are known 
to be altered, which may explain these affects. For instance reduced protein 
expression and/or activity of SERCA2a, the main cardiac SERCA isoform, has been 
demonstrated in human HF (Hasenfuss et al. 1994;Piacentino et al. 2003). 
Although the protein expression of PLN is unchanged in failing hearts (Dash et al. 
2001;Lou et al. 2011), a reduction in the phosphorylated form of PLN has been 
reported (Dash et al. 2001;Schwinger et al. 1999). This would therefore result in 
a reduction in SERCA activity and may explain the reduced Ca2+ SR store. 
Ca2+ influx, mainly through the LTCCs, is generally unaltered in human HF (Mewes 
and Ravens 1994;Piacentino et al. 2003). However, disorganisation of T-tubules 
along with decreased co-localisation of LTCCs and RyRs in HF may contribute to 
impaired contraction (Crossman et al. 2011). Additionally, the RyR has been shown 
to have a damaged “leaky” phenotype in human HF, which is thought to be a result 
of hyperphosphorylation (Marx et al. 2000). This increased leak of Ca2+ from the 
SR can contribute to reduced Ca2+ SR store as well as an increase in cytosolic Ca2+ 
concentration, a risk factor for the development of delayed afterdepolarisations 
(DADs) (Antoons and Sipido 2008). A DAD is an abnormal depolarisation following 
completion of repolarisation. This can occur when cytosolic Ca2+ concentration is 
high due to activation of the INCX and the production of an inward current (Nagy 
et al. 2004). INa is activated if the inward current induces a substantial 
depolarisation (Tse 2016), consequently triggering an AP and the development of 
focal arrhythmias (Antoons and Sipido 2008). 
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1.7 Current treatment of arrhythmias   
Current pharmacological treatments for the prevention of arrhythmias can 
typically be categorised by the ion channel which the drug targets. Class I, III and 
IV drugs block Na+, K+ and Ca2+ channels respectively whereas class II act to inhibit 
β-adrenergic receptors (β-blockers) and class V have a wide range of actions 
(Karagueuzian et al. 2017). The use of these drugs has been limited by modest 
antiarrhythmic efficacy, toxicity and paradoxically, the promotion of arrhythmias 
(Williams and Viswanathan 2013).  
Amiodarone and sotalol are the main pharmacological treatments for VT. 
Amiodarone was originally developed as an antianginal therapy due to its 
vasodilatory action but later shown to suppress arrhythmias (Vassallo and Trohman 
2007). It has properties of class I, II, III and IV drugs and been demonstrated, in a 
meta-analysis of randomised trials, to reduce overall mortality by 10-19 % in 
patients at risk of SCD (Sim et al. 1997). Although, amiodarone causes prolongation 
of the QT interval, there was no development of torsade de pointes (TdP), a 
ventricular arrhythmia known to be induced by increased QT intervals, in MI 
survivors with a LVEF of ≤40 % (Julian et al. 1997). However, in the same study, 
nearly twice as many participants discontinued amiodarone treatment (38.5 %) in 
comparison to placebo group (21.4 %) due to a range of reasons, of which the most 
common was endocrine disorders (Julian et al. 1997). Other side effects of 
amiodarone include corneal microdeposits, pulmonary toxicity and hepatotoxicity 
(Vassallo and Trohman 2007). Additionally, as amiodarone is an iodine-containing 
drug it has been reported to cause thyroid dysfunction. Consequently a similar 
agent which is noniodinated has now been developed, known as dronedarone. This 
drug was reported to reduce hospitalisation as well as overall, 
cardiovascular-related and arrhythmic death of atrial fibrillation (AF) patients 
(Hohnloser et al. 2009), and is now approved for the treatment of AF. Dronedarone 
has not been investigated for VT/VF treatment but an increase in mortality of 
severe HF patients (Kober et al. 2008) as well as in patients with sustained AF 
which have a high risk of major vascular events such as MI, (Connolly et al. 2011) 
has raised safety concerns of this drug in these subset of patients.   
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Although used less often, sotalol is given to suppress ventricular arrhythmias (Dev 
et al. 2014). Sotalol is a racemic mixture of D-sotalol and L-sotalol which results 
in APD prolongation. Both stereoisomers have K+ channel blocking properties, 
therefore a member of the class III anti-arrhythmics, however L-sotalol also acts 
as a β-blocker (Williams and Viswanathan 2013). Interestingly, in a small 
randomised trial, sotalol was shown to be more efficient at reducing mortality in 
patients with an ischemic compared to a nonischemic cardiomyopathy (Furushima 
et al. 2007). Like amiodarone, sotalol prolongs the QT interval, but is thought to 
pose a greater risk in the development of TdP (MacNeil 1997). 
Currently, patients deemed at risk of lethal ventricular arrhythmias, including 
those presenting a LVEF of ≤35 % and/or sustained VT/VF are subjected to an 
implantable cardioverter-defibrillator (ICD) (Epstein et al. 2013). This device 
monitors the heart rate for dangerously high or low frequencies where on 
occurrence delivers a shock to re-start sinus rhythm. ICDs have been demonstrated 
to be more effective at preventing mortality in survivors of VF or patients with 
sustained VT than the front line antiarrhythmic drug, amiodarone (Connolly et al. 
2000). However, one of the major limitations to ICD therapy is the discomfort 
caused by, sometimes inappropriate, shocks resulting in decreased quality of life 
(Irvine et al. 2002;Schron et al. 2002). Additionally, while an ICD terminates 
arrhythmias it does not prevent them, therefore they are normally used in 
combination with antiarrhythmic drugs (Dev et al. 2014). Indeed, oral sotalol was 
found to decrease the risk of death and ICD shock in comparison to placebo 
(Pacifico et al. 1999). Furthermore, combination therapy of with amiodarone and 
β-blockers was shown to decrease the incidence of shocks in comparison to β-
blockers or sotalol alone (Connolly et al. 2006). Despite these successes no new 
antiarrhythmic therapies have been developed for the treatment of VT in over a 
decade, therefore greater understanding of basic mechanisms are required to 
develop new therapeutics. 
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1.8 Cardiac myocyte: fibroblast interactions 
Due to the close proximity demonstrated between CMs and CFs (Camelliti et al. 
2005a), strong heterocellular interactions are likely to exist. Membrane fusion, 
paracrine, electrical and mechanical interactions have been postulated.  
1.8.1 Membrane fusion interactions 
Membrane nanotubes were characterised as long, thin continuous membrane 
structures in cultured rat pheochromocytoma PC12 cells (Rustom et al. 2004). 
Similar structures have also been reported in many other cell types including 
normal rat kidney (NRK) cells, dendritic cells and rat CMs and have been proposed 
to be involved in the transport of electrical signals, Ca2+ and mitochondria 
(Plotnikov et al. 2008;Wang et al. 2010;Watkins and Salter 2005). However, the 
transfer of calcein through nanotubes in PC12 cells was prevented, suggesting 
impedance to passive transfer (Rustom et al. 2004). Interestingly, nanotube 
formation has also been demonstrated between neonatal CFs and CMs, with a 
mean length of 13.9 ± 10.4 μm (He et al. 2011). The transport, in both directions, 
of small swelled vehicles was demonstrated within nanotubes connecting CFs and 
CMs. Additionally, mitochondria transfer and Ca2+ signal propagation via 
membrane nanotubes was demonstrated (He et al. 2011). Although regular 
punctate Cx43 expression was shown at one end of nanotubes connecting NRK cells 
(Wang et al. 2010), no Cx43 expression was detected in nanotubes between CFs 
and CMs (He et al. 2011). The presence of nanotube-like structures within the 
intact mouse heart has also been reported, suggesting a physiological role in vivo 
(He et al. 2011;Quinn et al. 2016). Membrane fusion between cultured adult CFs 
and CMs has also been reported (Driesen et al. 2005). Further elucidation of the 
role of membrane nanotubes in electrical communication is required.  
1.8.2 Paracrine interactions  
As CFs are known to be a major secretory cell, many studies have focussed on the 
effect of mediators released by CFs and their effect on the function of CMs. For 
instance, fibroblast conditioned media (FCM) is well established to promote the 
hypertrophy of CMs (Fredj et al. 2005a;Fredj et al. 2005b;LaFramboise et al. 2007) 
which has been attributed to many mediators including IL-6 and Ang II (Fredj et 
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al. 2005a;Fredj et al. 2005b). Additionally, the packaging of mediators within 
exosomes has become an interesting means of communication between CFs and 
CMs. The passenger strand, miR21*, was demonstrated to be in high abundance in 
exosomes released from CFs, which was reported to induce CM hypertrophy (Bang 
et al. 2014). Furthermore, miR21* antagomir treatment was shown to reduce 
Ang II-mediated hypertrophy (Bang et al. 2014). 
Paracrine factors released from neonatal CFs were also shown to reduce the CV 
by 52 %, decrease the rate of AP upstroke by 80 %, increase the RMP by 21 % and 
finally induce a 217 % APD prolongation of neonatal CMs monolayers (Pedrotty et 
al. 2009). Additionally, in the same study gene expression of the channels 
responsible for INa, IK1 and Ito were downregulated by 3.8-, 6.6-fold and to 
undetectable levels respectively in CMs treated with FCM (Pedrotty et al. 2009), 
which may explain these electrophysiological changes. In agreement with this 
study, the peak of the Ito in rat adult CMs was reduced in cells treated with FCM 
(Kaur et al. 2013). However in contrast, the INa was enhanced in these cells (Kaur 
et al. 2013). Both effects on Ito and INa were attenuated by a TGFβ1 neutralising 
antibody and mimicked by TGFβ1 treatment. Furthermore, TGFβ1 was shown to 
prolong the APD of adult CMs, suggesting TGFβ1 released by CFs, which was 
increased by more than 3 fold in FCM, could be promoting electrical dysfunction 
in CMs (Kaur et al. 2013).  
Furthermore, Cartledge et al. (2015) demonstrated that the phenotype of CFs can 
modify their effect on CM function. This study utilised a transwell co-culture 
method to determine the paracrine interactions between adult CMs and CFs. 
Freshly isolated CFs (αSMA negative) and MFs from pressure overloaded hearts 
(αSMA positive) not only reduced the viability of CMs but also shortened the Ca2+ 
transient and promoted hypertrophy. However, freshly isolated CFs were shown 
to increase the CM Ca2+ transient amplitude whereas MFs had the opposite effect. 
Through in-depth studies, all these effects were attributed to a TGFβ1–dependent 
interaction between the cells (Cartledge et al. 2015). This differential behaviour 
between healthy and diseased CFs was also shown in a study by Vasquez et al. 
(2010) using CFs isolated from rat MI (CF-MI) and healthy hearts. Here, conditioned 
media from CF-MI induced a significant reduction in the CV and APD of rat neonatal 
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cultures, whereas conditioned media from healthy CFs had no effect (Vasquez et 
al. 2010).  
Additionally, CM conditioned media (CCM) can modulate CF activity. For example, 
Ang II was only able to increase collagen I and III mRNA levels in CFs when CCM 
was present, demonstrating mediators released from CMs potentiate the CF 
response to Ang II (Sarkar et al. 2004). Furthermore, CCM was shown to increase 
CF proliferation (Cartledge et al. 2015). In summary, the studies described in this 
section suggest that bidirectional paracrine interactions exist between CFs and 
CMs.  
1.8.3 Electrical interactions and the role of connexins 
CFs are regarded as an electrically inactive cell type (Ongstad and Kohl 2016). 
Despite this, CFs are known to express connexin proteins (Camelliti et al. 
2004a;Camelliti et al. 2004b;Miragoli et al. 2006), and are thought to partially 
mimic APs of coupled CMs (Kohl et al. 1994). Although, GJs between CFs and CMs 
may be less abundant and distinct in comparison to GJs between CMs (Camelliti 
et al. 2004a), there is growing evidence for their presence. In fact, computer 
modelling has suggested that CFs could have an effect on CMs with as little as 10-
30 connexin channels between them (Kohl et al. 1994), which may be difficult to 
detect.  
1.8.3.1 Evidence for electrical coupling between cardiac myocytes and 
fibroblasts  
Evidence to support the presence of GJs between CFs and CMs has come from dye 
transfer studies (Chilton et al. 2007;Driesen et al. 2005) where transfer of the 
fluorescent dye, calcein, has been shown to occur as early as 1 h from initiation 
of co-culture (Cho et al. 2007). Dye transfer between CFs and CMs has also been 
reported in situ in the rabbit SAN, an area very abundant in fibroblasts (Camelliti 
et al. 2004b). In this study, Cx45 was reported to be the most likely contributor, 
due to the greater presence at CM and CF contact points. Conversely, Cx43 was 
undetectable and Cx40 was shown at homocellular CF junctions (Camelliti et al. 
2004b). 
40 
 
Although electrically unexcitable, CFs may assist in conduction between CM layers 
and through scar tissue. A study by Gaudesius et al. (2003) demonstrated that 
when CMs were separated by CFs in culture over distances of up to 300 µm, 
electrical signals were conducted between the bands of CMs (Gaudesius et al. 
2003). Interestingly, greater conduction delays were correlated with increasing 
length of separation between the CMs (from 50 to 300 µm), typical of post cardiac 
injury (Gaudesius et al. 2003). Cx43 and Cx45 expression was identified at the 
heterocellular contact points, hence supporting a role for them in the electrical 
conduction (Gaudesius et al. 2003). Furthermore, electrical propagation through 
scar tissue resulting from MI in a rabbit and mouse model has been reported 
(Mahoney et al. 2016;Walker et al. 2007). Interestingly, in mice with a FSP1 driven 
KO of Cx43 (Cx43fsp1KO) no conduction through the scar was detected (Mahoney 
et al. 2016). Together these studies suggest that CFs have the ability to passively 
conduct electrical impulses both in vitro and in the intact heart in situ. 
1.8.4 Electrophysiological consequences of cardiac myocyte: 
fibroblast coupling 
The levels of Cx43 have been reported to be substantially increased in CFs derived 
from rat MI hearts in comparison to control hearts (Vasquez et al. 2010;Zhang et 
al. 2010). Additionally, a progressive increase in Cx45 and Cx43 expression within 
in infarct area was reported 1 to 6 days (Cx45) and 6 to 30 days (Cx43) post 
ischaemia respectively in sheep MI model (Camelliti et al. 2004a). These studies 
suggest that CF connexin expression is altered in a complex fashion following 
infarction. An enhanced Cx43 expression in CFs-MI, and therefore mostly likely of 
a myofibroblast phenotype, may augment CM: CF coupling resulting in a 
heightened electrical influence. 
1.8.4.1 Effects on the cardiac myocyte resting membrane potential  
The RMP of CFs has been shown to be relatively depolarised in comparison to CMs 
(-15 to -35 mV (Askar et al. 2012;Vasquez et al. 2010) vs. -65 to -80 mV (Askar et 
al. 2012;Nguyen et al. 2012); CFs vs. CMs). Therefore a modest depolarisation of 
CMs could be consequence of enhanced CM: CF coupling which may be 
arrhythmogenic by increasing the probability of ectopic beats due to nearing the 
threshold value. This depolarisation effect was demonstrated in a rat neonatal 
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CM: CF co-culture model, where increasing densities of αSMA positive CFs resulted 
in a progressive increase in the maximal diastolic potential (MDP; the most 
negative point of the AP) of CMs to values up to -55 mV (Miragoli et al. 2006). Both 
Cx43 and Cx45 were shown to be present at heterocellular contact points and 
therefore likely to be responsible. An increase in the CM MDP by CFs was also 
demonstrated by Askar et al. (2012), which was reduced by lentiviral (LV) vector-
mediated silencing of Cx43 in CFs (Askar et al. 2012). Interestingly, this reduction 
induced by Cx43 silencing was reverse by inhibition of the repolarisation current, 
IK1 (Askar et al. 2012). Together these data support the role of Cx43 expression in 
CFs in the partial depolarisation of CMs. However, CF-MI were shown to have a 
more hyperpolarised reversal potential to that of healthy CFs (-51.0 ± 1.5 mV vs. 
-32.0 ± 3.5 mV, CFs-MI vs. healthy CFs) (Vasquez et al. 2010), which may alleviate 
the depolarising effects on coupled CMs. On the contrary, the elevated Cx43 levels 
in CFs-MI (Vasquez et al. 2010;Zhang et al. 2010) may enhance heterocellular 
coupling consequently increasing the RMP of CMs. 
1.8.4.2 Effects on the conduction velocity between cardiac myocytes 
Similar to within an infarct, CV is altered in CM: CF co-culture models. A biphasic 
effect on CV along cultured neonatal CM strands was reported when the density 
of CFs was increased (Miragoli et al. 2006). That is, a gradual increase in CV was 
seen at CM: CF ratios of up to 100:7, however at greater ratios a progressive 
slowing of CV was observed (Miragoli et al. 2006). This could be explained by weak 
cell coupling at low densities, resulting in CM depolarisation nearing the AP 
threshold. However, following increased coupling at greater CFs densities, the 
larger depolarising effect on the CM could lead to the inactivation of voltage-
gated Na+ channels, essential channels for phase 0 of the AP, hence slowing 
conduction (Miragoli et al. 2006). This phenomenon has been termed 
“supernormal conduction” whereby CV has the same biphasic relationship with 
increasing membrane potential of the CM. Supernormal conduction has been 
described by elevating external K+ concentrations to depolarise the RMP (Rohr et 
al. 1998). Additionally, the rate of CM depolarisation (dV/dtmax) followed a similar 
trend to CV, thought to be due to the same depolarising effect (Miragoli et al. 
2006). Furthermore, at a CM: CF ratio of 1:1, CV was reduced by approximately 2 
fold compared to cultured CMs alone (Askar et al. 2012), providing additional 
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evidence of this effect. In the same study, LV vector-mediated Cx43 knockdown 
in CFs resulted in a significant increase in CV in comparison to CFs treated with a 
control LV (Askar et al. 2012). The negative correlation between CV of monolayers 
of the murine atrial CM cell line, HL-1 cells, and the percentage of neonatal rat 
CFs (NRCFs) was attenuated when NRCFs were substituted for the mouse 
embryonic fibroblast cell line which had no Cx43 expression (Fahrenbach et al. 
2007). These studies provide evidence for heterocellular coupling between CMs 
and CFs and suggest that enhanced Cx43 expression in CFs may promote 
proarrhythmic effects.  
1.8.4.3 Arrhythmic consequences of cardiac myocyte: fibroblast coupling  
Co-culture studies have also been utilised to investigate the impact of CFs on the 
vulnerably of CMs to arrhythmias. In a hybrid biological-computational study, 
where adult rabbit CMs were patch-clamped to a computer generated virtual CF 
based on mathematical models of their electrical profile (Nguyen et al. 2012), 
early EADs were more common in comparison to CMs alone. Interestingly, when 
the RMP of the virtual CF was more depolarised (-25 vs. -50 mV) the probability of 
EAD generation was greater (Nguyen et al. 2012). Spontaneous depolarisations of 
CMs has also been shown when CF density is greater than 15 % in a co-culture 
model (Miragoli et al. 2007). Interestingly, the ability of CFs to trigger spontaneous 
AP generation in myocytes is dependent on αSMA expression in CFs, suggesting a 
specific effect of the MF phenotype (Rosker et al. 2011). Additionally, αSMA 
expression was shown to contribute to the relatively depolarised RMP of CFs 
(Rosker et al. 2011).  
Ectopic activity and re-entrant arrhythmia incidence were shown to be enhanced 
in CM: CF co-culture versus CM monolayers (Askar et al. 2012). This effect was 
partially attributed to Cx43 expression in CFs (Askar et al. 2012). Zlochiver et al. 
(2008) also demonstrated an increase in the number of activation waves as the 
density of CFs increased, indicating a highly arrhythmic environment (Zlochiver et 
al. 2008). Antiproliferative treatment of CM: CF cultures over nine days was shown 
to supress ectopic activity and re-entrant arrhythmias in comparison to untreated 
cultures (Askar et al. 2011), which may indicate a potential therapeutic avenue.  
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Figure 1-9 Schematic of potential electrical consequences of increased cardiac myocyte: 
(myo)fibroblast coupling. 
In the healthy heart connexin expression is primarily localized to the intercalated discs between 
myocytes (pink cells). Fibroblasts (purple) are thought to form gap junctions with myocytes which 
may assist the electrical impulse to be transmitted through myocyte layers. However following 
ischaemia, the fibroblasts are activated and become myofibroblasts. Myofibroblasts (fibroblasts from 
infarcted hearts – green cells) have been reported to increase connexin expression and therefore 
potentially increase heterocellular coupling. Connexin expression in myocytes in disease is reduced 
and is relocated to the lateral surfaces of the myocyte. The resulting pro-arrhythmic effects are 
detailed at the right-hand side of the figure (This figure was originally published in McArthur et al. 
2015). 
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1.8.5 Mechanical interactions 
In both neonatal and adult CM: CF co-culture models, heterocellular mechanical 
interactions have been demonstrated. CFs are shown to pull on CMs in culture 
(Driesen et al. 2005;Thompson et al. 2014) and cadherin, a component of AJs, has 
been detected at CM: CF cell contact points (Thompson et al. 2011;Thompson et 
al. 2014).  
Mechanosensitive channels (MSCs) are channels activated by stretching, for 
instance in diastole of the cardiac cycle. As MFs are known to express αSMA and 
have the ability to contract (Dobaczewski et al. 2010;Thompson et al. 2011), the 
role of MSCs in CF/MFs has been investigated. MSCs were demonstrated to be 
constitutively active in CFs and were shown to contribute to their less negative 
RMP (Grand et al. 2014). Interestingly, inhibition of MSCs with streptomycin or 
gadolinium in CM strands coated with CFs at a CM: CF ratio of 3:1 was shown to 
partially inhibit the slowing of CV and dV/dtmax induced by CFs, despite no effect 
in control CM strands. Additionally, physiological stretching by plating cells onto 
silicone membranes to which stretch force was applied led to MSC activation and 
resulted in depolarisation of both neonatal CMs and CFs. Furthermore, in CM: CF 
strands, conduction was significantly slowed in comparison to control CM strands 
when 5 % stretch was applied (Grand et al. 2014). The CV of neonatal rat 
ventricular cells (NRVCs) was also found to be slowed when treated with TGFβ1, 
with the aim of promoting the MF phenotype. However, in this cellular model 
effects of TGFβ1 directly on the CMs may occur and is therefore difficult to state 
an effect of the MF phenotype, nonetheless this was representative of a fibrotic 
culture. Additionally, the dV/dtmax and the APD were shown to be prolonged in 
fibrotic cultures in comparison to control. The effects on CV, dV/dtmax and the 
APD were reversed when treated with the EC upcoupler, blebbistatin, or the MSC 
blockers; streptomycin and gadolinium (Thompson et al. 2011). In a follow up 
study, the CV slowing of NRVCs was seen as soon as 30 min following the addition 
of MFs (TGFβ1-treated CFs) (Thompson et al. 2014). Interestingly, this was 
reversed when, the AJ component, N-cadherin, was silenced in MFs (Thompson et 
al. 2014). Together these studies demonstrate a role for MSCs in CFs and AJ 
between CMs and CFs in conduction slowing, which are likely to have implications 
in fibrotic hearts.  
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1.9 Hypothesis and aims 
CFs are known to play an integral role in the pathogenesis of heart disease by 
secreting numerous factors contributing to cardiac fibrosis and arrhythmogenesis. 
Co-culture CM: CF studies, mainly from neonatal origin, have suggested that CFs 
can couple to and alter the function of CMs. Therefore it was hypothesised that 
the function of CMs would be altered in an in vitro adult CM: CF co-culture model 
in comparison to CMs in culture alone and that RACFs implanted into the left 
ventricle would alter the electrical activity in that region of the heart.  
The primary aim of this thesis was to determine the effects of RACFs on the 
function of CMs both in vitro and in situ. This was addressed by the following 
experimental aims: 
• Develop a viral vector to overexpress Cx43 which is suitable for in vitro 
investigation and in situ imaging. 
• Identify potential mediators that could be responsible for enhanced Cx43 
expression reported in CFs from MI hearts, and to further dissect 
mechanisms for this upregulation.  
• Assess the effect of different phenotypes of RACFs on adult CM contraction 
and electrical activity in an in vitro CM: CF co-culture model. 
• Establish a model to investigate CM: CF interactions in situ. 
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Chapter 2 Materials and methods 
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2.1 Materials  
All tissue culture reagents, reverse transcription and quantitative real-time 
polymerase chain reaction (qRT-PCR) reagents were purchased from ThermoFisher 
Scientific (Loughborough, UK). Tissue culture plastics were purchased from Sigma-
Aldrich (Poole, UK). All restriction endonucleases were obtained from New 
England BioLabs (NEB; Ipswich, UK). Sutures for surgery were attained from Herny 
Schein (Dumfries, UK).  
2.1.1 Solutions 
• ADS buffer (in mM): 116.4 NaCl, 199.7 HEPES, 1.0 NaH2PO4, 5.6 Glucose, 
5.4 KCl, 0.8 MgSO4.  
• 1x Citric saline (in mM): 130.0 KCl, 17.0 sodium citrate dihydrate 
• Kraft Bruhn buffer (KB) (in mM): 70.0 KOH, 40.0 KCl, 50.0 L-Glutamic Acid, 
20.0 Taurine, 20.0 KH2PO4, 3.0 MgCl2.6H20, 10.0 Glucose (Anhydrous), 10.0 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 0.5 ethylene 
glycol-bis[β-aminoethyl ether]-N,N,N',N'-tetraacetic acid (EGTA). pH to 7.2 
with KOH at 37 ⁰C. 
• Krebs-henseleit solution (in mM): 120.0 NaCl, 20.0 HEPES, 5.4 KCl, 0.5 
NaH2PO4, 3.5 MgCl2.6H20, 20.0 Taurine, 10.0 Creatine, 11.0 Glucose 
(Anhydrous). pH to 7.4 with NaOH at 37 ⁰C 
• 10x Phosphate-buffered saline (PBS) (in mM): 1369.0 NaCl, 27.0 KCl, 101.0 
Na2HPO4, 17.0 KH4PO4. pH to 7.4 with HCl at room temperature. 
• 1x Protein lysis buffer stock (in mM): 50.0 Tris-HCl, 50.0 NaF, 1.0 Na4P2O7-
10H2O, 1.0 ethylenediaminetetraacetic acid (EDTA) and 1 EGTA 
• 10mM Sodium citrate (in mM): 10.0 sodium citrate dihydrate. pH to 6.0 with 
HCl at room temperature. 
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• Transfer buffer: 192.0 mM Glycine, 25.0 mM Tris-Base, 20 % 
volume/volume (v/v) methanol  
• 10x Tris-buffered saline (TBS) (in mM): 247.6 Tris-Base, 1368.9 NaCl, 26.8 
KCl. pH to 7.4 with HCl at room temperature. 
• 10x Tris density (TD) buffer (in mM): 750.0 NaCl, 50.0 KCl, 250.0 Tris-base, 
10.0 Na2HPO4-12H2O. pH to 7.4 with HCl at room temperature.  
• 10x Tris-EDTA (TE) buffer (in mM): 10.0 Tris-HCl, 1.0 EDTA. pH to 8.0 at 
room temperature.  
• Tyrodes (in mM): 116.0 NaCl, 20.0 NaHCO3, 0.4 Na2HPO4, 1.0 MgSO4-7H2O, 
5.0 KCl, 11.0 glucose, 1.8 CaCl2 
2.2 Cell isolation and culture 
All cell culture was performed within a sterile class II biological vertical laminar 
flow cabinet to maintain sterility. Cells were cultured in 75 or 150 cm2 tissue 
culture flasks in a humidified chamber at 37 ⁰C and 5 % carbon dioxide (CO2).   
2.2.1 Cell lines  
The immortalised human cervical epithelial carcinoma cell line, HeLa, and Human 
Embryonic Kidney (HEK) 293 cells and 293Ts were cultured in minimal essential 
media (MEM) supplemented with 10 % (v/v) foetal bovine serum (FBS), 2 mM L-
glutamine, 100 international units (I.U)/mL penicillin and 100 µg/mL 
streptomycin. Cells were cultured in 150 cm2 flasks and the media was changed 
every 2-3 days.  
2.2.2 Obtaining hearts for cell isolation 
Adult male Wistar rats were killed by Schedule 1 according to the UK Animals 
(Scientific Procedures) Act 1986. Hearts were removed from the thorax and lungs, 
placed in ice cold ADS buffer (for RACF isolation) or heparinised Krebs solution 
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(for CM isolation). Instruments for both RACF and CM isolation were soaked in 70 % 
ethanol to sterilize prior to use.  
2.2.3 Rat adult cardiac fibroblast culture 
Isolated RACFs were cultured in Dulbecco’s Modified Eagle Medium: Nutrient 
Mixture F-12 (DMEM/F-12) reconstituted from powder in 1 L of double distilled H2O 
(ddH2O) with 14.3 mM sodium bicarbonate added and the pH adjusted to 7.2 at 
room temperature. The media was then filter sterilised and supplemented with 
10 % or 0.5 % (v/v) FBS (culture media and reduced serum media respectively), 
100 I.U/mL penicillin and 100 µg/mL streptomycin. 
Plastics used to culture RACFs were treated with poly-L-lysine unless stated 
otherwise. To coat, poly-L-lysine (Sigma-Aldrich) was added and incubated for 
5 min at room temperature. The poly-L-lysine was then removed and two washes 
with sterile PBS performed. 
2.2.4 Rat adult cardiac fibroblast isolation  
RACF cultures were obtained by an enzymatic digestion method of the ventricular 
heart muscle, modified from previous published papers (Louch et al. 
2011;Shivakumar et al. 2003). Hearts were prepared for digestion in cold ADS 
buffer in a sterile class II biological vertical laminar flow cabinet. Atria were 
discarded and blood was removed by gently pressing on the walls of the ventricles. 
Hearts were then moved into fresh ADS buffer and minced using small scissors. 
Pieces of heart were transferred into a sterile 100 mL Duran bottle and ADS buffer 
removed by allowing the tissue to gravitate to the bottom when the bottle was 
slightly tilted on its side. Next, 10 mL of an enzyme solution (0.8 mg/mL 
collagenase type II [Worthington Chemicals, US] and 0.6 mg/mL pancreatin 
[Sigma-Aldrich] made up in ADS buffer and filter sterilised using a 0.2 μm syringe 
filter) was added to the tissue and incubated in a shaking water bath (180 
strokes/min) at 37 ⁰C for 10 min. The supernatant from this first digestion, 
containing digested ECM components, was discarded and 10 mL of enzyme solution 
added before being incubated again at 37 ⁰C in the shaking water bath at 160 
strokes/min. Following the 2nd digestion the supernatant was taken and added to 
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2 mL FBS prior to centrifugation at 310 × g for 5 min. The supernatant was 
discarded; the pellet gently resuspended in 4 mL FBS and incubated in a 
humidified incubator at 37 ⁰C and 5 % CO2 in a 50 mL Falcon tube with the lid 
loosened. This was repeated for digestion steps 3-10 (Table 2.1) with varying 
enzyme solution volumes, times and strokes/min. Following each digestion, cells 
were collated. On completion of digestion step 10 the cells were subjected to 
centrifugation at 310 × g for 6 min. The supernatant was discarded, resuspended 
in 12 mL culture media and added to a poly-L-lysine coated 75 cm2 vented flask. 
Cells were left to attach for 2-3 h in a humidified incubator at 37 ⁰C and 5 % CO2 
before being washed twice with sterile PBS and fresh media applied. The media 
was then changed the following day.    
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Table 2.1 Enzymatic digestion protocol for RACF isolation. 
 
Digest 
Volume of the enzyme 
solution (mL) 
Time (min) 
Speed (strokes/min) 
at 37 ⁰C 
1 10 10 180 
2 10 10 160 
3 8 10 150 
4 8 10 150 
5 6 10 160 
6-9 6 10 150 
10 6 30 150 
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2.2.5 Adult rat cardiac myocyte isolation 
Adult rat CMs were isolated using a Langendorff perfusion set up. Prior to the 
isolation; 200 mL 70 % ethanol followed by 500 mL sterile dH2O was used to clean 
the perfusion apparatus. All solutions used for the isolation were filtered sterilised 
in a sterile class II biological vertical laminar flow cabinet. 
Hearts were washed in ice cold Krebs, aortas isolated by dissection and cannulated 
using a 2 mm diameter catheter and 4-0 silk braided suture (Pearsalls, Somerset, 
UK). Hearts were retrograde perfused with Krebs heated to 37 °C at a constant 
flow rate of 8 mL/min. Following clearance of blood, the heart was perfused with 
0.25 U/mL collagenase type I constituted in a 0.1 % (weight/volume [w/v]) bovine 
serum albumin (BSA) Krebs solution. The enzyme was recirculated only once the 
initial enzyme level was low to prevent unnecessary dilution and deactivation of 
the enzyme. The enzyme was perfused until suitable digestion was completed, 
determined by a spongy texture of the heart. The time taken for each heart to 
complete digestion varied (approximately 12 min). The ventricles were then cut 
from the atria and transferred into the laminar flow cabinet for the remainder of 
the digestion. Kraft Bruhn (KB) buffer containing 1 % (w/v) BSA was added and the 
hearts were minced using sterile scissors. The solution was triturated for 1-2 min 
using a sterile Pasteur pipette, prior to filtering through a 250 μm polyamide mesh 
to separate the solution from undigested tissue. Next, 1 % (w/v) BSA in KB buffer 
was added to the remaining heart tissue and the process repeated. The solutions 
were subjected to centrifugation for 2 min at 300 × g and CMs examined under the 
microscope.  
The cells were allowed to recover from the digestion in KB buffer for 30 min. The 
solution was then removed and cells slowly introduced to increasing 
concentrations of calcium by incubation in 100 µM followed by 1 mM CaCl 
containing sterile Krebs for 20 mins per solution. Cells were then added to reduced 
serum media (0.5 % (v/v) FBS) and live CMs (rods) counted using a 
haemocytometer.  
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2.2.6 Cell passage and cryopreservation  
All cell types were passaged once the cells had reached 80-90 % confluency. This 
was achieved by washing twice with sterile PBS followed by the addition of 3 or 5 
mL 0.05 % (v/v) trypsin- EDTA (for HeLas and RACFs) or 1x citric saline (HEK  293 
and 293Ts), for 75 cm2 or 150 cm2 flasks respectively. Cells were incubated for 
approximately 5 min at 37 ⁰C and 5 % CO2 until the cells had detached and at least 
2 volumes of media containing 10 % (v/v) FBS added to the flasks. Next, the cells 
were subjected to centrifugation at 460 × g for 5 min and the pellet resuspended 
in the appropriate volume of media prior to addition to the culture flask.  
Cryopreservation was performed by harvesting the cells as described above and 
the pellet resuspended in media containing 10 % dimethyl sulfoxide (DMSO). Cells 
were then aliquoted into 1 mL aliquots in cryovials and stored in the vapour phase 
of liquid nitrogen (ranging from -135 to -195 ⁰C). 
To recover cells from a frozen stock, cells were rapidly thawed at 37 ⁰C before 
being added to fresh media. Cells were then subjected to centrifugation at 460 × g 
for 5 min to remove DMSO and the pellet resuspended in the appropriate volume 
of media and added to a culture flask.  
2.3 Stimulation of RACFs 
RACFs where seeded at 2 × 105 cells per well in a 6 well plate or down scaled for 
smaller well formats. To induce quiescence the cells were washed once with PBS 
to remove the serum prior to the addition of reduced serum media. Cells were 
left for 24 h before stimulation detailed in sections 2.3.1 and 2.3.2. 
2.3.1 Stimulation of RACFs with proinflammatory mediators 
Subsequent to serum starvation, as detailed above, cells were cultured in reduced 
serum media, stimulated with a range of proinflammatory mediators in reduced 
serum media or reintroduced into normal culture media. Mediators examined were 
Ang II, TGFβ1, tumor necrosis factor α (TNFα), recombinant human IL-1β, 
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recombinant rat IL-1α and the recombinant human IL-6 (with or without the 
recombinant human soluble IL-6 receptor α [sIL-6Rα]). Preparation of the 
proinflammatory mediator stocks, final concentrations used and the supplier is 
detailed Table 2.2. 
2.3.2 IL-1β pathway inhibitor experiments 
A range of IL-1β pathway inhibitors were utilised to dissect the IL-1β pathway. A 
nuclear factor (NF)-κB inhibitor, SC-514, was diluted in reduced serum media to a 
final concentration of 100 μM from a stock solution which was reconstituted in 
DMSO (see Table 2.3). Reduced serum media containing 0.1 % DMSO was also 
prepared. Cells were incubated with SC-514, 0.1 % DMSO or media alone for 30 
min before the addition of 10 ng/mL IL-1β. In a subset of experiments cells were 
pre-incubated with a p38 MAPK, a c-Jun N-terminal kinase (JNK) or a MAPK/ERK 
kinase (MEK1) inhibitor (SB203580, SP600125 and AZD6244 respectively), at the 
concentrations detailed in Table 2.3 for 1 hour prior to stimulation with 10 ng/mL 
IL-1β. 
Finally, 10 ng/mL IL-1β and recombinant human IL-1 receptor antagonist (IL-1Ra) 
at 0.25, 0.5 or 1 μg/mL were added simultaneously to the cells. All stimulations 
were performed for 24 h. 
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Table 2.2 Proinflammatory mediators used to stimulate RACFs. 
 
Proinflammatory mediator Dilution buffer 
Stock 
concentration 
Final 
concentration 
Company 
Ang II Sterile dH2O 10 μM 500 nM Sigma-Aldrich 
Recombinant human TGF-β1 Sterile 4mM HCl  containing 1mg/mL BSA 20 μg/mL 10 ng/mL R & D systems 
Recombinant human TNF-α Sterile dH2O containing 5 % (w/v) trehalose 50 μg/mL 10 ng/mL Peprotech 
Recombinant human IL-1β Sterile PBS containing 0.1 % (v/v) BSA 10 μg/mL 10 ng/mL R & D systems 
Recombinant rat IL-1α Sterile dH2O containing 0.1 % (v/v) BSA 10 μg/mL 10 ng/mL Peprotech 
Recombinant human IL-6 Sterile dH2O containing 5 % (w/v) trehalose 20 μg/mL 50 ng/mL Peprotech 
Recombinant human sIL-6Rα Sterile dH2O containing 0.1 % (v/v) BSA 20 μg/mL 50 ng/mL Peprotech 
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Table 2.3 IL-1β pathway inhibitors. 
 
Inhibitor Target Dilution buffer 
Stock 
concentration 
Final 
concentration 
Company 
SC-514 NF-κB DMSO 100 mM 100 μM Cayman Chemical 
SB203580 p38 MAPK DMSO 25 mM 10 μM InvivoGen 
SP600125 JNK DMSO 50 mM 20 μM InvivoGen 
AZD6244 MEK1 DMSO 10 mM 10 μM Selleckchem 
Recombinant human IL-1Ra IL-1R 
Sterile dH2O containing 0.1 % 
(v/v) BSA 
100 μg/mL 
0.25, 0.5 and 
1 μg/mL 
Peprotech 
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2.4 Nucleic acid extraction 
2.4.1 Ribonucleic acid (RNA) and micro RNA extraction 
Ribonucleic acid (RNA) and micro RNA (miRNA) were isolated using the miRNeasy 
mini kit (Qiagen, Manchester, UK) as per manufacturer’s instructions, including 
the DNase digest step to remove contaminating deoxyribonucleic acid (DNA). 
RNase-free filter tips and plastics were used throughout the procedure and all 
steps were performed at room temperature unless stated otherwise. 
Briefly, cells were washed in PBS before the addition of 700 μL QIAzol lysis reagent 
to each well. Wells were scraped using the end of a 1000 μL tip to remove any 
cells which were still attached and the lysates transferred to 1.5 mL Eppendorf 
tubes. Lysates were stored at -80 °C or extraction performed immediately 
following lysis.  
To extract the RNA, 140 µL chloroform was added to each sample and shaken 
vigorously for 15 s. Samples were incubated for 2-3 min prior to centrifugation at 
12,000 × g for 15 min at 4 °C. The upper clear phase, containing RNA, was 
transferred to a fresh Eppendorf tube and 525 µL ethanol (1.5 volumes) was added 
to assist binding of RNA to the RNeasy® Mini column. Samples were mixed by 
pipetting and 700 µL added to an RNeasy® Mini column in a 2 mL collection tube. 
Samples were subjected to centrifugation at 8,000 × g for 15 s and the flow 
through discarded. This was repeated with the remaining sample before a wash 
using 350 µL RWT buffer, a guanidine salt and ethanol containing buffer, to 
remove contaminates was performed. Columns were then subjected to 
centrifugation at 8,000 × g for 15 min to remove the buffer. A stock solution of 
DNase was then prepared by dissolving DNase (1,500 Kunitz units) in 550 μL RNAase 
free water. This was then diluted 1:7 in RDD buffer to make a working DNase 
solution and 80 μL added to each column. The column was incubated for at least 
15 min before a further wash with 350 µL RWT buffer and subjected to 
centrifugation at 8,000 × g for 15 s. Columns were then subjected to 2 x 500 µL 
washes with RPE buffer to remove salts introduced by RWT washes. The columns 
were subjected to centrifugation at 8,000 × g for 15 s following the first RPE wash, 
whereas for the second wash they were subjected to centrifugation at 8,000 × g 
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for 2 min. The columns were then placed in new collection tubes and subjected 
to centrifugation at 1 min at 16,000 × g to dry the membrane. To elute the RNA, 
columns were added to 1.5 mL Eppendorf tubes, 30 μL RNase-free water added 
and incubated for 5 min prior to centrifugation at 8,000 × g for 1 min. The elute 
was then passed back through the column to concentrate the RNA. RNA was 
quantified as detailed in section 2.4.3.  
2.4.2 Deoxyribonucleic acid (DNA) extraction  
2.4.2.1 Mini-Preparation  
DNA extractions from 10 mL bacterial cultures were completed using the 
PureLink® Quick Plasmid Miniprep Kit (Invitrogen, Paisley, UK). Overnight bacterial 
cultures were prepared as described in section 2.7.6. All centrifugation steps were 
performed at room temperature unless stated otherwise. 
Briefly, 3 mL of the overnight bacterial culture was subjected to centrifugation at 
3,000 × g and the pellet resuspended in 250 µL resuspension buffer (R3) containing 
100 µg/mL RNase A until the sample was homogeneous. To lyse cells, 250 µL lysis 
buffer (L7) was added to each sample and the sample mixed by inverting, again 
until homogeneous. This was incubated for 5 min, prior to the addition of 350 µL 
precipitation buffer (N4) and mixed by inverting. Lysates were subjected to 
centrifugation at 12,000 × g for 10 min. Supernatants were transferred into a spin 
column in a collection tube prior to centrifugation at 12,000 × g for 1 min. The 
flow through was discarded and 500 µL of an ethanol-based wash buffer (W10) 
added to each column. Columns were subjected to centrifugation at 12,000 × g 
for 1 min and 700 µL of a second ethanol-based wash buffer (W9) added. 
Centrifugation was repeated and a further centrifugation at 12,000 × g for 1 min 
performed to fully remove any remaining buffer. To elute the DNA, columns were 
transferred into 1.5 mL Eppendorf tubes and 30 µL nuclease free water added. 
Columns were incubated for 5 min prior to centrifugation at 12,000 × g for 2 min. 
DNA concentration was then determined (section 2.4.3) and stored at -20 °C. 
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2.4.2.2 Maxi-Preparation 
To produce a large-scale DNA preparation, 500 mL bacterial cultures were 
prepared as described in section 2.7.6. DNA was extracted using the PureLink® 
HiPure Plasmid Filter Maxiprep Kit (Invitrogen) as per manufacturer’s instructions. 
All centrifugation steps were performed at room temperature unless stated 
otherwise. 
The bacterial pellet was obtained through centrifugation at 6,000 × g for 15 min 
at 4 ⁰C using and resuspended in 10 mL resuspension buffer (R3) containing 
100 µg/mL RNase A. Cells were lysed by the addition of 10 mL lysis buffer (L7) and 
mixed by inverting. Following a 5 min incubation, 10 mL precipitation buffer (N3) 
was added and was mixed by inverting until the mixture was homogeneous. The 
lysate was then subjected to centrifugation at 20,000 × g for 20 min. Meanwhile 
30 mL equilibration buffer (EQ1) was added to an anion-exchange resin PureLink® 
HiPure filter column and allowed to pass by gravity flow to equilibrate the column. 
Following centrifugation and only once the EQ1 had drained; the clear DNA 
containing supernatant was added to the column and allowed to pass through. This 
column was then washed by the addition of 60 mL wash buffer (W8) which again 
was allowed to pass by gravity flow. DNA was then eluted by adding 15 mL elution 
buffer (E4) and was collected in a sterile centrifuge tube. To precipitate and 
desalt the DNA, 10.5 mL isopropanol was added prior to mixing by inversion and 
subjected to centrifugation at 15,000 × g for 30 min at 4 °C. The supernatant was 
then discarded and the DNA pellet washed in 4 mL 70 % ethanol. The DNA was then 
subjected to centrifugation at 16,000 × g for 5 min at 4 °C and the supernatant 
discarded. The pellet allowed to air dry prior to the addition of 200 μL nuclease 
free water. DNA concentration was determined by NanoDrop™ as described in 
section 2.4.3.  
2.4.2.3 DNA extraction for lentiviral vector titre 
DNA for LV vector titration (section 2.9.1) was extracted using the DNeasy blood 
and tissue kit (Qiagen) as per manufacturer’s instructions. Briefly, 20 µL 
proteinase K (600 Anson unit [AU]/mL) was added to the 200 µL cell suspension in 
PBS (see section 2.9.1) to digest cellular proteins. To lyse the cells, 200 µL buffer 
60 
 
AL was added to each sample and vortexed prior to incubation at 56 °C for 10 min. 
Next, 100 % ethanol was added and the components mixed by vortexing. The 
mixture was then added to a DNeasy Mini spin column and subjected to 
centrifugation at 6000 × g for 1 min in order to isolate the DNA, which binds to 
the membrane of the spin column, from the solution. The flow through was then 
discarded and 500 µL of the ethanol containing wash buffer, buffer AW1, was 
added prior to centrifugation at 6000 × g for 1 min. This was followed by a second 
wash step involving the addition of 500 µL buffer AW2 (ethanol containing buffer). 
The columns were subjected to centrifugation at 20,000 × g for 3 min and the flow 
through discarded. Next the DNA was eluted by adding 50 µL nuclease free H2O 
and incubated for 5 min prior to centrifugation at 6,000 × g for 1 min. This was 
repeated by adding the flow through back into the column to maximise DNA 
concentration. DNA concentration was determined by NanoDrop™ as described in 
section 2.4.3. 
2.4.3 Nucleic acid quantification 
The concentration and quality of both RNA and DNA was quantified using a 
NanoDrop™ 1000 Spectrophotometer (ThermoFisher Scientific). Initially, 1.4 μL of 
the sample was loaded onto a receiver fibre optic cable and the source fibre optic 
cable lowered onto the sample. Light was then passed through the sample using a 
xenon flash lamp and the absorbance at different wavelengths measured by a 
spectrometer. Nucleic acids absorb light at 260 nm and can therefore be used to 
determine the concentration of the sample using the Beer-Lambert equation as 
follows: 
c	= A ×	e
b
 
Where:  c is the concentration (ng/µL) 
A is the absorbance (arbitrary units [AU]) 
  e is the wavelength-dependent extinction coefficient (ng-cm/µL) 
  b is the path length (cm) 
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260/280 nm ratios of approximately 1.8 and 2 were considered pure for DNA and 
RNA respectively.  
2.5 Reverse transcription  
Complementary DNA (cDNA) was produced by reverse transcription of mRNA or 
miRNA to allow the levels to be detected and analysed.  
2.5.1 Gene expression 
mRNA templates were transcribed into cDNA using Taqman® Reverse Transcription 
Reagents. Reactions were prepared in a 96 well plate and contained 1x RT buffer, 
5.5 mM MgCl2, 2.0 mM dNTPs mix (0.5 mM each), 2.5 μM random hexamers, 
0.4 U/μL RNase inhibitor, 1.25 U/μL multiscribe RT and 300 ng of the mRNA 
template. RNase free water was added to each reaction to adjust all reactions to 
the same volume. To allow the synthesis of cDNA, reactions were placed on a 
thermal cycler at 25 °C for 10 min to allow the random hexamers to anneal to the 
mRNA templates, followed by 48 °C for 30 min to permit reverse transcription and 
finally 95 °C to inactivate the multiscribe RT. cDNA was then stored at -20 °C for 
future use. 
2.5.2 miRNA expression 
MiRNA templates were reverse transcribed into cDNA using the Taqman® MicroRNA 
Reverse transcription Kit, with specific primers for each miRNA supplied in 
Taqman® miRNA assays. Each reaction was composed of 1 mM dNTP (with dTTP), 
3.3 U/µL multiscribe RT, 1x RT buffer, 0.25 U/µL RNase inhibitor, 1x RT primer 
and 2.1 µL RNase free water. All RNA was diluted in RNase free water to 2 ng/µL 
prior to the addition of 2.5 µL to each reaction, to give 5 ng RNA in total. Reactions 
were then subjected to 16 °C for 30 min to allow primers to anneal to the miRNA 
templates, 42 °C for 30 min for reverse transcription to occur and 85 °C for 5 min 
to deactivate the multiscribe RT using a thermal cycler. 
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2.6 Quantitative PCR  
Gene/miRNA expression was quantified by Taqman® qRT-PCR. Taqman® assays 
contain both a forward and reverse primer which is specific to the gene/miRNA of 
interest and a Taqman® probe. The probe has a fluorescent reporter dye attached 
to the 5’ end and a quencher at the 3’ end. When the probe is intact minimal 
fluorescence is emitted due to the close proximity of the fluorescent dye to the 
quencher, established by the principle of fluorescence resonance energy transfer 
(FRET) (Cardullo et al. 1988). The Taqman® probe binds to DNA downstream of the 
primers; therefore once the primer extension reaches the probe, Taq polymerase 
cleaves it. This releases the fluorescent reporter from the quencher resulting in 
an increase in fluorescence. The increase in fluorescence is exponential over time; 
therefore a plateau will eventually be reached, hence the end point is not a 
reliable measure of gene expression. The threshold cycle (Ct) is the PCR cycle at 
which fluorescence reaches an arbitrarily placed threshold on the exponential 
phase of amplification (Schmittgen and Livak 2008). The Ct value can be used to 
consistently measure expression (Higuchi et al. 1993). On all plates a housekeeper 
is measured to allow discrepancies in RNA concentrations to be accounted for. 
Data can then be normalised to the housekeeper levels and the fold change 
expressed as relative quantification (RQ) using the 2-ΔΔCt method (Schmittgen and 
Livak 2008). All Taqman® assays used in this thesis utilised 6-carboxyfluorescein 
(FAM) as the fluorescent reporter dye and 6-carboxytetramethylrhodamine 
(TAMRA) as a quencher. The housekeeping gene used was Ubiquitin C (UBC).  
2.6.1 Gene and miRNA expression 
Taqman® was performed in a 384 well plate. For gene expression each reaction 
contained a final volume of 12.5 µL including 5.25 µL 2x Taqman® Universal Master 
Mix II - no UNG, 0.625 µL 20x probe/primer mix (assay details are included in Table 
2.4), 3.625 µL RNase free water and 2 µL cDNA. MiRNA expression was examined 
in a similar manner although a final reaction volume of 10 µL was used. This 
consisted of 5 µL 2x Taqman® Universal Master Mix II - no UNG, 0.5 µL miRNA 
probe/primer mix (assay details are included in Table 2.5), 3.838 µL RNase free 
water and 0.67 µL cDNA. Plates was then sealed with an optical adhesive lid and 
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qRT-PCR performed on either the Applied Biosystems 7900HT Sequence Detection 
System or the QuantStudio 12K Flex Real-Time PCR System. The thermal cycling 
conditions were as follows; 95 °C for 10 min to activate the polymerase followed 
by 40 cycles of 95 °C for 15 sec to denature the DNA then 60 °C for 1 min for the 
primer/probe to anneal and extend. 
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Table 2.4 List of Taqman gene expression assays 
 
Gene Assay ID RefSeq Gene ID 
GJA1 Rn01433957_m1 NM_012567.2 
GJA5 Rn00570632_m1 NM_019280.1 
GJA7 Rn01750705_m1 NM_001085381.1 
UBC Rn01499642_m1 BC103477.1 
ACTA2 Rn01759928_g1 NM_031004.2 
CTGF Rn01537279_g1 NM_022266.2 
SERPINE Rn01481341_m1 NM_012620.1 
SNAI1 Rn00441533_g1 NM_053805.1 
SNAI2 Rn01404476_m1 NM_013035.1 
 
Table 2.5 List of Taqman miRNA expression assays 
 
miRNA Assay ID MIRBASE ID 
hsa-miR-19b 000396 Rno-miR-19b-3p 
hsa-miR-30c 000419 Rno-miR-30c-5p 
hsa-miR-101 002253 Rno-miR-101a-3p 
mmu-miR-101b 002531 Rno-miR-101b-3p 
U87 001712 AF272707 (NCBI accession) 
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2.7 Molecular cloning 
2.7.1 Restriction endonuclease digestion 
Restriction endonuclease digestions were performed to check DNA for the 
presence of restriction sites or to prepare DNA for ligation into a plasmid 
backbone. All digests were performed as per manufacturer’s instructions in a total 
volume of either 20 μL or 250 μL for small or large quantities of DNA, respectively. 
Each reaction contained the appropriate DNA, reaction buffer and restriction 
endonuclease(s) and was incubated at 37 °C for 2 hours or overnight for small or 
large digests, respectively. The success of restriction endonuclease digestion was 
analysed by performing gel electrophoresis (section 2.7.2).  
2.7.2 Agarose gel electrophoresis  
The percentage of agarose gel prepared was determined by the size of DNA 
fragments expected. UltraPure™ Agarose (Thermo Fisher Scientific) was added to 
x1 UltraPure™ Tris/Boric acid/EDTA (TBE) buffer and dissolved by heating. The gel 
was allowed to cool for 5 min prior to the addition of 150 ng/mL ethidium bromide 
to enable DNA imaging. The gel was poured into mould and a comb used to create 
appropriate sized wells. Samples were prepared by adding the appropriate volume 
of 6x blue/orange loading dye (Promega, Southampton, UK). Samples and a 
suitable ladder (100 bp and/or 1 Kb; Promega) were loaded into the wells of the 
gel in an electrophoresis tank submerged in TBE buffer. Gels were subjected to 
10 V/cm to allow DNA fragments to separate. DNA bands were visualised using a 
Bio-Rad ChemiDoc XRS ultra violet (UV) transilluminator. 
2.7.3 DNA extraction from ethidium bromide gel 
The Wizard® SV Gel and PCR Clean-up System (Promega) was used to extract DNA 
from agarose gel as per manufacturer’s instructions. This kit is based on the ability 
of DNA to bind to a silica membrane in the presence of chaotropic salts (Boom et 
al. 1990).  
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Following agarose gel electrophoresis (section 2.7.2), DNA was visualised using a 
UV transilluminator and the segment of gel containing the DNA band excised from 
the excess gel. A guanidine isothiocyanate (chaotropic salt) containing solution 
(Membrane Binding Solution) was added to the agarose gel segment at a ratio of 
10 μL to 10 mg gel segment. This was incubated at 50-56 °C for approximately 10 
min until the gel had fully dissolved. The solution was then transferred into a SV 
Minicolumn, incubated for 1 min and subjected to centrifugation at 16,000 × g for 
1 min. The flow through was discarded and 700 μL of the ethanol containing 
Membrane Wash Solution was added to each column prior to centrifugation at 
16,000 × g for 1 min. This was repeated with a volume of 500 μL preceding 
centrifugation at 16,000 × g for 5 min. The columns were then subjected to 
centrifugation at 16,000 × g for 1 min without the centrifuge lid to allow maximal 
ethanol evaporation. The columns were then transferred to a 1.5 mL Eppendorf 
tube and 40 μL nuclease-free water was added directly to the membrane in 
preparation for DNA elution, followed by 5 min incubation and centrifugation at 
16,000 × g for 1 min. The eluted DNA was passed through the column one further 
time to increase the yield. DNA concentration was then quantified (section 2.4.3).  
2.7.4 Phenol chloroform clean-up of DNA 
To remove potential contaminates from DNA, a phenol chloroform extraction was 
performed. An equal volume of a phenol:chloroform:isoamyl alcohol (Sigma-
Aldrich) was slowly added on top of the DNA solution. The mixture was then 
subjected to vortexing for 30 sec prior to centrifugation at 16,000 × g for 2 min. 
The upper phase, containing DNA, was then transferred into a fresh Eppendorf 
tube and an equal volume of chloroform added to remove phenol. Next, the 
solution was subjected to vortexing for 30 sec, prior to centrifugation at 
16,000 × g for 2 min and the upper phase transferred to a clean Eppendorf tube. 
A tenth of the total volume of 3M sodium acetate (pH 5.2) was added along with 
2 volumes of 100 % ethanol followed by incubation on dry ice for 15 min. The 
sample was then subjected to centrifugation at 16,000 × g for 10 min to pellet the 
DNA. The DNA pellet was resuspended in 70 % ethanol to de-salt and subjected to 
centrifugation at 16,000 × g for 2 min. Next, the solution was discarded and the 
pellet left to air dry prior to being resuspended in nuclease free water.  
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2.7.5 DNA dephosphorylation and ligation 
In preparation for ligation of a DNA fragment into a vector, linearised vectors 
underwent dephosphorylation of 5’ DNA ends in order to prevent the re-ligation 
of vector “sticky ends”. Reactions consisted of 1 µg DNA, 5 units Antarctic 
phosphatase, 1x Antarctic phosphatase buffer and nuclease free water which was 
incubated at 37 °C for 15 min followed by 70 °C for 5 min to heat inactivate the 
Antarctic phosphatase.  
Ligation reactions were performed using a range of insert:vector molar ratios. The 
mass of vector backbone was maintained at 50 ng and the mass of insert calculated 
using the following equation: 
Mass of insert (ng) = 
mass of vector	ng ×	size of insert (Kb)
size of vector (Kb)
 x molar ratio	
Ligation reactions were performed in a total volume of 10 µL and consisted of the 
appropriate insert/dephosphorylated vector masses, 1 µL T4 DNA Ligase (NEB), 1x 
T4 DNA Ligase Buffer (NEB) and nuclease free water. Reactions were incubated at 
15 °C overnight then stored at 4 °C until transformation into bacteria (section 
2.7.6) the same day.  
2.7.6 Transformation of DNA and bacterial culture 
To allow the amplification of intact vectors, they were transformed into bacteria 
via heat shock or electroporation (section 2.10.1). Both methods cause bacterial 
cell membranes to briefly become permeable to allow the vectors to pass into the 
cell. Vectors utilised contain an antibiotic resistance gene which was used to 
select colonies that contain the vector of interest. Ampicillin or kanamycin at 100 
µg/mL or 50 µg/mL, respectively were used.  
For heat shock, JM109 competent Escherichia coli (E. coli), produced in-house or 
purchased from Promega were used. Cells were stored at -80 °C and thawed on 
ice. For each ligation reaction (section 2.7.5), 5 µL of the reaction was added to 
50 µL of cells. For vectors, 1 or 10 ng was added to 50 µL cells. Cells and DNA were 
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then mixed gently and incubated on ice for 30 min. Next, samples were heated at 
42 °C for 30 sec and rapidly placed back on ice for 2 min. Next, 450 µL Super 
Optimal broth with Catabolite repression (SOC) medium was gently added to the 
sample and agitated at 37 °C for 1 hr prior to spreading on an agar plate containing 
the appropriate antibiotic. Agar plates were incubated at 37 °C overnight to allow 
the bacteria to form colonies.  
The following day, single colonies were picked and added to 10 mL Luria Broth 
(LB) containing the appropriate antibiotic and incubated at 37 °C overnight 
shaking at 200 rpm. Mini preparations (section 2.4.2.1), diagnostic restriction 
endonuclease digests (section 2.7.1) and cryopreservation of the bacteria (section 
2.7.6.1) were performed at this stage. The remainder of the bacterial culture was 
added to 500 mL LB containing the appropriate antibiotic to grow a large scale 
culture and a maxi preparation (section 2.4.2.2) performed. Diagnostic restriction 
endonuclease digests and cryopreservation were also completed on the extracted 
DNA. 
2.7.6.1 Cryopreservation of bacterial stocks 
To preserve bacterial cultures, 800 µL of the culture and 200 µL sterile glycerol 
were mixed together in a cryovial and stored at -80 °C. To re-establish bacterial 
growth from a frozen stock, it was thawed on ice and a small volume added to an 
agar plate containing the appropriate antibiotic to allow single colonies to grow.   
2.7.7 DNA sequencing 
DNA sequencing was performed to confirm the success of cloning and to identify 
any DNA mutations. BigDye™ Terminator v3.1 Cycle sequencing kit (ThermoFisher 
Scientific) utilises Sanger sequencing to allow sequencing in a single reaction and 
detection by fluorescence. 
Sequencing was performed by first performing a PCR reaction consisting of 100 ng 
of DNA template (in a total volume of 1-2 µL), 1x BigDye™ Terminator v3.1 
Sequencing Buffer, 1 µL BigDye™ Terminator v3.1 Ready Reaction Mix, 2 µL 2 µM 
primer and nuclease free water in a final volume of 20 µL. Samples were then 
subjected 25 cycles of the following temperatures on a thermal cycler; 96 ⁰C for 
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45 sec to allow DNA denaturing, 50 ⁰C for 25 sec for primers to anneal and 60 ⁰C 
for 4 min for extension. The reaction was then cooled to 4 ⁰C prior to DNA clean 
up.  
The PCR product was then cleared of all reagents using Agencourt® CleanSeq® 
(Beckman Coulter, High Wycombe, UK) as per manufacturer’s instructions. Briefly, 
10 μL CleanSeq® reagent, which contains magnetic beads that DNA is able to bind 
to, was added to the 20 μL PCR reaction followed by 62 μL 85 % ethanol. The 
samples were then vortexed prior to incubation on a magnetic plate for 2 min. 
Next, the solution was discarded while still on the magnetic plate to avoid losing 
the DNA/magnetic beads. DNA was washed with 150 μL 85 % ethanol and vortexed 
to mix. Samples were incubated on the magnetic plate for a further 2 min, the 
solution removed and left to air dry for 10 min. To detach the DNA from the beads, 
40 μL of nuclease free water was added to each sample and resuspended by 
pipetting. Finally, to remove the beads from the samples, they were placed on 
the magnetic plate and 20 μL of the water containing DNA was removed and added 
to a MicroAmp® Optical 96-well reaction plate (ThermoFisher Scientific). DNA 
sequencing was performed on the 3730 DNA Analyser (ThermoFisher Scientific) 
and electropherograms analysed using CLC Genomics Workbench 7.0 software.  
2.8 Transfection of DNA to cultured cells  
Xfect™ transfection regent (Takara Bio, Saint-Germain-en-Laye, France) was used 
as per manufacturer’s instructions to introduce DNA to cultured cells. A day prior 
to transfection, cells were seeded in the appropriate well format so that they 
were 50-70 % confluent at the time of transfection. All steps were completed 
under laminar flow to maintain sterility. A range of DNA masses (2.5-7.5 μg for 1 
well of a 6 well plate) were combined with Xfect™ reaction buffer to achieve a 
final volume appropriate for that well format (100 μL for a 6 well plate). The 
samples were mixed by vortex for 5 sec prior to the addition of the Xfect™ polymer 
at a ratio of 0.3 μL polymer: 1 μg DNA. Samples were then vortexed for 10 sec and 
incubated for 10 min to allow nanoparticle complexes to form. Fresh complete 
media was then replaced on the cells (1 mL for a 6 well plate) and the entire 
volume of nanoparticle complex solution slowly added. Cells were incubated at 
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37 ⁰C and 5 % CO2 and the media replaced 4 h after the initial transfection. 
Typically, cells were cultured for 48 h before DNA expression was examined.  
2.9 Lentiviral vector production and purification 
A second generation, self-inactivating (SIN) LV vector expressing eGFP was 
produced in-house using published methods (Demaison et al. 2002). This system 
utilises 3 plasmids whereby the HIV genes are split across the 3 plasmids; a transfer 
vector, an envelope plasmid and a packaging plasmid (Merten et al. 2016;Sakuma 
et al. 2012). The transfer vector contains the gene to be expressed by the LV 
vector along with the promoter that will drive the expression. Two long terminal 
repeats (LTRs) are located either side of this segment of DNA allowing insertion 
into the genome (Sakuma et al. 2012). The envelope plasmid used (pMDG) 
expresses the glycoprotein (gp) of vesicular stomatitis virus (VSV-G). Finally, the 
packaging plasmid (pCMVΔ8.74) encodes Gag, Pol, Rev and Tat genes. pMDG and 
pCMVΔ8.74 were a gift from Didier Trono (Addgene plasmid #12259 and #22036 
respectively). 
One day prior to transfection, 80-90 % confluent 293T HEK cells in 150 cm2 flasks 
were passaged at a ratio of 1:2 to make 13 flasks. The following day, 12 flasks 
were triple transfected with a transfer vector containing eGFP under the control 
of the spleen focus-forming virus (SFFV) promoter (pHR-SIN-SFFV-GFP), pMDG and 
pCMVΔ8.74. For each flask 50 μg pHR-SIN-SFFV-GFP, 17.5 μg pMDG and 32.5 μg 
pCMVΔ8.74 was added to 5 mL Optimem (ThermoFisher Scientific). Next, the 
transfection reagent, polyethylenimine (PEI) (Sigma-Aldrich), was added to a 
further 5 mL per flask to produce a final concentration of 6 μM. These solutions 
were mixed, filtered and left for 20 min at room temperature to allow DNA:PEI 
complexes to form. Meanwhile each flask was gently washed with 5 mL Optimem 
before the addition of 10 mL of the DNA:PEI complexes. Cells were incubated for 
4 h at 37 ⁰C and 5 % CO2. The transfection media was then removed and 20 mL 
complete MEM added.  
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LV vectors were harvested 48 h later by filtering the media and storing at 4 ⁰C. 
Next, 10 mL of fresh media was added and cells were incubated for a further 24 
h. The media was then filtered and the two sets of media mixed prior to 
ultracentrifugation.  
Beckman 17 mL thinwalled, ultra-clear ultracentrifuge tubes were sterilised using 
70 % ethanol followed by sterile PBS. Tubes were then loaded with media and 
subjected to centrifugation at 90,000 × g for 1 h at room temperature. The 
supernatant was then discarded and more media loaded into the tubes. This 
centrifugation step was repeated until all the media had been loaded. Subsequent 
to the final spin tubes were placed on ice and 100 μL Optimem added to each 
tube. The tubes were then left on ice for 20 min and the virus resuspended. The 
virus was then aliquoted and stored at -80 ⁰C. 
2.9.1 Lentiviral vector titration 
293T HEK cells were seeded at 5 × 104 cells per well in a 12 well plate. The 
following day the media was replaced with 1 mL complete MEM. Next, the LV 
preparation was initially diluted 1 in 100 in media and four serial 1 in 10 dilutions 
prepared thereafter. These dilutions were then added to the cells giving the final 
dilutions that ranged from 3 × 10-7 - 1 × 10-4. The cells were left for 72 h before 
media was removed and 200 μL PBS was added to each well. Cells in PBS were 
stored at -20 ⁰C and thawed before DNA extraction performed as detailed (section 
2.4.2.3). All samples were diluted to 250 ng/μL ready for titration. 
The concentration of LV vector was determined by qRT-PCR (section 2.6). The 
primer/probe mix used consisted of a forward and reverse primer (both at 1.2μM) 
as well as a FAM labelled probe containing a TAMARA quencher at 0.4 μM (primer 
and probe sequences are shown in Table 2.6). Serial dilutions of pHR-SIN-SFFV-
GFP were performed in nuclease free H2O ranging from 1 × 1013 to 1 × 104 copies 
of the plasmid to produce a standard curve. The top standard was prepared by 
performing the following calculations:  
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1. Calculate the weight of one plasmid copy 
Size of plasmid (bp) × Weight of 1 bp (Da)
Avogadro's constant
= g/plasmid copy 
Where: The weight of 1 bp = 660 Da 
Avogadro’s constant = 6.023 × 1023 molecules/mole 
2. Determine the number of plasmid copies in 1 mL 
Concentration of plasmid stock (g/mL)
g/plasmid copy 
=	no. of plasmid copies/mL 
3. Preparation of the top standard 
no. of	plasmid copies/mL
1 ×10
13
=	dilution factor for top standard	
1000
dilution factor for top standard
 
= μL of plasmid stock required to make 1 mL 1 ×10
13
standard 
Each reaction was comprised of 6.25 μL Taqman® Universal Master Mix II - no UNG, 
3.125 μL primer/probe mix (described above), 2.125 μL nuclease free H2O and 1 
μL standard or sample. All samples were performed in triplicate and the plate run 
in the same manner as described (section 2.6.1).  
To determine the final LV titer the Ct values from the standards were plotted 
against the plasmid copies and a logarithmic trendline applied. The equation of 
the line was then applied to the Ct values of the samples to determine the number 
of plasmid copies within the samples. This was then corrected for the volume and 
dilution of the virus added to the cells in the titer plate by performing the 
following calculations:  
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1. DNA concentration (ng/μL) × volume of DNA eluted (30μL)  
= total DNA extracted (ng) 
2. Determine the percentage of DNA used in the qRT-PCR 
DNA used in qRT-PCR (250ng)
total DNA extracted (ng)
	  ×	100 =	% of total cell DNA used	
3. Determine the number of cells used for qRT-PCR	
no. of cells (5 ×104)
100
	 × % of total cell DNA used = no. of cells used 
4. Determine the copies of plasmid in 1 cell 
no. of plasmid copies in samples
no. of cells used
	=	plasmid copies/cell 
5. Calculate the titre of the LV vector in particle infectious units (PIU) 
per mL 
plasmid copies/cell × dilution of virus stock  ×	1000
μL of virus dilution added
	 = PIU/mL 
Obvious outliers were excluded and an average of the PIU/mL values were taken 
to produce a final titre. Two batches of a LV vector overexpressing eGFP (LVeGFP) 
were produced giving similar titers of 1.2 × 109 and 1.1 × 109 PIU/mL. 
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Table 2.6 Sequences of primers and probe used in lentiviral vector titration. 
 
Primer/probe Sequence 
Forward primer 5’-TGTGTGCCCGTCTGTTGTGT-3’ 
Reverse primer 5’-GAGTCCTGCGTCGAGAGAGC-3’ 
Probe 5’FAM-CAGTGGCGCCCGAACAGGGA-(TAMRA)-3’ 
 
  
75 
 
2.10 Adenoviral vector production and purification 
The commercially available AdEasy system (Agilent Technologies, Stockport, UK) 
was used to produce first generation Ad vectors. Ad production followed a 
published protocol (Alba et al. 2012). HEK 293 cells contains the left-hand portion 
of the adenovirus serotype 5 genes (Graham et al. 1977) for the production of 
recombinant Ad vectors and were therefore used in this study. 
2.10.1 Electroporation and homologous recombination  
Homologous recombination of a shuttle vector, containing the gene of interest, 
and the pAdEasy-1 vector, a gift from Bert Vogelstein (Addgene plasmid #16400) 
(He et al. 1998), which contains most of the Ad serotype 5 genes, was performed 
in electrocompetent BJ5183 cells (Agilent Technologies). The shuttle vector used 
was pShuttle-CMV. Prior to transformation, pShuttle-CMV was linearised using the 
restriction endonuclease, PmeI, overnight (section 2.7.1). The DNA was then 
dephosphorylated (section 2.7.5) and excess reagents removed by a phenol 
chloroform extraction (section 2.7.4).  
BJ5183 cells that contain pAdEasy-1 were thawed on ice and 100 ng of the 
linearised pShuttle-CMV, made up in 6 μL, was added to 50 μL BJ5183 cells. The 
solution was gently mixed, transferred to a chilled 2 mm electroporation cuvette 
(Geneflow, Lichfield, UK) and incubated on ice for 3 min. The sample was then 
pulsed at 200 Ω, 2.5 kV and 25 μF using a BioRad MicroPulser™. Next, 450 μL SOC 
media was added and cells were shaken at 37 ⁰C for 1 hr. Either, 25 or 100 μL was 
spread over an agar plate containing 50 μg/mL kanamycin and incubated at 37 ⁰C 
overnight. The following day the smallest colonies were picked and processed as 
detailed in section 2.7.6.   
2.10.2 Transfection of adenoviral genomes to HEK 293 cells  
Ad genomes are required to be linear prior to transfection into HEK 293 cells, to 
prevent the expression of the antibiotic resistance gene and the origin of 
replication. This was achieved by digesting 50 µg DNA with PacI (section 2.7.1) 
and subsequently performing phenol: chloroform extraction of the DNA as detailed 
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in section 2.7.4. Next, 5 µg of linearised DNA was transfected into HEK 293 cells 
in 6 well format as described in section 2.8. Media was replaced every 2-3 days 
and the cells monitored for the presence of plaques which represent generation 
of Ad vector progeny.  
2.10.3 Generation of crude adenovirus stocks 
Successful transfections, showed the presence of plaques after 6-10 days. At this 
point the media was not changed, to allow the cytopathic effect (CPE) to move 
through the well (Figure 2-1). Once CPE was complete the media and cells were 
collected and subjected to centrifugation at 300 × g for 10 min. The pellet was 
resuspended in 1 mL sterile PBS and an equal volume of Arklone P (1,1,2-Trichloro-
trifluoroethane [Sigma-Aldrich]) added to the sample. The sample was inverted 
for 10 sec followed by shaking for 5 sec. This mixing step was repeated and the 
sample subjected to centrifugation at 800 × g for 10 min. The upper, virus 
containing layer was then removed and stored at -80 ⁰C in 50 μL aliquots. This 
crude preparation was plaque purified as detailed in section 2.10.4. 
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Figure 2-1 Cytopathic effect in HEK 293 cells.  
Images of control HEK 293 cells and cells showing cytopathic effect (CPE), following adenoviral 
vector production. CPE is an indication of cell lysis. Scale bar represents 100 μm.  
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2.10.4 Plaque purification 
To ensure the Ad vector purified has originated from a single generated virion, 
two rounds of plaque purification were performed. HEK 293 cells from a confluent 
T150 cm2 flask were resuspended in 15 mL media and 3 mL of the cell suspension 
was added to 10 mL fresh media. Next, 100 μL of the diluted cell suspension was 
added to each of 80 wells of a 96 well plate which produced cells at a confluency 
of 50-60 % at the time of Ad vector addition. The following day, serial dilutions of 
the crude preparation (section 2.10.3) were performed to produce 1×10-4 and 
1×10-6-1×10-11 dilutions. The media was then removed from the cells and 100 µL of 
the diluted Ad preparations or fresh media (for control cells) were added. The 
media was replaced the following day and every 2-3 days thereafter. The plate 
was monitored daily and the presence of plaques noted. Once plaques were 
apparent, the media was not replaced in that well. Seven days after the addition 
of the crude Ad vector dilutions, a second 96 well plate was prepared in the same 
manner as above for the second plaque purification. On the eighth day, the 
media/cells from wells at the greatest dilution that were CPE positive were 
collected. All samples were subjected to centrifugation at 300 × g for 10 min and 
all except one of the pellets were stored at -80 ⁰C. One pellet was resuspended in 
200 μL PBS and the Ad vector extracted in the same manner as detailed (section 
2.10.3). Next, 50 μL of Ad vector stock was used to prepare the same serial 
dilutions and added to the cells seeded the day before as described above. This 
second plaque purification plate was completed in the same manner and 100 μL 
of the plaque pure Ad vector stock added to an 80-90 % confluent flask of HEK 293 
cells. Once CPE was completed the media/cells were collected and subjected to 
centrifugation at 300 × g for 10 min. The pellet was resuspended in 1 mL PBS and 
the Ad vector extracted as previously described (section 2.10.3). This Ad vector 
seed stock was stored in 100 μL aliquots at -80 ⁰C. A large scale Ad preparation 
was then performed as detailed (section 2.10.5). 
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2.10.5 Large scale adenovirus production 
To amplify a pure recombinant Ad vector, 50 µL of the Ad seed stock was added 
to 500 mL complete media. Next, media on 20 T150 cm2 flasks of 80-90 % 
confluent HEK 293 cells was removed and replaced with 20 mL of the Ad vector 
containing media. The media was replaced every 3 days until CPE was apparent, 
fresh media was then added (not replaced) until CPE complete. Next, the media 
and cells was collected and subjected to centrifugation at 300 × g for 10 min.  The 
pellet was resuspended in 6 mL sterile PBS and an equal volume of Arklone P added 
to the sample. The sample was inverted for the slightly longer time of 30 sec 
followed by shaking for 10 sec. This mixing step was repeated and the sample 
subjected to centrifugation at 800 × g for 15 min. The upper virus containing layer 
was then removed and subjected to double caesium chloride gradient 
ultracentrifugation (section 2.10.6). 
2.10.6 Caesium chloride gradient ultracentrifugation 
Caesium chloride (CsCl) gradient ultracentrifugation was performed using two 
gradients to both purify and concentrate Ad vector preparations. CsCl solutions 
were prepared by dissolving the appropriate densities in 1x Tris density (TD) buffer 
to produce 1.25, 1.34 and 1.40 g/mL solutions. Beckman 14 mL thinwalled, ultra-
clear ultracentrifuge tubes were sterilised using 70 % ethanol and rinsed with 
sterile PBS prior to the addition of 2.5 mL 1.25 g/mL density CsCl. This was 
followed by the gentle addition of 2.5 mL 1.40 g/mL density CsCl creating a 
gradient with the 1.25 g/mL density above the CsCl 1.40 g/mL density CsCl. The 
Ad vector solution was then gently added avoiding disruption to the CsCl gradient 
and PBS added to fill the tube. The samples were then subjected to centrifugation 
at 90,000 × g for 90 min at 20 °C. Following centrifugation, three distinct bands 
were observed; the top band contained cellular debris, the middle band consisted 
of empty viral capsids and the bottom white layer at the intercept of the two CsCl 
layers was the Ad vector (Figure 2-2). Next, a 21-gauge needle was used to pierce 
the tube just below the adenoviral vector layer and the virus collected into a 
syringe. This was then added to a second CsCl gradient which consisted of 5 mL 
1.34 g/mL density CsCl in a fresh ultracentrifuge tube. The samples were then 
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subjected to centrifugation at 90,000 × g overnight at 20 °C. The following day, 
one distinct band was present and removed in the same manner as above. Dialysis 
of the Ad vector was then performed as described (section 2.10.7). 
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Figure 2-2 Purification of the mature virus following double CsCl gradient 
ultracentrifugation. 
(A) Following the first ultracentrifugation, three clear bands can be observed; the top band contains 
cellular debris, the middle band consists of empty capsid and the bottom band at the intercept of the 
CsCl layers is the mature virus. (B) The mature virus is then extracted and subjected to a second 
CsCl gradient ultracentrifugation, where one distinct band of mature virus is detected.   
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2.10.7 Adenoviral vector dialysis 
To remove CsCl from the Ad preparations, dialysis was performed. The Ad vector 
preparation was added to a Slide-A-Lyzer™ cassette with a molecular weight cut 
off of 10,000 kDa (ThermoFisher Scientific) and dialysed in a beaker containing 2 
L of sterile 1x TE buffer for 90 min. The buffer was then replaced and the dialysis 
continued for 2 h. Finally, the buffer was changed to 5 L 1x TE buffer containing 
10 % glycerol and dialysed for a further 3 h. The Ad vector was then removed from 
the cassette and stored in aliquots at -80 °C. The titer of the purified Ad vector 
was determined as detailed in section 2.10.8. 
2.10.8 Adenoviral vector titration 
The titer of the Ad vector was determined by two methods; end point dilution, to 
determine the ability of the vector to transduce cells, and micro-BCA, to examine 
the number of viral particles (vp).  
2.10.8.1 Titration by end point dilution  
HEK 293 cells were seeded into a 96-well plate and serial dilutions added as 
previously detailed (section 2.10.4). Following 8 days from addition of Ad vector 
to the cells, the plate was examined for the presence of plaques. The following 
calculations were then performed to obtain the titer of the purified Ad vector 
(Alba et al. 2012).  
Proportionate distance	 = 	 % positive above 50	% -50	%
% positive above 50	% -	% positive below 50	%	
	
Log infectivity dose ID
50
=	Log dilution above 50	% + Proportionate distance × -1 
 
Tissue culture TC	ID50	(per mL) = 1ID50  × Dilution factor (10)  
83 
 
As one TCID50 is equal to 0.7 particle forming units (pfu) the TCID50 was multiplied 
by 0.7 to calculate the final titer in pfu/mL. An identical process was also 
completed in HeLa cells to ensure the Ad preparation was free from replication 
competent adenovirus. The Ad vectors overexpressing Cx43 and eGFP, AdCx43 and 
AdeGFP, used in the current study had a titer of 1.5 × 1010 and 1.1 × 1011 pfu/mL, 
respectively. 
2.10.8.2 Viral particle titration by micro-BCA  
A micro bicinchoninic acid (BCA)™ Protein Assay Kit (ThermoFisher Scientific) was 
used to determine the number of viral particles in the purified Ad vector 
preparation as per manufacturer’s instructions. This assay utilises the reduction 
of copper from its Cu2+ state to its Cu1+ form by protein. Chelation of one Cu1+ ion 
with two BCA molecules results in the formation of a purple-coloured product 
which can be quantified through its absorbance at 562 nm. The protein 
concentration has a linear relationship with absorbance and therefore a standard 
curve can be used to determine unknown concentrations of protein samples.  
Briefly, BSA standards ranging from 0-200 μg/mL were prepared in PBS and 150 μL 
added in duplicate to individual wells of a 96-well plate. Next, 1, 3 and 5 μL of 
the Ad vector were added in duplicate to wells of the plate and the total volume 
made up to 150 μL with PBS. The micro-BCA working reagent was prepared by 
mixing the micro-BCA reagent A (MA), B (MB) and C (MC) at a ratio of 25:24:1. 
Next, 150 μL of the working reagent was added to each well and incubated at 
37 ⁰C for 2 h and the absorbance at 562 nm measured on the Perkin Elmer 
Victor x3 plate reader.  
The protein concentrations were calculated by subtracting the average blank 
absorbance value and applying to the equation of the linear line of best fit created 
from the standards. The concentrations were then corrected for the volume of 
virus used. As 1 μg of protein is equal to 4 × 109 vp (Alba et al. 2012) the corrected 
protein concentration in μg/mL was multiplied by 4 × 109 to calculate the final 
titre in vp/mL. The AdCx43 used in the current study had a titer of 2.8 × 1011 
vp/mL. 
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2.11 Viral vector addition to cells 
LV and Ad vectors, produced by methods described in sections 2.9 and 2.10 
respectively, were added to target cell types in complete media. Cells were 
seeded in the appropriate well format one day prior to viral vector addition. The 
viral vector required was added to the cells at a range of multiplicity of infection 
(MOI). The volume of viral vector required was calculated using the following 
equation: 
Volume of viral vector required (mL) per well =
no. of cells × MOI
Viral titre (PIU/mL or pfu/mL) 
 
The viral vector was diluted in complete media prior to the addition to the cells.  
2.12 Protein preparation for western immunoblotting 
On the day of cell lysate preparation, 1x complete protease inhibitor cocktail 
(Roche Diagnostics, West Sussex, UK), 1 % (v/v) Triton X-100, 250 mM mannitol, 
1 mM dithiothreitol (DTT), 1 mM Na3VO4 and 0.1 mM phenylmethylsulfonyl fluoride 
(PMSF) was added to protein lysis buffer. To prepare cell lysates, cells were placed 
on ice and washed once with ice cold PBS. Next, 200 μL of complete protein lysis 
buffer was added to each well and scraped with the end of a 1 mL syringe plunger. 
Lysates were then added to a 1.5 mL Eppendorf tube and rotated at 4 °C for at 
least 30 min to allow sufficient lysis of the cells. This was followed by 
centrifugation at 16,000 × g at 4 °C and the protein containing supernatants 
stored at -20 °C. 
2.12.1 Protein quantification 
Protein concentrations were determined using a Pierce™ BCA Protein Assay Kit 
(ThermoFisher Scientific), as per manufacturer’s instructions. This assay is based 
on the same principle as the micro-BCA (section 2.10.8.2). Briefly, standards were 
prepared by performing serial dilutions of the top BSA solution (2000 µg/mL) in 
protein lysis buffer. Final concentrations were as follows: 2000, 1500, 1000, 750, 
500, 250, 125, 25 and 0 µg/mL. Samples were prepared as described (section 
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2.12), thawed on ice and a 1:5 dilution in lysis buffer performed prior to 
quantification. In a 96 well plate, 25 µL of each standard or diluted sample were 
added to the plate in duplicate. The BCA working reagent was prepared by mixing 
reagent A and B in a ratio of 50:1 prior to the addition of 200 µL to each well. The 
plate was then incubated for 30 min at 37 °C protected from light and the 
absorbance at 562 nm measured on a Perkin Elmer Victor x3 plate reader. The 
concentration of protein was determined by applying the standard curve to the 
absorbance values of the unknown concentration of the protein samples and 
corrected for dilution.  
2.13 Western immunoblotting 
Protein samples were separated by polyacrylamide gel electrophoresis (PAGE). 
This method allows proteins to be separated according to size and charge, 
whereby smaller proteins travel further the through the gel (Mahmood and Yang 
2012). TBS contained 0.1 % (v/v) Tween 20 (TBS-T).  
Depending on protein concentration, as determined by BCA assay (section 2.12.1), 
9-15 µg of each sample was prepared for PAGE. All samples were corrected to the 
same volume using lysis buffer and the appropriate volume of NuPAGE® LDS sample 
buffer (ThermoFisher Scientific) added to produce a final concentration of 1x. 
Samples were mixed by vortex and denatured at 95 °C for 5 min using a thermal 
cycler. Meanwhile NuPAGE® MES SDS running buffer (x20) (ThermoFisher Scientific) 
was prepared by adding 50 mL to 950 mL dH2O and added to the gel tank.  
Following denaturing, samples were placed on ice to cool before loading into wells 
of 4-12 % Bis-Tris precast polyacrylamide gel (ThermoFisher Scientific). A full 
range rainbow ladder (GE Healthcare Life Sciences, Buckinghamshire, UK) was also 
added to a well to allow the size of proteins to be identified. A current of 150-
200V was then passed through the gel for approximately one hour to separate the 
proteins.  
Prior to transfer of protein to a 0.2 µm nitrocellulose membrane (GE Healthcare 
Life Sciences, UK), the membrane was soaked in dH2O for 5 min to permeabilise 
the membrane. The membrane and four sheets of filter paper were then soaked 
in transfer buffer 10 min prior to transfer. The gel was removed from its cassette 
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and placed in transfer buffer to prevent drying out. A sponge was placed on the 
black (negative) side of the transfer tank cassette, followed by two filter sheets 
of paper, the gel then the membrane. Another two filter papers were placed on 
top and pressure applied to the stack rolled to remove any air bubbles. Finally a 
sponge was positioned on top, the cassette closed and moved into the transfer 
tank. Transfer was performed at 100 V for 1 hr 30 min at 4 °C. 
Following transfer, the membrane was washed once in PBS for 5 min then blocked 
in blocking buffer (TBS-T:SEA BLOCK Blocking buffer [ThermoFisher Scientific]) at 
a ratio of 1:1) to prevent non-specific binding of antibodies. The primary antibody 
was then made up in blocking buffer at the dilution indicated in Table 2.7. 
Antibodies for GAPDH or β-tubulin were used as a loading control. Two antibodies, 
could be incubated simultaneously providing the antibodies were raised in 
different species. The antibody mixtures were applied to the membrane and 
incubated at 4 °C overnight on a shaker.  
The following day, the primary antibody was removed and four 15 min washes in 
TBS-T performed. To detect antibody binding, membranes were then incubated 
for 1 hr at room temperature on a shaker with a 1:15,000 dilution of the IRDye® 
680RD Goat anti-Mouse IgG (H + L) secondary antibody (LI-COR Biosciences, 
Cambridge, UK) and Alexa Fluro® 790 Goat anti-Rabbit IgG secondary antibody 
(ThermoFisher Scientific) in blocking buffer. This step and all preceding steps 
were protected from light. The membrane was then washed three times in TBS-T 
for 10 min per wash followed by a 10 min wash in PBS. The membrane was then 
imaged on the Odyssey® CLx Imaging System (LI-COR Biosciences) using the 
appropriate channel and quantified using Image Studio Lite v5 Software. 
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 Table 2.7 Primary antibody details used in western immunoblotting 
 
 
 
 
 
 
Protein Host Species Antibody Clonality Concentration 
Molecular Weight 
(kDa) 
Dilution 
Company  
(clone number) 
Connexin 43 Rabbit Polyclonal 0.8  mg/mL 43 1: 5,000 Sigma-Aldrich 
GAPDH Rabbit Monoclonal - 37 1: 2,000 
Cell Signalling Technology 
(14C10) 
β-tubulin Mouse Monoclonal 2.4 mg/mL ~50 1: 5,000 Sigma-Aldrich (clone AA2) 
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2.14 Immunocytochemistry (ICC)   
To fix cells the media was removed and 3 washes in PBS performed. Cells were 
then incubated with 4 % (v/v) paraformaldehyde (PFA) for 15 min at room 
temperature. This was followed by 3 washes in PBS to remove PFA and cells were 
stored submersed in PBS at 4 °C until ICC performed.  
On the day of staining, cells underwent 3 x 5 min washes in PBS containing 0.1 % 
Tween 20 (PBS-T). Cells were then permeabilised by adding 0.1 % Triton X-100 in 
PBS and incubated for 10 min. This was followed by 3 x 5 min washes in PBS-T to 
remove the residual Triton X-100 prior to blocking in 10 or 20 % goat serum made 
up in PBS-T (see Table 2.8) for 1 h. The blocking buffer was then removed and 
primary antibodies diluted as appropriate (Table 2.8) in blocking buffer added to 
the cells. To control for non-specific antibody binding, some cells were incubated 
with rabbit IgG or mouse IgG (both from Vector Laboratories, Peterborough, UK) 
the same final concentration as the primary antibodies. Primary antibodies and 
IgGs were incubated overnight at 4 °C. The following day cells were washed in the 
same manner as above and incubated with an 1:500 dilution (in blocking buffer) 
of a Alexa Fluro® 488 Goat anti-Rabbit IgG or a Alexa Fluro® 555 Goat anti-Mouse 
IgG secondary antibody (both from ThermoFisher Scientific) for primary antibodies 
raised in rabbit and mouse, respectively. Secondary antibodies were incubated for 
1 hr protected from light. All steps from this point onwards were performed in the 
dark. Cells were then washed as described above prior to mounting on glass slides 
with ProLong® Gold Antifade Mountant with 4',6-diamidino-2-phenylindole (DAPI) 
(ThermoFisher Scientific) which counterstains nuclei. Slides were left to dry prior 
to imaging on the LSM 510 Meta laser scanning confocal microscope and the 
LSM510 software (Zeiss, Cambridge, UK). The Argon/2 (488), HeNe543 or Diode 
405-30 lasers were used to detect green, red and blue fluorescence respectively.
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Table 2.8 Primary antibodies used in immunocytochemistry. 
 
 
Protein 
Host 
Species 
Antibody 
Clonality 
Concentration 
(mg/mL) 
% goat serum in 
blocking buffer 
Dilution Company (clone number) 
Connexin 43 Rabbit Polyclonal 0.80  20 1:1000 Sigma-Aldrich 
αSMA Mouse Monoclonal 0.04 10 1:200 Sigma-Aldrich (IA4) 
DDR2 Rabbit Polyclonal 1.00 10 1:200 ThermoFisher Scientific 
FSP1 Rabbit Polyclonal 0.72 10 1:100 Abcam  
Vimentin Mouse Monoclonal 0.70 10 1:400 Sigma-Aldrich (LN-6) 
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2.15 Cardiac myocyte and fibroblast co-culture model 
RACFs were seeded at 5 × 104 cells/35 mm glass bottomed petri dish and cultured 
for 48 h to allow the cells to reach a confluent monolayer. Cells were then serum 
starved for 24 h prior to the addition of 1 × 104 CM rods. In experiments that 
involved the stimulation of RACFs with 10 ng/mL IL-1β, RACFs were serum starved 
for 24 h before stimulation. Cells were then washed once with sterile PBS prior to 
the addition of 1 × 104 CM rods. CMs were seeded at the same density on laminin 
coated plates. To coat plates, laminin from Engelbreth-Holm-Swarm murine 
sarcoma basement membrane (Sigma-Aldrich) was diluted in sterile PBS to 
4 μg/mL and 2 mL added to each plate. Plates were incubated at 37 ⁰C for at least 
1 h and washed once with sterile PBS before the addition of CMs to the plate. CMs 
for calcein dye transfer (section 2.15.1) and CM contraction experiments (section 
2.15.2) were added to RACF monolayers in phenol red, reduced serum DMEM/F-12 
whereas cells for CM AP measurements (section 2.15.3) were maintained in phenol 
red-free, reduced serum DMEM/F-12.  
2.15.1 Calcein dye transfer co-culture experiments 
In order to determine if GJ channels between CMs and RACFs were functional 
calcein dye transfer studies were performed. Calcein acetoxymethyl ester (AM) is 
a cell-permeant dye, which once inside cells is converted to green fluorescent 
calcein following hydrolysis by cytosolic esterases (Neri et al. 2001). The green 
fluorescent calcein is cell impermeable due to its lipid insolubility, therefore 
retained within live cells and can be transferred through functional GJs (Neri et 
al. 2001).  
Calcein AM (ThermoFisher scientific) was reconstituted in DMSO at 1 mg/mL and 
stored in aliquots at -20 ⁰C. Freshly isolated CMs (section 2.2.5) were loaded with 
5 µM calcein made up in media and incubated for 30 mins at 37 °C. CMs were then 
washed 3 times in PBS before the addition of 1 × 104 CM rods to each dish. Images 
were taken on the on the LSM 510 Meta laser scanning confocal microscope using 
the Argon/2 (488) laser, immediately and 20 h following CM addition, both 
focusing on the CM and RACF layer to detect the calcein location. The laser 
intensity was increased at the 20 h time point due to the calcein fluorescence 
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fading over time and to detect the transfer of calcein to the underlying RACF 
layer.   
2.15.2 Cardiac myocyte contraction measurement 
CM contraction measurements were recorded following 24 h of culture while cells 
were maintained at 5 % CO2, 37 ⁰C and in phenol red, reduced serum media for 
the duration of the recordings. A myopacer field stimulator (IonOptix, Dublin, 
Ireland) was used to pace the cells at 1 Hz and at 2 ms duration V pulses. The 
threshold voltage of each cell was determined by increasing the voltage by 1 V 
increments until the cell started to contract. The threshold value was noted and 
the CM paced at 30 % above the threshold for 1 min before images were taken at 
100 frames per second (fps) for 10 s using HCImage Live software. Typically, the 
contraction of 13 cells per condition was recorded. The individual images were 
then stacked to construct a video of CM contraction and analysed on Image J using 
a macro (kind gift from Dr. Francis Burton). This macro measures optical 
differences from a reference frame (typically frame 1) to determine the 
contraction duration (CD) at numerous points as described in Table 2.9 and Figure 
2-3. This indirect measure of contraction is plotted as the sum of absolute 
difference (SAD) against time.  
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Table 2.9 Definition of contraction parameters measure. 
 
Contraction parameter Description 
Up90 Time from 10 % contraction to 90 % contraction 
Dn90 Time from 10 % relaxation to 90 % relaxation 
CD10 Time from 10 % contraction to 90 % relaxation 
CD25 Time from 25 % contraction to 75 % relaxation 
CD50 Time from 50 % contraction to 50 % relaxation 
CD75 Time from 75 % contraction to 25 % relaxation 
CD90 Time from 90 % contraction to 10 % relaxation 
 
 
Figure 2-3 Visual representation of contraction parameters measured.  
Contraction transients measured using an image J macro based on optical differences from a 
reference image of the cell, where a greater sum of absolute difference depicts increased shortening. 
Parameters are indicated by red lines.  
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2.15.3 Cardiac myocyte action potential measurement 
AP recordings were taken from CMs that had been freshly isolated and from CMs 
that had been cultured for 24 h. Phenol red can produce fluorescence (Ettinger 
and Wittmann 2014) potentially generating artefacts in the AP traces so all 
recordings were performed in reduced serum media absent of phenol red. 
FluoVolt™ membrane potential kit (ThermoFisher Scientific) was used to detect 
changes in the CM membrane potential. To load cells, media was replaced with a 
1:6000 dilution of FluoVolt™ in media. Cells were then incubated for 25 min at 5 % 
CO2 and 37 ⁰C prior to the replacement of fresh media. Loading of the cells in 
each plate was staggered so that the recordings were taken soon after loading was 
complete. AP measurements were performed at 37 °C within a darkened room. 
Similar to contraction experiments, cells were paced at 1 Hz and at 2 ms duration 
40 V pulses using the IonOptix field stimulator. Cells were allowed to acclimatise 
for 5 min prior to the first recording. Next, cells were chosen at random and a 
shutter positioned around an individual cell using HCImage Live software to 
restrict the area of recording and reduce noise in the trace. The white light was 
then switched off and 470 nm light used to excite the FluoVolt™ within the CMs. 
Changes in membrane potential detected by CellOPTIQ software (Clyde 
Biosciences, Lanarkshire, UK) over a 10 s period amplified by two photomultipliers 
set at 550. 
APs were analysed using the CellOPTIQ software, where APs were averaged and 
the average TRise (time taken from 10-90 % depolarisation), APD20, APD50 and 
APD80 values recorded for each cell.    
2.16 In vivo intramyocardial injection 
All animal procedures were performed in accordance with the Animals Scientific 
Procedures Act (1986). Male Wistar rats (Envigo, Alconbury, UK) were housed in a 
controlled environment including a 12 h light/dark cycle, ambient temperature 
and a standard chow diet. Animals were allowed to acclimatise for at least 1 week 
prior to surgery. 
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2.16.1 Fibroblast and eGFP adenoviral vector preparation 
In preparation for RACF injection into the heart, cells were plated at 6 × 105 
cells/100 mm dish. The following day cells were transduced with a LVeGFP at an 
MOI of 25. The media was replaced the following day to allow cells to recover. 
The following day, RACFs were then removed from the dish by incubation with 
trypsin-EDTA at 37 °C for 5 min, counted and resuspended in the appropriate 
volume so that 1 × 106 cells were present in 60 µL PBS. For control animals, 60 µL 
PBS containing 5 × 108 pfu of AdeGFP was prepared. Both cells and AdeGFP were 
placed on ice until injection was performed (section 2.16.2).  
2.16.2 Surgical procedure of intramyocardial injection 
All surgery was performed under an aseptic technique. Animals (280-390 g) were 
placed in an induction box filled with 5 % (v/v) isofluorane and 2 L/min oxygen to 
anaesthetise. Once anaesthetised, animals were shaven on the left side of the 
chest and the area sterilised using betadine. Animals were then intubated and 
artificially ventilated at a tidal volume of 1.5 mL and a respiratory rate of 
60 strokes/min with 3 % (v/v) isofluorane and 0.2 L/min oxygen. Animals were 
placed on their right side on a sterile drape which was positioned on top of a 
heated mat. The left front leg was then taped over the head to expose the left 
side of the chest. To ensure all unshaven hair was separated from the surgical 
area a small drape with an area cut out was placed over the animal followed by 
an 10 cm x 12 cm 3M™ Tegaderm™ transparent film dressing (Nu-Care products 
Ltd, Bedfordshire, UK). An incision from the xiphisternum across the left side of 
the chest perpendicular to the sternum was made and a left thoracotomy 
performed in the fourth intercostal space. The ribs were retracted to allow access 
to the chest cavity and the left lung collapsed by the insertion of a small 
non-woven swab. The heart was then removed from the pericardium and two 30 µL 
injections of either the cell or AdeGFP solution (prepared as detailed in section 
2.16.1) performed above and below the left anterior descending artery using a BD 
Micro-Fine™ 0.5 mL insulin syringe with 29 gauge needle (Nu-Care products Ltd). 
The lung was then re-inflated and the chest rapidly closed using a 3-0 Ethicon 
Monocryl® suture ensuring all air was expelled from the chest cavity. The muscle 
layers were then sutured using 3-0 Ethicon Ethibond Excel® suture, followed by a 
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continuous internal stitching with a 2-0 Polysorb™ suture. Finally, three external 
stitches were applied with the same suture used for the continuous stitching.  
Following chest closure the isofluorane was progressively decreased throughout 
the remaining surgery to speed up the recovery on completion of surgery. Animals 
were given post-operative analgesia of 60 μg buprenorphine and 1.5 mg carprofen 
by intraperitoneal injections and monitored throughout recovery (Home Office 
licence number: 60/4286). 
2.17 Ex vivo heart optical mapping  
2.17.1 Experimental set up  
The isolated retrograde-perfused Langendorff heart in a horizontal orientation 
was used for this study. Tyrodes was heated to 37 ⁰C and bubbled with Carbogen 
(5 % CO2 and 95 % O2) for at least 20 min before the addition of 1.8 mM CaCl. The 
myosin II inhibitor, blebistatin (Enzo, Exeter, UK) reconstituted in DMSO was then 
added to a stock of Tyrodes solution to produce a final concentration of 10 µM. 
Blebistatin was used to inhibit excitation contraction coupling, hence preventing 
movement artefacts in the AP trace recordings. A glass coverslip was typically 
placed over the surface of the heart as an extra preventative movement measure. 
ECG electrodes were positioned at both sides of the apex to provide a marker of 
electrical activity and a pacing electrode was positioned on the epicardial surface 
the heart to allow pacing protocols to be conducted. All experiments were 
performed in a darkened room and excess Tyrodes solution was aspirated by a 
vacuum positioned next to the heart mould. 
Hearts were loaded with the voltage sensitive dye, RH-237 (Biotium, Fremont, 
US), for AP recordings. To excite eGFP and RH-237 simultaneously, two 
light-emitting diodes (LEDs) were fitted with a 470/20 nm filter and focussed on 
the surface of the left ventricle. Since the emission spectrums of eGFP and 
RH-237, have little overlap, with eGFP typically having an emission peak around 
510 nm (Spiess et al. 2005) and RH-237 emitting light in the red part of the 
spectrum, wavelengths can be separated using a dichroic mirror. Following 
excitation, fluorescence was collected by a camera lens and directed at a long 
96 
pass dichroic mirror at 593 nm, enabling the longer wavelengths to travel through 
and the shorter wavelengths to be reflected. The longer wavelengths were then 
passed through an >715 nm emission filter to a MiCAM complementary metal-
oxide-semiconductor (CMOS) camera (SciMedia Ltd., California, USA) and the 
shorter wavelengths passed through a 520/28 nm emission filter to another 
identical CMOS camera (Figure 2-4). CMOS cameras were set up to image an array 
of 100 × 100 pixels.  
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Figure 2-4 Experimental set up for ex vivo heart optical mapping. 
(A) An illustration and (B) image of experimental set up showing the main components, labelled 1-5 
in B. 1 = LEDs emitting 470/20 nm light, 2 = lense, 3 = box holding the dichroic mirror, 4 = CMOS 
camera detecting the eGFP signal and 5 = CMOS camera detecting voltage signals. 
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2.17.2 Removal of heart under terminal anaesthesia  
One week following surgery (section 2.16.2), animals were anaesthetised in an 
induction box filled with 5 % (v/v) isofluorane and 2 L/min oxygen. The animal 
was then moved to a facemask supplying the same gas mixture and front legs 
taped to the mask to allow access to the chest. The hair from the leg was removed 
and the skin pulled to one side so an incision could be made without damaging the 
underlying femoral vein. The femoral vein was visualised under a light microscope 
and pressure applied to the upper part of the vein to stop flow for a few seconds 
before the insertion of a slightly bent 29 gauge needle, with bevel side facing up. 
Next, the pressure was removed and 350 µL of 1000 I.U/mL heparin sodium 
(Wockhardt, Wrexham, UK) was injected. The needle was then removed and 
pressure placed on the site of injection. The heparin was allowed to reach the 
heart by waiting approximately 30 s and the heart rapidly excised from the thorax 
and place in ice cold heparinised Tyrodes solution. The heart was then quickly 
transferred to the experimental room where it was rapidly retrograde perfused 
with Tyrodes solution (section 2.17.3). 
2.17.3 Action potential measurements in the intact heart 
Aortas were isolated by dissection and cannulated using a 2 mm diameter catheter 
and 4-0 silk braided suture (Pearsalls). This allowed for retrograde perfusion with 
Tyrodes solution at an initial flow rate of 10 mL/min. Following cannulation, 
hearts were placed horizontally in a mould suitable for a rat heart. The flow rate 
was altered to maintain a pressure of 80-120 mmHg as measured by a pressure 
monitor. If the pressure became too high an outlet was created by inserting small 
piece of tubing through an incision in the left atrium to the left ventricle. The 
heart was orientated so the eGFP signal could be observed. Tyrodes solution 
containing blebistatin was then supplied to the heart to stop movement. Next, 
50 µL RH-237 (Biotium, California, US), reconstituted in DMSO at 1 mg/mL, was 
administered very slowly through a port proximal to the catheter. The pressure 
was closely monitored during administration. An AP recording was taken at sinus 
rhythm before pacing.  
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The pacing threshold for each heart was determined by slowly increasing the 
voltage until the heart could be paced at a cycle length (CL) of 200 ms (5 Hz). 
Double the threshold value was chosen for pacing, unless it above 1 V, where only 
an additional 1 V was applied. A dynamic pacing and an extra stimulus (S1S2) 
pacing protocol was performed in each preparation. In dynamic pacing the heart 
rate was progressively increased by decreasing the CL. Initially, the CL was 200 ms 
for 300 stimuli which was then decreased by 20 ms every 300 stimuli until 100 ms 
was reached. Next, the CL was reduced by 10 ms every 300 stimuli until the heart 
could no longer be paced. The S1S2 protocol consisted of pacing at a constant CL 
of 200 ms (S1) for 200 stimuli followed by a single premature stimulus (S2), 
consequently decreasing the S1-S2 interval. The extra stimulus was progressively 
reduced below 200 ms until the ERP of each heart was noted.  
A ten second AP recording was captured at each CL in the dynamic pacing protocol 
and at every S1S2 combination using the OPTIQ software (developed by Dr Francis 
Burton at the University of Glasgow, Glasgow UK). OPTIQ software was also used 
to perform data analysis whereby areas of the heart were selected and an average 
AP trace created for each area. To prepare the data for analysis, a Gaussian spatial 
filter and temporal filters were applied. In dynamic pacing, typically six 
consecutive APs were analysed for each CL. One S1 AP and the S2 AP were analysed 
from the traces obtained from the S1S2 pacing. The 10-90 % rise time and APD80 
were examined in both protocols.   
2.18 Histology 
2.18.1 Tissue processing  
Hearts were harvested one week following surgery or after the OM experiments 
were complete and washed once in PBS. The section(s) containing the injection 
site was noted at this time and cut transversely into 4 pieces using a scalpel. Heart 
sections were fixed in 4 % PFA (v/v) for 48 h at 4 °C, washed twice in PBS and 
stored in 70 % ethanol until processing. 
Heart sections were processed on a Shandon Excelsior tissue processor 
(ThermoFisher Scientific) which slowly dehydrates the tissues prior to the addition 
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of paraffin wax using the solution sequence detailed (Table 2.10). The Shandon 
Histocenter 3 was used to embed heart tissue in paraffin wax in transverse 
orientation. Heart sections were then cut at 5 µm using a microtome and baked 
on to glass slides by overnight incubation at 60 °C. The paraffin block containing 
the injection site was continually cut with minimal sections discarded to maximise 
the likelihood of detecting the eGFP signal.   
2.18.2 Immunohistochemistry 
Prior to staining, tissue sections were deparaffinised and rehydrated by adding 
them to a sequence of solutions, for 5 min each (Table 2.11). To perform antigen 
retrieval, 10 mM sodium citrate was heated until boiling and the slides added. The 
slides were then further heated, covered with cling film at medium to low heat 
for 15 min. Slides were then left to cool at room temperature for 30 min to allow 
the antigens to fold correctly. The slides were then put under running tap water 
for 5 min to fully cool. Slides were then transferred to TBS for 3 x 5 min washes. 
To prevent non-specific binding of primary antibodies, sections were incubated 
with 15 % (v/v) goat serum in TBS-T (0.05 % [v/v] Tween 20 – used throughout 
protocol) and incubated for 30 min in a humidified chamber. Primary antibodies 
were made up in 10 % goat serum in TBS-T at the dilution indicated (Table 2.12). 
Normal rabbit and mouse IgG were used at the same final concentration as the 
primary antibodies to provide an antibody control. Primary antibodies and IgG 
controls were incubated overnight at 4 °C in a humidified chamber. The following 
day, slides were washed 3 x 5 min in TBS before addition of secondary antibodies. 
Alexa Fluor® 488 Goat anti-Rabbit and Alexa Fluor® 555 Goat anti-Mouse were 
diluted 1:250 in TBS-T and incubated with heart sections for 3 h at room 
temperature protected from light. All subsequent steps were performed at 
minimal light exposure to prevent photo-bleaching of fluorophores. Following a 
further 3 x 5 min washes in TBS, 0.1 % (v/v) Sudan Black B prepared in 70 % ethanol 
was added to the sections to remove lipofuscin-mediated autofluorescence. Sudan 
Black B was incubated for 10 min in a humidified chamber prior to 3 x 5 min washes 
in TBS. Nuclei were then stained using 100 µg/mL DAPI (Sigma-Aldrich) in TBS for 
10 min. Finally, slides were mounted on glass coverslips using ProLong® Gold 
Antifade Mountant DAPI before being imaged on the LSM 510 Meta laser scanning 
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confocal microscope using the Argon/2 (488), HeNe543 or Diode 405-30 lasers to 
detect green, red and blue fluorescence respectively.   
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Table 2.10 Solution sequence for tissue embedding in paraffin wax 
 
Solution Incubation time (min) 
70 % Ethanol 30 
95 % Ethanol 30 
100 % Ethanol 30 
100 % Ethanol 30 
100 % Ethanol 45 
100 % Ethanol 45 
100 % Ethanol 60 
Xylene 30 
Xylene 30 
Xylene 30 
Paraffin wax 30 
Paraffin wax 45 
Paraffin wax 45 
 
Table 2.11 Solution sequence to deparaffinise and rehydrate tissue sections for 
immunohistochemistry 
 
Solution 
Histoclear 
Histoclear 
100 % Ethanol 
100 % Ethanol 
90 % Ethanol 
70 % Ethanol 
50 % Ethanol 
Running tap water 
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Table 2.12 Primary antibodies used in immunohistochemistry  
 
Protein Host Species Antibody Clonality Concentration Dilution Company (clone number) 
eGFP Rabbit Polyclonal 0.5 mg/mL 1:1,250 Abcam 
Cardiac troponin I Mouse Monoclonal 2.0 mg/mL 1:4,000 Abcam (4C2) 
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2.19 Statistical analysis 
Data from qRT-PCR experiments is represented as RQ ± rqmax, where rqmax is 
indicative of the standard error of the mean (SEM) and is calculated from the ΔCt 
value from each experiment. All other data is represented as mean ± SEM. In 
experiments where two conditions are present, an unpaired, two-tailed Student’s 
t-test was performed. A repeated measures one-way analysis of variance (ANOVA) 
with a Dunnett’s or Tukey’s multiple comparisons test was performed on qRT-PCR 
data where there were three or more conditions. For single CM data, statistical 
analysis was performed on the mean values for each heart and a one-way ANOVA 
with Tukey’s multiple comparisons test used in experiments containing three or 
more conditions. No statistical analysis was completed on whole heart 
experiments due to small n-numbers. All statistical analysis was performed using 
Graphpad Prism 4 software (GraphPad Software Inc., California, USA) and a P value 
<0.05 was considered statistically significant.  
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Chapter 3 Generation of viral vectors to 
modulate connexin 43 expression in cardiac 
fibroblasts for use in vitro and in vivo   
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3.1 Introduction 
Viral vectors have been extensively used to modulate genes both in vitro and in 
vivo. Due to the pathogenic nature of many WT viruses, parts of the viral genome 
have been deleted, consequently rendering them replication-defective and of low 
toxicity (Bouard et al. 2009). The main viral vectors used in research studies 
include LV, Ad and adeno-associated viral (AAV) vectors, each of which have 
particular features which are suited to different research questions. Both LV and 
Ad vectors have been used to overexpress Cx43 (Fernandes et al. 2009;Kizana et 
al. 2005;Reinecke et al. 2004;Zlochiver et al. 2008). 
LV vectors are a subtype of retroviral vectors, modified from the human 
immunodeficiency virus 1 (HIV-1). LV vectors have many desirable characteristics 
as a gene transfer vector (TV) including the ability to transduce both dividing and 
non-dividing cells as well as the capability to integrate into the target cell genome 
resulting in the permanent modification and presence of the introduced DNA in 
descendant cells (Sakuma et al. 2012). Additionally, transduction into target cells 
does not result in viral protein expression and allows for complex DNA sequences, 
for instance polycistronic sequences, to be expressed (Sakuma et al. 2012).  
Retroviral vectors are characterised by their use of RT and integrase to convert 
viral single stranded RNA into double stranded DNA once inside the host cell and 
prior to integration into host DNA. HIV-1 has nine viral genes amounting to 
approximately 9 Kb (Sakuma et al. 2012). These genes include: gag, pol, env, tat, 
rev and genes which encode the accessory proteins; Vif, Vpr, Vpu and Nef. Gag 
and pol encode both the core viral proteins and enzymes necessary for viral 
replication (RT, integrase and protease) respectively (Ramezani and Hawley 
2002). The env gene encodes gp160 which is subsequently cleaved into the 
proteins gp120 and gp41 prior to expression on the outer viral membrane. Gp120 
and gp41 bind to the CD4 receptor, mainly present on immune cells, initiating the 
fusion of the viral membrane with the cell membrane, allowing entry of the viral 
genome into the cell cytoplasm (Sakuma et al. 2012). Next, viral RT mediates the 
synthesis of double stranded DNA, which is transported to the nucleus and 
integrated into the host DNA by integrase (Nisole and Saib 2004;Sakuma et al. 
2012). LTRs are positioned at either end of the viral genome and are important 
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for integration and transcription (Ramezani and Hawley 2002;Sakuma et al. 2012). 
The regulatory genes, tat and rev, encode the proteins transactivator of 
transcription (Tat) and regulator of expression of virion proteins (Rev) 
respectively. Tat binds to the trans-activation response (TAR) element to regulate 
viral gene transcription (Feng and Holland 1988), whereas Rev associates with the 
Rev response element (RRE) to allow transportation of viral transcripts to the 
cytoplasm (Malim et al. 1989).  
As an alternative to the gp120 and gp41 expression on the outer membrane of 
HIV-1, most current LV vectors display the VSV-G increasing tropism for a broad 
range of cell types (Sakuma et al. 2012). The exact receptor for VSV-G remains 
elusive; however there is evidence to suggest that the ubiquitous membrane lipid, 
phosphatidylserine, assists in membrane fusion (Carneiro et al. 2002;Schlegel et 
al. 1983). Conversely, other studies have disputed the role of phosphatidylserine, 
by demonstrating a lack of correlation between the levels of phosphatidylserine 
within the plasma membrane and VSV (which expresses VSV-G as its envelope 
protein) infection and binding (Coil and Miller 2004).    
Replication-defective and non-pathogenic LV vectors are produced by dividing the 
LV genome over three (1st and 2nd generation) or four (3rd generation) plasmids. 
First generation LV vectors consist of a packaging plasmid; which includes the gag, 
pol and accessory protein genes, an env encoding plasmid; which commonly 
contains the VSV-G gene, and a TV. Within the TV, the transgene and cis-active 
sequences necessary for packaging, reverse transcription and integration (the 
packaging signal, 5’ and 3’LTRs and RRE) are present (Sakuma et al. 2012). Second 
generation LV vectors are very similar to first generation, however the accessory 
proteins are deleted, increasing the safety by only including four of the nine 
original HIV genes. Safety is then further enhanced in third generation LV vectors 
whereby the tat gene is removed and the rev gene is positioned on a separate 
plasmid; hence 4 plasmids are required (Sakuma et al. 2012).  
Dissimilar to lentiviruses, the Ad genome exist as a stable extra chromosomal 
episome within the host nucleus (Thomas et al. 2003). Due to the lack of 
integration into host DNA, transient expression occurs which may be advantageous 
in some cases, such as in the treatment of the saphenous vein prior to coronary 
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artery bypass grafting (George et al. 2011). The Ad genome consists of linear 
double stranded DNA, which is packaged into a viral capsid consisting of three 
main proteins: the fiber, penton base and hexon (Reddy and Nemerow 2014). First 
generation Ad vectors, derived from serotype 5 (Ad5) are the most common gene 
transfer vector (Wold and Toth 2013). Entry of Ad5 into cells is initiated by binding 
of the fiber protein to the coxsackievirus and adenovirus receptor (Meier and 
Greber 2004). Consequently, the virion is endocytosed by the cell and transported 
within endosomal compartments (Meier and Greber 2004). The adenovirus 
however quickly escapes from the endosome and travels into the nucleus where 
gene transcription and replication can occur (Rauschhuber et al. 2012).     
Replication-defective vectors are produced by deleting the E1 gene of the Ad 
genome, consequently allowing a relatively small cloning capacity of around 5 Kb 
(Graham et al. 1977). In order to enhance transgene capacity, to approximately 
8 Kb, Ad vectors with additional deletions in the E3 gene were developed 
(Danthinne and Imperiale 2000). Further deletions in the E2 and/or E4 genes have 
resulted in second generation Ad vectors (Danthinne and Imperiale 2000). 
Additionally, third generation vectors, also known as helper-dependent Ad (HDAd) 
vectors, have been developed whereby all of the viral coding sequences have been 
deleted except the inverted terminal repeats and the viral packaging signal 
(Rosewell et al. 2011). These vectors rely on co-transfection with a helper virus 
in the packaging cell line to promote replication and packaging of the HDAd 
genome which makes purification technically challenging (Rosewell et al. 2011). 
In comparison to first and second generation Ad vectors, HDAd vectors have been 
demonstrated to reduce the inflammatory response in vivo, increase the longevity 
of transgene expression (Maione et al. 2001) and create a larger cloning capacity; 
up to 36 Kb (Rauschhuber et al. 2012). First-generation E1/E3-deleted E4+ Ad 
vectors (AdE4+) have been reported to increase Cx40 and decrease Cx43 
expression in endothelial cells promoting their survival (Zhang et al. 2005). Hence 
some caution may be required when using Ad vectors to modulate connexin 
proteins. 
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In this chapter a second generation LV vector utilising an artificial αSMA promoter 
to drive expression of the gene of interest was sought. The artificial αSMA 
promoter hybrid selected, was developed by Hirschfeld et al. (2009), who 
reported it drove eGFP expression specifically in αSMA expressing cells (Hirschfeld 
et al. 2009). This promoter consisted of three components; a 720 bp regulatory 
sequence of the rat SMA gene, a 754 bp intron 1 enhancer sequence of the chicken 
β actin gene and a 93 bp intron/exon junction of the rabbit β globin gene (Figure 
3-1). The 720 bp regulatory sequence was found to provide additional flanking 
sequences to drive expression specifically in αSMA expressing cells in comparison 
to shorter regulatory fragments that contained components which permitted 
expression in a non-SMC specific fashion. Additionally, as the first intron of the 
SMA gene, containing a conserved CArG box, has been shown to be important in 
expression of αSMA in SMCs and MFs (Mack and Owens 1999;Tomasek et al. 2005), 
an enhancer sequence containing this CArG box was included. Finally, an 
intron/exon junction was incorporated to ensure intron termination (Hirschfeld et 
al. 2009). RACFs utilised in the current study have been shown to express high 
levels of αSMA (section 4.3.1) and therefore the artificial promoter would be 
suitable in these cells.   
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3.2 Aims 
• Design and produce viral gene transfer vectors which can overexpress Cx43 
in RACFs and are suitable for in vitro investigation and in situ imaging.  
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3.3 Results 
A vector which allowed the expression of Cx43 as well as a reporter which was 
nuclear localised, both under the control of the artificial αSMA promoter hybrid, 
was designed with the aim of facilitating optimal in situ imaging of transduced 
RACFs. An internal ribosome entry site (IRES) allowing the attachment of 
ribosomes to begin transcription of a reporter protein separately from the 
connexin (Martinez-Salas 1999) was incorporated into the vector. Nuclear 
localisation of the reporter may provide a discrete structure for identification of 
RACFs in the myocardium using whole heart imaging, hence enhancing the 
resolution. The insert, αSMA_eGFPNLS (Figure 3-2A), was designed to offer 
flexibility in cloning prior to the synthesis by Invitrogen GeneArt Gene Synthesis 
(ThermoFisher Scientific). Unique restriction endonuclease sites (Figure 3-2B), 
were positioned throughout the insert to allow the αSMA promoter to be 
exchanged for the cytomegalovirus (CMV) promoter, connexins to be cloned into 
the MCS and the nuclear localised high energy, readily detectible emitter, eGFP, 
to be exchanged for a far-red fluorescent protein, such as mCherry, which is more 
suited to deep tissue imaging (Deliolanis et al. 2008).  
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Figure 3-1 Components sought in an artificial αSMA promoter hybrid. 
An artificial promoter hybrid consisting of the regulatory sequence of the rat αSMA gene, the intron 
1 enhancer sequence of the chicken β actin gene and the intron/exon junction of the rabbit β globin 
gene, designed by Hirschfeld et al. (2009).  
 
Figure 3-2 Schematic of designed insert, αSMA_eGFPNLS, and pLenti-promoter plasmid. 
(A) αSMA _eGFPNLS (3081 bp) was designed with flexible enzyme restriction sites to allow the 
promoter to be altered, the gene of interest to be subcloned into the multiple cloning site (MCS) and 
the nuclear localised eGFP to be changed to a far-red emitter. (B) Plasmid map of pLenti-promoter. 
The SpeI and NotI restriction sites (red boxes) can be used to clone the αSMA_eGFPNLS insert into 
the commercial pLenti-promoter plasmid. IRES; internal ribosome entry site, NLS; nuclear 
localisation signal, PolyA; polyadenylation signal. 
  
Regulatory sequence 
720bps 
Rat SMA gene
Intron 1 enhancer sequence 
754 bps 
Chicken β actin gene
Intron/Exon junction
93bp
Rabbit β globin gene
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3.3.1 Lentiviral and adenoviral transduction into RACFs 
Initially, the ability of LV and Ad vectors to transduce RACFs was assessed. RACFs 
were transduced with LV or Ad vectors overexpressing eGFP (LVeGFP and AdeGFP 
respectively) at varying MOI and imaged following 72 or 48 h transduction, 
respectively. A dose dependent increase in eGFP expression with little toxicity 
was observed when cells were transduced with LVeGFP at a MOI of 3, 6 or 12 
(Figure 3-3). The majority of cells had detectable eGFP expression at a MOI of 12, 
suggesting an optimal concentration for use in further LV studies. High expression 
of eGFP was observed when cells were transduced with AdeGFP at MOIs of 100 or 
250, however toxicity was observed in cultures transduced with an MOI of greater 
than 500 (Figure 3-4).  
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Figure 3-3 Representative images of RACFs transduced with LVeGFP. 
LVeGFP was added to RACF cultures at a multiplicity of infection (MOI) of 3, 6 or 12 and cells imaged 
72 h thereafter (n=1). Cells maintained in culture media were used as a control. The eGFP signal 
and an overlay on to the bright field image are shown. Scale bar represents 100 µm. 
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Figure 3-4 Representative images of RACFs transduced with different concentrations of 
AdeGFP. 
AdeGFP was added to RACFs cultures at a multiplicity of infection (MOI) of 100, 200, 500, 750 and 
1000. Cells were imaged 96 h thereafter (n=1). Cells maintained in culture media were used as a 
control. The eGFP signal and an overlay on to the bright field image are shown. Scale bar represents 
100 µm.  
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3.3.2 Cloning of αSMA_eGFPNLS into a lentiviral shuttle plasmid 
Prior to ligation of the αSMA_eGFPNLS insert (Figure 3-2A) into pLenti-promoter, 
the intact insert, was subjected to endonuclease restriction digestion analysis in 
its parental shuttle vector to ensure the presence of functional restriction sites. 
All unique sites including; SpeI, SbfI, BspEI, Xbal, BsiWI, BstZ17I, MluI, FseI (Figure 
3-5A) and NotI (Figure 3-5B), were confirmed by the presence of a DNA fragment 
upon agarose gel electrophoresis which migrated with an apparent molecular mass 
of 5,500 bp. SbfI and FseI only partially digested the plasmid, demonstrated by 
two further bands which resembled uncut (UC) plasmid. The αSMA_eGFPNLS 
(3081 bp) fragment was excised from the shuttle vector via dual SpeI and NotI 
restriction endonuclease digestion (DC) as shown by the presence of a DNA 
fragment migrating with an apparent molecular mass of approximately 3000 bp 
(Figure 3-5B).  
The functionality of αSMA_eGFPNLS was assessed by transfection of the shuttle 
vector (pαSMA_eGFPNLS) into RACFs using the transfection reagent, Xfect. Cells 
were also transfected with a LV plasmid which overexpressed eGFP under the 
control of the SFFV promoter as a positive control. Toxicity was apparent in cells 
treated with the Xfect reagent alone in comparison to untransfected cells (Figure 
3-5C). The transfection efficacy was also very low however, eGFP positive nuclei 
in cells transfected with pαSMA_eGFPNLS were evident in comparison to 
cytoplasmic eGFP expression in pSFFV_eGFP transfected cells (Figure 3-5C). 
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Figure 3-5 Diagnostic digests and transfection of the pαSMA_eGFPNLS into RACFs. 
(A) Ethidium bromide agarose gel showing the presence of a DNA band around 5,500 bp following endonuclease restriction digests of the plasmid containing the 
αSMA_eGFPNLS insert with SpeI, SbfI, BspEI, Xbal, BsiWI, BstZ17I, MluI, FseI and (B) NotI. Separation of the αSMA_eGFPNLS insert (3081 bp – red box) from the 
plasmid was observed following a double SpeI and NotI restriction digest. (C) RACFs were transfected with 2µg pSFFV_eGFP or pαSMA_eGFPNLS using the transfected 
reagent, Xfect (n=2). Cells which were untransfected or received Xfect alone were used as controls. Images were taken 48 hr subsequent to transfection. Specific cells 
have been expanded for illustrative purposes. 1Kb; 1 Kb ladder, UC; uncut, DC; double cut with SpeI and NotI. 
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Next, the αSMA_eGFPNLS insert was excised from the shuttle vector and the 
pLenti-promoter plasmid linearised by dual SpeI and NotI restriction endonuclease 
digestion. Following gel extraction of the DNA, separation by agarose gel 
electrophoresis was performed to confirm the expected DNA fragment sizes of 
3,081 and 7344 bp (αSMA_eGFPNLS and pLenti-promoter respectively; Figure 3-6). 
However, on assessment of the purified αSMA_eGFPNLS insert via agarose gel 
electrophoresis, two faint extra DNA bands were also apparent, suggesting 
contaminating DNA was present. Unfortunately, numerous attempts to eliminate 
this contaminating DNA and to clone the αSMA_eGFPNLS insert into the pLenti-
promoter plasmid were unsuccessful.   
An alternative strategy to generate a vector suitable for LV production was 
attempted via cloning of the αSMA_eGFPNLS insert into an alternative LV shuttle 
vector, pLenti-III-promoterless (Figure 3-7A), using the same restriction 
endonuclease sites (SpeI and NotI) was investigated. However, contaminating DNA 
was again observed in the extracted DNA fragments (Figure 3-7B) and no colonies 
were formed following ligation. Blunt cloning of the insert into pLenti-III-
promoterless following Klenow treatment was also attempted without success.  
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Figure 3-6 Purification of the αSMA_eGFPNLS insert and linearised pLenti-promoter. 
Ethidium bromide agarose gel showing the DNA fragments following gel extraction of the 
αSMA_eGFPNLS insert (i) and the linearised pLenti-promoter (ii) after double SpeI and NotI digests. 
 
Figure 3-7 Purification of αSMA_eGFPNLS insert and linearised pLenti-III-promoterless. 
(A) Plasmid map of pLenti-III-promoterless containing SpeI and NotI restriction sites in the multiple 
cloning site (MCS) which are compatible with the αSMA_eGFPNLS insert. (B) Ethidium bromide 
agarose gel showing separation of DNA fragments following gel extraction of the αSMA_eGFPNLS 
insert (i) and the linearised pLenti-III-promoterless (ii) after double SpeI and NotI digestions. 1Kb; 1 
Kb ladder. 
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3.3.3 Cloning of αSMA_eGFPNLS into an adenoviral shuttle 
plasmid 
Due to the unsuccessful attempts to clone αSMA_eGFPNLS into a compatible LV 
plasmid, a cloning strategy was formulated to produce two Ad plasmids; one which 
would enable the expression of eGFPNLS under the control of the hybrid αSMA 
promoter and the other under the control of the CMV-immediate early (CMV-IE) 
promoter. For this the RAPAd® system shuttle vectors (Anderson et al. 2000), 
pVQ_K-NpA or pVQ_CMV_K-NpA (Figure 3-8Ai and ii respectively) were utilised. 
SpeI and NotI restriction endonuclease sites present in both vectors facilitated the 
insertion of full length αSMA_eGFPNLS sequence into the promoterless, pVQ_K-
NpA vector. Conversely, XbaI and NotI sites facilitated the DNA fragment 
downstream of the αSMA promoter (eGFPNLS) to be inserted into CMV-IE promoter 
driven, pVQ_CMV_K-NpA vector. 
Following double SpeI and NotI or XbaI and NotI restriction endonuclease digestion 
of the respective inserts and vectors and gel extraction of the fragments, agarose 
gel electrophoresis was performed to confirm the purity of the DNA prior to 
ligation (Figure 3-8B). Only one DNA band was observed in the eGFPNLS insert (Bii) 
and in the linearised pVQ_K-NpA (Biii) and pVQ_CMV_K-NpA (Biv) lanes. 
Conversely, there was an additional faint band with an apparent molecular mass 
of approximately 7,000 bp in the αSMA_eGFPNLS (Bi) lane. 
Next, ligation of αSMA_eGFPNLS: pVQ_K-NpA and eGFPNLS: pVQ_CMV_K-NpA 
(insert: vector) and transformation into E.coli was performed. Unfortunately, no 
colonies were detected from the αSMA_eGFPNLS: pVQ_K-NpA culture. However, 
screening of colonies produced in the eGFPNLS: pVQ_CMV_K-NpA culture 
demonstrated two positive colonies, as confirmed by a DNA fragment of 
approximately 1,500 bp following a double XbaI and NotI restriction endonuclease 
digestion (Figure 3-8C).  
In order to produce an adenoviral vector from this plasmid, first PacI was used to 
linearise both the pVQ_CMV_K-NpA containing the eGFPNLS insert and the RAPAd® 
Ad backbone vector. Next, cotransfection of these linearised vectors into HEK 293 
121 
 
cells was performed. However following 15 days of observation no CPE, which 
would indicate production of a recombinant Ad vector, had occurred.   
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Figure 3-8 Cloning of αSMA_eGFPNLS or eGFPNLS into pVQ_K-NpA or pVQ_CMV_K-NpA 
respectively. 
(A) Plasmid maps of pVQ_K-NpA and pVQ_CMV_K-NpA showing the endonuclease restriction sites 
compatible (underlined) to clone in the full αSMA_eGFPNLS insert or eGFPNLS without the αSMA 
promoter respectively. (B) Ethidium bromide agarose gel showing separation of the 
αSMA_eGFPNLS insert (i), eGFPNLS insert (ii) and the linearised pVQ_K-NpA (iii) and 
pVQ_CMV_K-NpA (iv) vectors following gel extraction and prior to ligation. (C) Gel showing 
separation of DNA fragments from a positive eGFPNLS: pVQ_CMV_K-NpA clone digested with XbaI 
or NotI alone or in combination. 1Kb; 1 Kb ladder, UC; uncut, DC; double cut with XbaI and NotI. 
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3.3.4 Production of an adenoviral vector overexpressing Cx43 
Following many issues with the development of a LV and Ad vectors expressing the 
αSMA_eGFPNLS insert, a simple Ad vector overexpressing Cx43 was produced. This 
involved the excision of the rat Cx43 sequence (1149 bp) which was already cloned 
into pcDNA3.1 using KpnI and NotI and subsequent ligation into pShuttleCMV. All 
colonies screened by double KpnI and NotI restriction endonuclease digestion were 
confirmed positive as shown by visualisation of a DNA fragment of approximately 
1,200 bp following agarose gel electrophoresis (Figure 3-9A). Next, pShuttleCx43 
was linearised via PmeI restriction endonuclease digestion and electroporated into 
BJ5183-AD-1 bacteria which are ready transformed with the Ad genome plasmid, 
pAdEasy-1. Colonies were screened by PacI endonuclease restriction digestion and 
successful recombination of the pShuttleCx43 and pAdEasy-1 confirmed by the 
presence of two DNA bands; one of approximately 30,000 bp and another at either 
3,000 or 4,500 bp depending on where recombination has occurred (between the 
left arms or at the origin of replications, respectively). Mini-culture preparations 
were performed and 5 individual colonies were detected as positive clones 
indicating recombination of the two vectors had occurred (Figure 3-9B). 
Sequencing analysis of the putative Cx43 positive recombinant plasmid showed a 
point mutation (G to A) at position 27, however this mutation was silent and 
therefore the clone was utilised to produce an Ad vector. The plasmid was 
amplified in a maxi-preparation, purified and linearised using PacI restriction 
endonuclease digestion and transfected into HEK 293 cells to produce an AdCx43. 
To confirm the functionality of AdCx43, HeLa cells or RACFs were transduced at a 
MOI of 50, 100 or 150 (RACFs only) and Cx43 protein expression assessed by 
western immunoblotting (Figure 3-10 and Figure 3-11) and ICC (Figure 3-12). 
Representative western blot analysis showed no change in the expression of Cx43 
in HeLa cells which were transduced with the control virus AdeGFP (0.9 fold 
change vs. control; Figure 3-10). Conversely, a dose-dependent increase in Cx43 
protein was demonstrated in HeLa cells transduced with AdCx43 (4.3 and 13.2 fold 
increase from control; MOI 50 and 100 respectively; Figure 3-10). To confirm 
AdCx43 was functional in the target cells the experiment was repeated in RACFs 
(Figure 3-11). AdeGFP transduction did not alter endogenous Cx43 expression in 
RACFs (0.7 fold change from control; Figure 3-11). While an 8.1, 27.1 and 67.1 
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fold increase in Cx43 levels following AdCx43 transduction at an MOI of 50, 100 
and 150, respectively, was observed (Figure 3-11). The increase in Cx43 was also 
confirmed by ICC (Figure 3-12), whereby punctate expression was observed 
throughout the cell and at the cell membrane. Very little Cx43 expression was 
seen in control cells, similar to western blot analysis. Furthermore, although green 
immunofluorescence was detected throughout AdeGFP transduced cells, this was 
likely to be residual eGFP fluorescence not removed by fixation. Despite this some 
basal Cx43 expression was detected as shown by the punctate areas. 
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Figure 3-9 Clone screening of pShuttle_Cx43 and the recombinant Ad plasmid containing 
Cx43. 
Ethidium bromide agarose gels showing (A) the separation of Cx43 from pShuttle following a double 
KpnI and NotI restriction digest and (B) successful recombination of pShuttle_Cx43 and pAdEasy-1 
vector in mini preparations 1, 4, 6, 7 and 13 cut with PacI. 1Kb; 1 Kb ladder, UC; uncut. 
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Figure 3-10 Representative western immunoblot of protein from HeLa cells transduced with 
AdCx43. 
(A) Cx43 and β-tubulin protein expression from replicate wells of HeLa cells that were not transduced 
(control), transduced with AdeGFP at a multiplicity of infection (MOI) of 100 or AdCx43 at an MOI of 
50 or 100. Protein was collected following at 48 h transduction. (B) Representative densitometry 
analysis of an experiment performed on two independent occasions showing Cx43 expression 
normalised to β-tubulin.  
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Figure 3-11 Representative western immunoblot of protein from RACFs transduced with an 
AdCx43. 
(A) Cx43 and β-tubulin protein expression from replicate wells of RACFs that were not transduced 
(control), transduced with AdeGFP at a multiplicity of infection (MOI) of 150 or AdCx43 at an MOI of 
50, 100 or 150. Protein was collected 48 h following transduction. (B) Representative densitometry 
analysis of an experiment performed on two independent occasions showing Cx43 expression 
normalised to β-tubulin.  
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Figure 3-12 Immunolocalisation of Cx43 in RACFs transduced with AdCx43. 
AdCx43 was added to RACF cultures at a multiplicity of infection (MOI) of 50, 100 or 150. Cells with 
no viral vector and cells transduced with AdeGFP, at a MOI of 150, were used as a control. Cells 
were fixed 48 h following transduction and immunocytochemistry for Cx43 (green) performed. Nuclei 
were counterstained with DAPI (blue). Images are representative of ICC performed on two 
independent occasions. Areas surrounded by the red boxes are expanded on the right. Punctate 
expression of Cx43 is depicted by white arrows. Scale bar represents 100 µm. 
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3.4 Discussion 
In this study, LV and Ad vectors were shown to efficiently transduce RACFs. 
Unfortunately, due to numerous issues with cloning, a LV vector overexpressing 
Cx43 and a nuclear localised eGFP under the control of the hybrid αSMA promoter 
was not produced. However, functional AdCx43 was successfully generated, as 
demonstrated by a dose dependent increase in Cx43 protein levels in HeLa cells 
and RACFs.  
Transgene expression is generally apparent 72 h following LV vector transduction 
(Kizana et al. 2005) and was therefore the time point selected to examine eGFP 
expression. The transfection reagent, polybrene, is often used to enhance 
retroviral transduction (Davis et al. 2002), and has been used in many studies to 
transduce fibroblasts with LV vectors. Despite this, high MOIs of 50-200 (Duan et 
al. 2012;Kane et al. 2010;Kizana et al. 2005) are still often used without toxicity, 
suggesting that fibroblasts are a difficult cell type to transduce and relatively 
resistant to LV vector toxicity. In the present study, an MOI of 12 produced eGFP 
expression in most cells. Therefore, in comparison to other studies, the LVeGFP 
vector produced appears to be efficient for transduction of CFs.  
Since the LVeGFP was shown to efficiently transduce RACFs, initial steps to 
produce a LV vector which would allow the expression of eGFPNLS under the 
control of the hybrid αSMA promoter (Hirschfeld et al. 2009) were taken. First, 
the functionality of the αSMA_eGFPNLS insert was examined by transfection. 
Green nuclei, although at very low levels, were demonstrated in RACFs 
transfected with pαSMA_eGFPNLS. RACFs transfected with the control plasmid, 
pSFFV_eGFP, were also shown to have low eGFP expression. It is well established 
that non-viral gene transfer is inefficient in comparison to viral-mediated delivery, 
therefore greater expression is likely to be observed via using an LV vector 
(Thomas et al. 2003). Indeed the SFFV promoter has been shown be a potent driver 
of eGFP expression when packaged into a LV vector in the current study and by 
others (Laurie et al. 2007). However, as the Xfect reagent was shown to be toxic 
to the cells this could also be a contributing factor to the low expression levels 
observed.  
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In theory, the cloning of αSMA_eGFPNLS into plenti-promoter or 
plenti-III-promoterless should have been straightforward. Interestingly, any 
cloning attempted involving the hybrid αSMA promoter was unsuccessful, 
suggesting an issue with the promoter. However, no issues were reported by 
Hirschfeld et al. (2009) and due to no other use of this hybrid promoter in the 
literature, it is difficult to predict the reason for the lack of success. Some 
explanations may include toxicity of the insert to E coli. or inefficient ligation 
potentially due to the presence of the contaminating bands of DNA that were seen 
following gel extraction. Although the size of the αSMA_eGFPNLS insert was within 
the cloning capacity of both LV and Ad vectors, and therefore should not have 
been an issue, the reduction in size following removal of the promoter (eGFPNLS) 
may explain successfully cloning into the Ad plasmid, pVQ_CMV_K-NpA. 
Ad vector expression has been examined at 48 h following transduction (Lovelock 
et al. 2005) and was therefore the time point examined in the Ad vector studies 
presented here. Indeed, high expression of eGFP was observed following AdeGFP 
transduction at a MOI of 100 and 150. However, toxicity was apparent when the 
MOI was increased to 500 and above. AdeGFP was used as the control vector in 
studies testing the functionality of AdCx43. Fixation has been shown to reduce 
eGFP fluorescence but not completely ablate it (Schnell et al. 2012), therefore to 
distinguish the detection of Cx43 expression in AdGFP transduced control cells via 
ICC, an empty control virus or a red emitting, such as Alexa Fluro® 555, secondary 
antibody should have been utilised. Regardless, little punctate expression was 
detected (similar to non-transduced cells) which also agrees with the western 
immunoblot analysis. Interestingly, Ad vectors which contain the AdE4 gene, 
similar to that used in the current study, have been reported to downregulate 
Cx43 expression in endothelial cells (Zhang et al. 2015). This effect was not 
apparent in the current study in RACFs. This may reflect differential cellular 
responses to Ad vectors in different cell types.  
A dose dependent increase in Cx43 protein expression was also observed over an 
MOI of 50-150, without toxicity. This is significantly greater than an MOI of 5 that 
was used in rat neonatal fibroblasts to overexpress Cx43 (Zlochiver et al. 2008). 
Furthermore, 500 vp/cell of an AdCx43 was reported to transduce skeletal 
myoblasts (SMs) (Reinecke et al. 2004) which is also substantially lower than the 
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700, 1400 and 2800 vp/cell (for an MOI of 50, 100 and 150 pfu/cell respectively) 
used in the present studies. Together this suggests low transduction efficiency for 
the Ad vector produced in the current study, however this may reflect different 
titering methods and therefore is difficult to make a direct comparison. Despite 
this, Cx43 expression pattern in neonatal rat fibroblasts was similar to that of the 
present study, whereby transduced cells showed expression throughout the cell 
with punctate expression at the cell membrane and surrounding the nucleus 
(Zlochiver et al. 2008). Interestingly, two nuclear localisation signals (NLSs) have 
been detected at the C-terminal of the Cx43 protein (Gago-Fuentes et al. 2015). 
This along with the rapid turnover of Cx43 (Beardslee et al. 1998;Hunter et al. 
2005;Laird et al. 1991) and therefore trafficking through the cytoplasm may 
explain the unconfined Cx43 localisation to the cell membrane. 
3.5 Summary 
Although a LV vector overexpressing Cx43 and nuclear localised eGFP under the 
control of a αSMA hybrid promoter was not produced, LVeGFP, AdeGFP and AdCx43 
were shown to be functional in RACFs. Therefore, in order to enable detection of 
injected RACFs in situ with the current viral vectors available, dual transduction 
of RACFs with LVeGFP or AdeGFP along with AdCx43 could be performed prior to 
injection. 
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Chapter 4 Interleukin 1β regulates connexin 43 
expression in primary cardiac fibroblasts  
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4.1 Introduction 
4.1.1 The role of interleukin-1 in inflammatory signalling in the 
heart 
It is well established that inflammation following a cardiac insult is both essential 
and detrimental to the healing heart. Initially, the death of CMs in response to 
ischaemia results in the release of damage-associated molecular patterns (DAMPs) 
including ATP, high-mobility group box 1 (HMGB1) and more recently IL-1α 
(Epelman et al. 2015;Forrester and Williams 1977;Xu et al. 2011b). DAMPs activate 
resident macrophages and attract neutrophils to the ischemic area (Epelman et 
al. 2015). A large neutrophil infiltration within 24 h following I/R injury has been 
reported in both canine and mouse experimental models (Dewald et al. 2004). 
This is followed by an influx of macrophages, a key cell in the removal of cellular 
debris (Frangogiannis 2015), 24 to 72 h post reperfusion in mouse and canine 
experimental models (Bujak et al. 2008;Dewald et al. 2004). Furthermore, mRNA 
levels of the inflammatory cytokines; IL-1β, TNFα, IL-6 and TGFβ have been 
reported to be increased as soon as 15 min following the initiation of reperfusion 
in a rat I/R injury model (Herskowitz et al. 1995). Although inflammation is 
essential for the infarct to be cleared of cellular debris and the scar forming 
process to begin, excessive production of ROS and inflammatory cytokines can 
potentiate CM death (Epelman et al. 2015).  
As well as inflammatory cells, fibroblasts are also known to be a major contributor 
to inflammatory cytokine production. CFs have been reported to be particularly 
resistant to cell death induced by oxidative stress in comparison to CMs as seen 
by their little or no DNA fragmentation in response to hydrogen peroxide (Zhang 
et al. 2001). This characteristic would allow CFs to respond to ischaemia instead 
of undergoing cell death. In vitro, hypoxia has been reported to induce MF 
transdifferentiation (Clancy et al. 2007), increase collagen synthesis (Tamamori 
et al. 1997) and promote TNFα production by CFs (Shivakumar et al. 2008). 
Furthermore, the inflammasome, a multi-protein complex which initiates the 
inflammatory process, has been shown to be activated in CFs but not CMs in 
response to lipopolysaccharide (Kawaguchi et al. 2011). Inflammasome activation 
results in the activation of caspase 1 which cleaves the inactive forms of pro-
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inflammatory cytokines to the active form, mainly pro-IL-1β to IL-1β (Toldo et al. 
2015). IL-1β is increased in numerous pathological conditions including congestive 
heart failure and acute MI (Di et al. 2003). Interestingly, hypoxia/reoxygenation 
was demonstrated to significantly augment IL-1β production by CFs suggesting 
inflammasome activation (Kawaguchi et al. 2011). Additionally, IL-1α released by 
necrotic CMs was identified to induce an inflammatory response in CFs, including 
activation of MAPKs and NF-κB along with secondary production of 
proinflammatory cytokines (Lugrin et al. 2015). These data together suggest an 
important role for CFs in the detection of cardiac injury and initiation of the 
inflammatory response. 
To mediate their effects, both IL-1α and IL-1β bind to IL-1 receptor type 1 (IL-1R1) 
to activate downstream signalling (Weber et al. 2010) (Figure 4-1). Mice lacking 
IL-1R1 have been shown to have a dampened inflammatory response to I/R injury, 
including a reduced number of neutrophils and macrophages as well as reduced 
mRNA levels of a variety of chemokines and cytokines 24 h after initiation of 
reperfusion (Bujak et al. 2008). Furthermore, MF infiltration, collagen deposition 
and MMP levels were all reduced in IL-1R1-/- mice vs. WT, despite there being no 
difference in infarct size (Bujak et al. 2008).  
Initial binding of IL-1 to the IL-1R1 mediates a conformational change in IL-1R1, 
consequently recruiting the IL-1R accessory protein (IL-1RacP), a co-receptor 
essential for IL-1 signalling (Weber et al. 2010). Intracellular proteins including 
myeloid differentiation primary response gene 88 (MYD88) and interleukin-1 
receptor-activated protein kinase (IRAK) 1, 2 and 4 are then recruited to the cell 
membrane (Weber et al. 2010). IRAKs interact with the TNF-associated factor 
(TRAF) 6 ultimately resulting in the activation of inhibitor of nuclear factor B (IκB) 
kinase (IKK), p38 MAPK, JNK and MEK1/2 (Weber et al. 2010). In the resting state, 
IκB is bound to the p50 and p65 subunits of NF-κB in the cytosol of the cell holding 
NFκB in an inactive state. Activated IKK phosphorylates IκB which leads to its 
polyubiquitination and consequent degradation (Chen 2005). Subsequently, the 
transcription factor, NF-κB, is activated and the p50 and p65 subunits translocate 
into the nucleus to mediate gene transcription (Chen 2005). IL-1β can also initiate 
gene transcription by activating p38 MAPK, JNK and ERK1/2, resulting in subunits 
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of the transcription factor, activator protein-1 (AP-1), becoming activated and 
translocating to the nucleus (Weber et al. 2010).  
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Figure 4-1 IL-1 signalling pathway. 
IL-1α and IL-1β bind to the IL-1 receptor (IL-1R1) resulting in a conformational change and 
subsequent recruitment of the co-receptor, IL-1 receptor accessory protein (IL-1RacP). The 
endogenous IL-1 receptor antagonist (IL-1RA) blocks IL-1 signalling. Following receptor activation 
myeloid differentiation primary response gene 88 (MYD88) and IL-1 receptor-activated protein kinase 
(IRAK) 1, 2 and 4 are recruited to the cell membrane. IRAKs interact with tumour necrosis factor-
associated factor (TRAF) 6 resulting in the transmission of downstream signals. Consequently, the 
inhibitor of nuclear factor B (IκB) kinase (IKK), p38 mitogen-activated protein kinase (MAPK), c-Jun 
N-terminal kinase (JNK) and MAPK/extracellular signal-regulated kinase (ERK) kinase (MEK)1/2 
(which subsequently activates ERK1/2) are activated. IKK phosphorylates IκB to signal its 
degradation freeing the p50 and p65 subunits of NF-κB, which are then able to translocate into the 
nucleus and initiate gene transcription. p38 MAPK, JNK and ERK1/2 activate activator protein-1 
(AP-1) subunits, which then move into the nucleus to mediate gene transcription. 
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4.1.2 Regulation of Cx43 by IL-1β 
The effect of IL-1β on Cx43 expression has been shown to vary between cell types. 
IL-1β was initially reported to downregulate Cx43 in both foetal human astrocytes 
(Duffy et al. 2000;John et al. 1999) and neonatal CMs (Baum et al. 2012a;Coppen 
et al. 2008). This finding led to speculation that enhanced IL-1β levels following 
cardiac injury could be a contributing factor to the reduced Cx43 levels seen in 
many cardiac pathologies (Baum et al. 2012b). Conversely, in other cell types 
including rabbit articular chondrocytes (Tonon and D'Andrea 2000) and a rabbit 
synovial fibroblast cell line (Niger et al. 2010) Cx43 expression has been shown to 
be upregulated by IL-1β. The mechanisms for up-regulation were attributed to an 
increase in cytosolic calcium and ERK signalling, respectively (Niger et al. 
2010;Tonon and D'Andrea 2000). Interestingly, one AP-1 binding site has been 
found within the human and mouse Cx43 promoter (Chen et al. 1995b;De Leon et 
al. 1994) and two sites have been identified in the rat Cx43 promoter (Teunissen 
et al. 2003;Yu et al. 1994). An NF-κB binding site has also been detected in the 
Cx43 promoter in rat SMCs (Alonso et al. 2010). However, NF-κB mediated 
regulation of Cx43 is complex, with studies reporting an increase and decrease in 
expression with different cell types and stimuli (Alonso et al. 2010;Zhao et al. 
2006). The effect of IL-1β on Cx43 expression in fibroblasts from cardiac origin is 
yet to be investigated. 
Cx43 regulation in fibroblasts by proinflammatory mediators is interesting due to 
studies reporting enhanced Cx43 expression in CFs from infarcted hearts in 
experimental models of MI (Vasquez et al. 2010;Zhang et al. 2010). Furthermore, 
TGFβ1-mediated CF-to-MF transition has been shown to involve Cx43 in rat 
neonatal CFs (Asazuma-Nakamura et al. 2009), although TGFβ1 did not alter Cx43 
expression (Asazuma-Nakamura et al. 2009).  
Interestingly, IL-1β inhibits TGFβ1-mediated MF transdifferentiation in cardiac, 
dermal and lung fibroblasts (Bronnum et al. 2013;Mia et al. 2014;Saxena et al. 
2013). This could be a consequence of IL-1β-mediated downregulation of the 
TGFβ1 receptor 1 (TGFβR1), the signal propagating receptor involved in TGFβ 
signalling, or downregulation of the TGFβ co-receptor, endoglin (Bronnum et al. 
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2013;Saxena et al. 2013). Although TGFβ1 is increased in the early stages of infarct 
healing following MI, MF accumulation is delayed, peaking at around 5-7 days post 
reperfusion in a canine model of I/R injury (Frangogiannis et al. 2000). As IL-1β is 
important in early inflammation it may act to inhibit premature fibroblast 
activation allowing the inflammatory phase to clear cellular debris before scar 
forming processes are underway.  
4.1.3 MicroRNA regulation of connexin 43 
MiRNAs are defined as short non-coding RNAs, consisting of approximately 22 
nucleotides, which negatively regulate protein expression. Binding of miRNAs to 
target mRNA strands can either inhibit gene translation or signal untranslated 
mRNA for degradation (van and Olson 2012). Many miRNAs have been shown to be 
dysregulated in cardiac pathologies. For example, miR-21 was found to be 
upregulated in the failing human myocardium as well as the infarct of a murine 
model of I/R injury (Roy et al. 2009;Thum et al. 2008). Additionally, inhibition of 
miR-21 promoted many beneficial effects, including reduced fibrosis by targeting 
the negative regulator of ERK, sprout homologue 1, in both a murine model of I/R 
injury and a rat MI model (Cardin et al. 2012;Thum et al. 2008). Another miRNA 
reported to promote anti-fibrotic effects is miR-101a/b, which targets c-Fos 
consequently reducing TGFβ1 expression (Pan et al. 2012). Furthermore, 
miR-101a/b are both downregulated in the peri-infarct area in a rat MI model 
(Leicht et al. 2000).  
MiRNAs have also been implicated in the regulation of Cx43. MiR-19a/b, which is 
part of the miR-17-92 cluster, was reported to directly target Cx43, consequently 
reducing cardiac Cx43 protein levels in transgenic mice overexpressing the 
miR-17-92 cluster (Danielson et al. 2013). MiR-125b, a vital miRNA for CF-to-MF 
transition and cardiac fibrosis (Nagpal et al. 2016), has also been shown to directly 
target Cx43 in HEK 293 cells (Jin et al. 2013). IL-1β is also able to regulate miRNAs 
including miR-101 and -146 (Perry et al. 2008;Wang et al. 2014b), however a link 
between IL-1β-mediated miRNA regulation and Cx43 expression has not yet been 
established. 
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4.2 Aims 
• To assess the effect of different proinflammatory cytokines on Cx43 
expression in RACFs.  
• Dissect the IL-1β signalling pathway for mechanisms of IL-1β mediated 
regulation of Cx43 in RACFs. 
  
140 
 
4.3 Results 
4.3.1 Characterisation of isolated adult rat cardiac fibroblasts 
Unfortunately, fibroblasts lack a specific cell marker (Souders et al. 2009) and 
should generally be stained with more than one marker to identify them. CFs 
isolated from adult male Wistar rats were cultured until passage 2 and stained 
with antibodies against a range of fibroblast/MF markers including; αSMA, 
vimentin, DDR2 and S100A4 (FSP1). A Cx43 antibody was also used to identify Cx43 
expression in normal cultured fibroblasts. All images were corrected to an IgG 
control for each antibody to remove false positive staining. 
High expression of the myofibroblast marker, αSMA, was detected in stress fibers 
of RACFs (Figure 4-2), suggesting fibroblast-to-myofibroblast differentiation had 
occurred in culture by passage 2. Fibroblasts were also shown to express vimentin, 
DDR2 and S100A4 (FSP1) throughout the cell (Figure 4-2). DDR2 expression was 
punctate and appeared to be concentrated around the nucleus in some cells (white 
arrows; Figure 4-2). Punctate expression of Cx43 at the cell membrane was also 
detected (white arrows; Figure 4-2), which may suggest the ability of these cells 
to form GJs when in close contact to other cells.  
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Figure 4-2 Immunolocalisation of αSMA, vimentin, DDR2, S100A4 and Cx43 in passage 2 
RACFs. 
Cells were seeded at 1.8 × 104 per chamber of a 4 well chamber slide and fixed 48 h thereafter. 
Staining was completed and normalised to individual IgG shown down the right hand side. White 
arrows show areas where DDR2 is in high abundance surrounding the nucleus or the punctate 
expression of Cx43. n=3,3,1,2,3 for αSMA, vimentin, DDR2, S100A4 and Cx43 respectively. Images 
were taken at x25 magnification. Scale bar represents 100 µm. 
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4.3.2 Assessment of Cx43 regulation by proinflammatory 
mediators  
Cx43 expression has been reported to be increased in CFs from infarcted hearts 
(Vasquez et al. 2010;Zhang et al. 2010). As proinflammatory mediators are also 
augmented in cardiac disease, the effect of a range of molecules able to mediate 
inflammatory responses, including Ang II, TGFβ1, IL-1β, IL-1α, TNFα, IL-6 and IL-6 
in combination with the sIL-6R on Cx43 mRNA expression was examined in RACFs. 
All RACFs were quiesced in reduced serum media (0.5 % FBS) for 24 h and 
subsequent stimulations performed in this media.  
Cx43 mRNA expression in RACFs reintroduced into culture media (10 % FBS) was 
shown to be significantly greater than in control cells (RQ: 3.3 ± 2.1; P<0.001; 
Figure 4-3). Stimulation of RACFs with TGFβ1, IL-1β, IL-1α or IL-6 in combination 
with the sIL-6R induced significant up-regulation of Cx43 mRNA expression 
(RQ: 1.7 ± 1.1 [P<0.05], 10.2 ± 3.1 [P<0.001], 10.0 ± 4.9 [P<0.001] and 2.0 ± 1.3 
[P<0.01] respectively; Figure 4-3). Conversely, there were no significant changes 
in Cx43 mRNA following stimulation with Ang II, TNFα or IL-6 alone (RQ: 0.7 ± 0.4, 
1.3 ± 0.8, 1.2 ± 0.8 respectively; Figure 4-3). 
Interestingly, a morphological change was observed in RACFs stimulated with IL-1β 
(Figure 4-4). Cells adopted a phenotype with an increased number of projections, 
the extent of which varied amongst individual cells. A representative cell which 
has a particularly high level of projections is shown as a magnified inset within 
the image of IL-1β-treated cells (Figure 4-4B). Interestingly these cellular 
projections were observed to extend towards surrounding cells, suggesting they 
were potentially involved in enhancing cell-to-cell contact.  
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Figure 4-3 Effect of proinflammatory mediators on Cx43 mRNA expression in RACFs. 
Quiesced cells were stimulated with 10 % FBS, Ang II (500nM), TGFβ1, IL-1β, IL-1α, TNFα (all 
10ng/mL) or IL-6 in the presence or absence of the sIL-6R (both 50 ng/mL) for 24 h. Cells maintained 
in 0.5 % FBS media were used as a control. Data represented as relative quantification (RQ) ±rqmax 
normalised to UBC (n=3). *P<0.05, **P<0.01, ***P<0.001 vs. control (one-way repeated measures 
ANOVA with Dunnett’s multiple comparison test). Average threshold cycle (Ct) values are shown 
above each bar. 
 
 
Figure 4-4 Representative images of control and IL-1β treated RACFs. 
Quiesced cells were (A) maintained in 0.5 % or (B) stimulated with 10 ng/mL IL-1β and images 
captured 24 h thereafter. The area surrounded by a red box is expanded within the image to highlight 
the morphology of specific cells (n=4). Images were taken at x10 magnification. Scale bar represents 
100 µm. 
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4.3.3 Dissection of the mechanism by which IL-1β stimulates 
Cx43 up-regulation 
As IL-1β was demonstrated to increase Cx43 mRNA levels, this was examined at 
the protein level. Cx43 protein was examined in normal cultured, quiesced and 
IL-1β stimulated RACFs by western immunoblotting (Figure 4-5A). RACFs 
maintained in reduced serum media for 48 h (quiesced cells) were shown to 
mediate a 1.9 fold reduction in Cx43 protein in comparison to cells in normal 
culture media (10 % FBS) (0.034 vs. 0.018 Cx43/GAPDH, 10 % FBS vs. 0.5 % FBS; 
Figure 4-5B). Cx43 protein was 8-fold greater when stimulated with IL-1β when 
compared to unstimulated cells (0.5 % FBS cells) (0.145 vs. 0.018 Cx43/GAPDH, 
IL-1β vs. 0.5 % FBS; Figure 4-5B).  
ICC was also performed to visualise the localisation of Cx43 in control (cells 
maintained in reduced serum media) and IL-1β stimulated cells. Although Cx43 
was present in control cells, staining was more pronounced in cells stimulated 
with IL-1β (Figure 4-5C). Interestingly, IL-1β enhanced the presence of Cx43 at the 
cell membrane, highlighted by white arrows in the area expanded within the red 
box in the lower right panel. All images were corrected to the IgG control (Figure 
4-5C – upper right panel).  
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Figure 4-5 Effect of IL-1β on Cx43 protein expression in RACFs. 
Quiesced cells were stimulated with 10ng/mL IL-1β for 24 h. Cells maintained in 0.5 % FBS media 
were used as a control. (A) Western blot of Cx43 protein and GAPDH from replicate wells of cells 
maintained in normal culture media (10 % FBS), 0.5 % FBS media or cells stimulated with 10 ng/mL 
IL-1β (n=1). (B) Densitometry analysis of Cx43 expression normalised to GAPDH (n=1). (C) 
Representative images of control RACFs (maintained in 0.5 % FBS media) or cells treated with 10 
ng/mL IL-1β (n=3). Images were normalised to an IgG control shown in the upper right panel. The 
areas surrounded by a red box are expanded within the merged image or in the lower right panel for 
control and IL-1β stimulated cells respectively. White arrows indicate punctate Cx43 expression. 
Images were taken at x25 magnification. Scale bars represent 100 µm.  
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4.3.3.1 Effect of inhibitors of the IL-1β pathway on Cx43 expression 
IL-1β pathway inhibitors were utilised to investigate the mechanism of 
IL-1β-mediated upregulation of Cx43 in RACFs. For experiments in which inhibitors 
were reconstituted in DMSO, DMSO was added to a subset of cells to determine its 
effect on Cx43 expression.  
NF-κB is known to be an important regulator of IL-1β actions on CFs (Xie et al. 
2004), and was therefore investigated using the specific inhibitor, SC-514 (SC) 
(Gomez et al. 2005;Riis et al. 2011). Quiesced cells were incubated with SC for 
30 min prior to stimulation with IL-1β. DMSO at a final concentration of 0.1 % 
(vehicle control) did not significantly affect the expression of Cx43 mRNA 
(RQ: 1.5 ± 0.2, Figure 4-6A), indicating that any changes with SC can be attributed 
to the action of SC and not the vehicle. IL-1β induced a significant upregulation of 
Cx43 mRNA, which was significantly inhibited by SC (RQ: 11.2 ± 1.3 vs. 4.3 ± 1.9, 
IL-1β vs. IL-1β + SC; P<0.05; Figure 4-6B). This pattern was also observed at the 
protein level as determined by western immunoblotting, however these changes 
were not considered significant due to large variation in extent of this response 
to IL-1β (Figure 4-7; Appendix figure 1 shows all immunoblots used in 
densitometry). There was no change in Cx43 protein expression when cells where 
stimulated with DMSO (0.066 ± 0.039 vs. 0.064 ± 0.036 Cx43/β-tubulin, control vs. 
DMSO; Figure 4-7B). IL-1β stimulation increased Cx43 protein expression by 31.6 
fold in comparison to cells treated with DMSO alone (2.001 ± 1.106 vs. 0.064 ± 
0.036 Cx43/β-tubulin, IL-1β vs. DMSO; Figure 4-7B). This effect was reduced to a 
5.3 fold increase when cells were stimulated with IL-1β in the presence of SC 
(0.336 ± 0.199 vs. 2.001 ± 1.106 Cx43/β-tubulin, IL-1β + SC vs. IL-1β + DMSO; Figure 
4-7B).  
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Figure 4-6 Effect of NF-κB inhibition on IL-1β mediated upregulation of Cx43 mRNA 
expression in RACFs. 
Quiesced cells were stimulated with (A) 0.1 % DMSO (vehicle), (n=2) or (B) 10 ng/mL IL-1β in the 
presence or absence of 100 µM SC-514 (SC), an NF-κB inhibitor (n=3). Cells were pre-incubated 
with SC for 30 min prior to IL-1β stimulation and all stimulations were performed for 24 h. Cells 
maintained in 0.5 % FBS were used as a control. Data represented as relative quantification (RQ) 
±rqmax normalised to UBC. No significant changes were detected between control and 0.1 % DMSO 
using an unpaired, two-tailed t-test. **P<0.01, ***P<0.001 vs. control, #P<0.05 vs. IL-1β (one-way 
repeated measures ANOVA with Tukey’s multiple comparison test). Average threshold cycle (Ct) 
values are shown above each bar. 
 
 
Figure 4-7 Effect of NF-κB inhibition on IL-1β mediated upregulation of Cx43 protein 
expression in RACFs. 
Quiesced cells were stimulated with 0.1 % DMSO (vehicle), 10 ng/mL IL-1β in combination with 
0.1 % DMSO or 100 µM SC-514 (SC), an NF-κB inhibitor. Cells were pre-incubated with SC for 30 
min prior to IL-1β stimulation and all stimulations were performed for 24 h. Cells maintained in 0.5 % 
FBS media were used as a control. (A) Representative Western immunoblot of Cx43 and β-tubulin 
(loading control) from replicate wells (n=3). (B) Densitometry analysis of Cx43 expression normalised 
to β-tubulin from three independent experiments. No significant changes were detected using a 
repeat measures ANOVA with Tukey’s multiple comparison test. 
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Next, the role of p38 MAPK, JNK and MEK1 in IL-1β-mediated up-regulation of Cx43 
was examined using pharmacological inhibitors for these proteins. At the mRNA 
level, inhibition of p38 MAPK with SB203580 (SB) did not significantly reduce IL-1β-
mediated upregulation of Cx43, although there was a partial reduction (RQ: 
4.4 ± 0.8 vs. 7.4 ± 1.1, IL-1β + SB vs. IL-1β + DMSO; Figure 4-8). AZD6244 (AZ), an 
inhibitor of MEK1, induced significant inhibition of IL-1β-induced increases in Cx43 
expression (2.4 ± 0.3 vs. 7.4 ± 1.1, IL-1β + AZ vs. IL-1β + DMSO; P<0.05; Figure 
4-8). Conversely, inhibition of JNK with SP600125 (SP) had no significant effect on 
IL-1β-mediated augmentation of Cx43 (12.6 ± 3.1 vs. 7.4 ± 1.1, IL-1β + SP vs. IL-1β 
+ DMSO; Figure 4-8). At the protein level, IL-1β alone or in the presence of DMSO 
induced an 11.7 or 9.6 fold increase in Cx43 protein in comparison to control cells 
(0.347 ± 0.073 or 0.286 ± 0.002 vs. 0.023 ± 0.166 Cx43/β-tubulin, IL-1β or IL-1β + 
DMSO vs. control; Figure 4-9B; Appendix figure 2 shows all immunoblots used in 
densitometry). This was reduced to a 4.6 or 5.3 fold increase from control in the 
presence of SB or AZ, respectively (0.136 ± 0.096 or 0.157 ± 0.057 vs. 0.023 ± 
0.166 Cx43/β-tubulin, SB + IL-1β or AZ + IL-1β vs. control; Figure 4-9B). Inhibition 
of JNK potentiated IL-1β-induced increases in Cx43 protein expression by 2.8 fold 
(26.9 fold increase from control) (0.801 ± 0.081 vs. 0.286 ± 0.002 Cx43/β-tubulin, 
IL-1β + SP vs. IL-1β + DMSO; Figure 4-9B). Although this change in Cx43 was not 
significant from IL-1β + DMSO it was shown to be significant from control cells 
(P<0.01).  
As IL-1β exerts its actions through the IL-1R, the endogenous IL-1Ra was utilised 
at range of concentrations. Indeed, IL-1Ra dose-dependently inhibited increases 
in Cx43 induced by IL-1β (Figure 4-10), confirming a role for the IL-1R in 
IL-1β-mediated Cx43 up-regulation. The RQ ± rqmax of Cx43 expression was 
significantly reduced from 10.1 ± 0.7 in IL-1β stimulated cells to 6.9 ± 0.8, 6.0 ± 
1.0 or 4.4 ± 0.5 in cells stimulated with IL-1β in the presence of 0.25, 0.5 or 
1 μg/mL IL-1Ra respectively (P<0.05, 0.01 and 0.001).  
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Figure 4-8 Effect of p38 MAPK, JNK or MEK1 inhibition on IL-1β mediated up-regulation of 
Cx43 mRNA expression in RACFs. 
Cells were quiesced in 0.5 % FBS for 24 h prior to the addition of 0.1 % DMSO, 10 µM SB203580 
(SB), 20 µM SP600125 (SP) or 10 µM AZD6244 (AZ) for vehicle control or inhibition of p38 MAPK, 
JNK or MEK1 respectively. Cells were incubated for 1 h with inhibitors prior to the addition of 
10 ng/mL IL-1β and stimulations were performed for 24 h. Cells maintained in 0.5 % FBS were used 
as a control. Data represented as relative quantification (RQ) ±rqmax normalised to UBC (n=3). 
*P<0.05, ***P<0.001 vs. control; ##P<0.01 vs. IL-1β + DMSO (one-way repeated measures ANOVA 
with Tukey’s multiple comparison test). Average threshold cycle (Ct) values are shown above each 
bar. 
 
 
Figure 4-9 Effect of p38 MAPK, JNK or MEK1 inhibition on IL-1β mediated up-regulation of 
Cx43 protein expression in RACFs. 
Quiesced cells were stimulated with 0.1 % DMSO, 10 µM SB203580 (SB), 20 µM SP600125 (SP) or 
10 µM AZD6244 (AZ) for vehicle control or inhibition of p38 MAPK, JNK or MEK1 respectively. Cells 
were incubated for 1 h with inhibitors prior to the addition of 10 ng/mL IL-1β and stimulations 
performed for 24 h. Cells maintained in 0.5 % FBS media were used as a control. (A) Representative 
Western blot from replicate wells. (B) Densitometry analysis of Cx43 expression normalised to β-
tubulin (n=2). **P<0.01 vs. control (one-way repeated measures ANOVA with Tukey’s multiple 
comparison test). 
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Figure 4-10 Effect of IL-1 receptor inhibition on IL-1β mediated up-regulation of Cx43 mRNA 
expression in RACFs. 
Quiesced cells were stimulated with 10 ng/mL IL-1β alone or in the presence of 0.25, 0.5 or 1 µg/mL 
human recombinant IL-1β receptor antagonist (IL-1Ra). Stimulations were performed for 24 h and 
cells maintained in 0.5 % FBS media were used as a control. Data represented as relative 
quantification (RQ) ±rqmax normalised to UBC (n=3). ***P<0.001 vs. control; #P<0.05, ##P<0.01, 
###P<0.001 vs. IL-1β (one-way repeated measures ANOVA with Tukey’s multiple comparison test). 
Average threshold cycle (Ct) values are shown above each bar. 
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4.3.3.2 Role of miRNAs in IL-1β regulation of Cx43 
MiRNAs have been implicated in the regulation of Cx43 (Danielson et al. 2013;Jin 
et al. 2013), hence the candidate miRNAs (miR-19b, -30 [predicted by target scan] 
and -125b) along with miRNAs, miR-1, -101 and -133a reported to be regulated by 
pro-inflammatory cytokines (Georgantas et al. 2014;Wang et al. 2014b) were 
examined in control and IL-1β stimulated RACFs.  
MiR-1 and -133a have been demonstrated to be downregulated and inversely 
correlated with proinflammatory cytokine levels in inflammatory myopathies 
(Georgantas et al. 2014). MiR-1 has also reported to target Cx43 and its 
overexpression in vivo leads to the downregulation of Cx43 (Curcio et al. 2013). 
Interestingly, miR-101 has been reported to be repressed by IL-1β in non–small cell 
lung cancer cells (Wang et al. 2014b) and is therefore a promising miRNA to 
investigate in CFs. Quiesced cells were stimulated with 10 ng/mL IL-1β or 
maintained in 0.5 % FBS (control) for 24 hr prior to cell collection. The expression 
of miR-1, -19b, -30c, -101a/b, -125b and -133a were examined by qRT-PCR. 
However, neither miR-1 nor -133a were detectable in control and IL-1β stimulated 
RACFs. MiR-19b and -125b have both been reported to target Cx43 (Danielson et 
al. 2013;Jin et al. 2013), however IL-1β did not alter the levels of these miRNAs 
(Figure 4-11 A and D). Next, the expression of miR-30 and -101 were assessed as 
these have been predicted to bind to Cx43 by Target Scan (version 6.2); a database 
which predicts genes containing the miRNA target seed sequence (Lewis et al. 
2005). However, again no significant changes were found between conditions 
(Figure 4-11B-C).  
As there was no change in these miRNAs following a 24 h IL-1β stimulation, the 
expression of Cx43, miR-19b, -30c, -101, -101b or -125b was examined following 
a 1, 3 or 6 h stimulation. IL-1β significantly up-regulated Cx43 mRNA expression 
within 1 h (RQ: 1.4 ± 0.1, P<0.05; Figure 4-12A), suggesting a rapid upregulation 
of Cx43. Cx43 mRNA expression was further increased after 3 h (RQ: 5.7 ± 0.2, 
P<0.001; Figure 4-12A) to levels that were maintained at 6 h IL-1β stimulation (RQ: 
5.6 ± 0.3, P<0.001; Figure 4-12A). No significant changes in miR19b, 30c, 101, 
101b or 125b expression was observed over the 1-6 h time course (Figure 4-12B-
F).  
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Figure 4-11 Effect of IL-1β on miR19b, 30c, 101 and 125b expression in RACFs. 
Quiesced cells were stimulated with 10ng/mL IL-1β for 24 h. Cells maintained in 0.5 % FBS were 
used as a control. The expression of (A-D) miR19b, miR30c, miR101 and miR125 was examined. 
Data represented as relative quantification (RQ) ±rqmax normalised to U87 (n=1). Threshold cycle (Ct) 
values are shown above each bar. Error bars show the variation between the technical replicates. 
Unpaired, two-tailed t-tests performed on technical replicates showed no significant differences. 
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Figure 4-12 Effect of IL-1β on Cx43 mRNA and miR-19b, -30c, -101, -101b and -125b expression 
in RACFs over different time periods. 
Quiesced cells were stimulated with 10 ng/mL IL-1β for 1, 3 and 6 h. Cells maintained in 0.5 % FBS 
media were used as a control (0 h). The expression of (A) Cx43 mRNA and (B-F) 
miR-19b, -30c, -101, -101b and -125b was examined. Data represented as relative quantification 
(RQ) ±rqmax normalised to UBC (Cx43) or U87 (miRNAs) (n=1). Error bars show the variation 
between the technical replicates. Statistics were performed on technical replicates; *P<0.05, 
***P<0.001 vs. 0 h (one-way ANOVA with Tukey’s multiple comparison test). Threshold cycle (Ct) 
values are shown above each bar. 
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4.3.4 IL-1β-mediated regulation of the TGFβ1 pathway  
IL-1β has been reported to inhibit TGFβ1-mediated fibroblast-to-MF transition 
(Bronnum et al. 2013;Mia et al. 2014;Saxena et al. 2013). To assess whether IL-1β 
prevented TGFβ1-induced gene expression, quiescent RACFs were stimulated with 
IL-1β, TGFβ1 or with a combination of both for 24 h. The expression of reported 
TGFβ-regulated genes including CTGF, αSMA, PAI-1 and the transcriptional 
repressors, Snail and Slug (Biswas and Longmore 2016;Chen et al. 2000;Cooley et 
al. 2014;Kawano et al. 2000;Li et al. 2008), were examined by qRT-PCR.  
IL-1β stimulation was found to have predominantly opposing actions on gene 
expression to TGFβ1. For instance, IL-1β promoted an 8 and 59 fold reduction in 
CTGF (RQ: 0.1 ± 0.03, P<0.001; Figure 4-13A) and αSMA (RQ: 0.02 ± 0.01, P<0.001; 
Figure 4-13B), respectively. Conversely, TGFβ1 induced a significant up-regulation 
of CTGF (RQ: 2.5 ± 0.2, P<0.05; Figure 4-13A) but no significant change in αSMA 
expression (RQ: 2.1 ± 0.1; Figure 4-13B). αSMA expression in IL-1β and TGFβ1 
co-stimulated cells was significantly reduced in comparison to cells treated with 
TGFβ1 alone (RQ: 0.3 ± 0.1 vs. 2.1 ± 0.1, IL-1β + TGFβ1 vs. TGFβ1 alone, P<0.05; 
Figure 4-13B).  
There were no significant changes in PAI-1 or snail expression by IL-1β (RQ: 
1.3 ± 0.2; Figure 4-13C and RQ: 0.6 ± 0.1; Figure 4-13D, respectively) or TGFβ1 
stimulation (RQ: 4.0 ± 1.2; Figure 4-13C and RQ: 1.3 ± 0.1; Figure 4-13D, 
respectively). A 6.5 fold decrease in Slug was also induced by IL-1β (RQ: 0.2 ± 0.01, 
P<0.001; Figure 4-13E), however no change was detected following TGFβ1 
stimulation (RQ: 1.0 ± 0.1; Figure 4-13E).  
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Figure 4-13 Effect of IL-1β or TGFβ1 alone or in combination on the mRNA expression of 
CTGF, αSMA, serpine, snail and slug in RACs. 
Quiesced cells were stimulated with IL-1β, TGFβ1 or IL-1β plus TGFβ1 (all at 10 ng/mL) for 24 h. 
Cells maintained in 0.5 % FBS media were used as a control. Data represented as relative 
quantification (RQ) ±rqmax normalised to UBC (n=3). *P<0.05 ***P<0.001 vs. control; #P<0.05, 
###P<0.001 vs. TGFβ1 (one-way repeated measures ANOVA with Tukey’s multiple comparison test). 
Threshold cycle (Ct) values are shown above each bar. 
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4.4 Discussion 
As Cx43 expression in CFs is enhanced following MI (Vasquez et al. 2010;Zhang et 
al. 2010), this study has investigated potential factors that may be responsible for 
this. Of the mediators investigated TGFβ1, IL-1α, IL-1β and IL-6 in combination 
with the sIL-6R significantly upregulated Cx43 mRNA in cells expressing numerous 
fibroblasts markers including αSMA, vimentin, DDR2 and S100A4. This upregulation 
was translated to the protein level with IL-1β stimulation, where enhanced Cx43 
expression was observed at the cell membrane and at cell-to-cell contact points. 
NF-κB, MEK1 and the IL-1R were shown to be involved in IL-1β-mediated 
upregulation of Cx43, by the use of specific pharmacological inhibitors. 
Conversely, the miRNAs; 19b, 30c, 101a/b or 125b did not appear to be regulated 
by IL-1β over a 1-24 h period, suggesting little or no participation in IL-1β-induced 
Cx43 up-regulation in primary RACFs.  
The ability of IL-1β to modulate TGFβ1 signalling in RACFs was also examined. 
TGFβ1 significantly upregulated CTGF mRNA but had no significant effects on 
αSMA, PAI-1 and snail mRNA, although trends for increases in these latter genes 
were observed. Stimulation of RACFs with IL-1β alone generally produced no effect 
or had the opposite effect on these genes to TGFβ1. IL-1β was found to 
significantly inhibit the trend for a TGFβ1-mediated increase in αSMA mRNA levels 
which is consistent with previous reports (Bronnum et al. 2013;Mia et al. 
2014;Saxena et al. 2013).  
Cx43 mRNA was significantly upregulated in RACFs stimulated with IL-6 in 
combination with the sIL-6R. IL-6 signalling can occur through the membrane 
bound IL-6R (mIL-6R) or the sIL-6R (Mihara et al. 2012). The sIL-6R lacks the 
intracellular fraction of the mIL-6R and can form an IL-6-sIL-6R complex prior to 
binding to gp130 to initiate IL-6 signalling (Mihara et al. 2012). Gp130 is expressed 
ubiquitously throughout tissues; therefore the IL-6-sIL-6R complex could 
hypothetically initiate IL-6 signalling in most cell types (Mihara et al. 2012). The 
results in the present study suggest that sIL-6R is required for IL-6 mediated 
upregulation of Cx43 mRNA in RACFs, suggesting little expression of the mIL-6R. 
Indeed, the sIL-6R was previously reported to be essential for IL-6-induced 
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CF-to-MF transition and collagen synthesis by CFs (Melendez et al. 2010). Cx43 
mRNA levels were also unchanged in human sub-urothelial MFs following the 
longer stimulation of 48 h with IL-6 alone (Heinrich et al. 2011). Despite this, the 
number of coupled cells and levels of Cx43 protein were augmented in the same 
study, suggesting post-translational regulation of Cx43 by IL-6 in the absence of 
the sIL-6R (Heinrich et al. 2011).  
A modest, but significant increase in Cx43 mRNA was detected in TGFβ1-treated 
RACFs. Conversely, no change in Cx43 protein levels was detected in neonatal CFs 
treated with TGFβ1 (Asazuma-Nakamura et al. 2009). This may suggest that the 
slight increase in mRNA is not substantial enough to induce an increase at the 
protein level, however this requires further investigation. Enhanced Cx43 reported 
in diseased CFs (Vasquez et al. 2010;Zhang et al. 2010) could be attributed to the 
action of another factor; one potential candidate is IL-1β. 
IL-1β is one of the earliest cytokines to be detected in the plasma of MI patients 
(Guillen et al. 1995), therefore its effects on CF function are particularly 
interesting. In the present study, IL-1β was shown to induce a morphological 
change in RACFs. An early report also described a similar morphological alteration 
by IL-1β in human synovial fibroblasts, where the cells were described as being a 
“stellate” fibroblasts (Heino 1986). A similar phenotype was also observed in 
RACFs treated with IL-1β; however this was attributed to the expression of 
inducible nitric oxide (NO) synthase (iNOS) leading to NO production and cellular 
apoptosis (Tian et al. 2002). Apoptosis was not investigated in the current study, 
highlighting an avenue for further investigation. The role of Cx43 in cell death has 
been controversial with studies reporting either an enhancement or reduction in 
Cx43 expression, as well as increased or decreased GJIC in different cell types and 
models of cell death (Decrock et al. 2009). Therefore, the suggestion that Cx43 
upregulation is a secondary result of IL-1β-induced apoptosis cannot be concluded 
from current literature. These morphological changes however have not been 
reported in other studies using rat and mouse CFs despite similar IL-1β 
concentrations being used (Bronnum et al. 2013;Saxena et al. 2013). 
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Although the effect of IL-1β on Cx43 expression in CMs has been investigated, 
inducing downregulation of Cx43 and inhibiting GJIC (Baum et al. 2012a;Coppen 
et al. 2008), the effect on CFs has generally been overlooked. In this study, both 
IL-1α and IL-1β were found to increase Cx43 mRNA levels to similar extents, 
suggesting the opposite result than that reported in CMs. This was further 
investigated at the protein level following IL-1β stimulation, which demonstrated 
a marked increase in Cx43. Interestingly, in a rabbit synovial fibroblast cell line 
(HIG-82 cells), Cx43 expression was only increased at the protein, not gene level 
following a 24 h IL-1β stimulation (Niger et al. 2010), suggesting post-
transcriptional regulation. These results differ to that reported in the current 
study where both Cx43 mRNA and protein were augmented, which may be a result 
of fibroblasts from a different species or tissue subtype. Interestingly, 
IL-1β-mediated Cx43 protein increase in HIG-82 cells was associated with 
enhanced GJIC (Niger et al. 2010). In the present study, Cx43 immunofluorescence 
following treatment with IL-1β demonstrated punctate expression at cell contact 
points, typical of GJ plaques, suggesting increased communication between 
fibroblasts. However, requires further investigation. Niger et al. (2010) also 
showed no additional increase in Cx43 protein when the stimulation was extended 
to 48 h supporting the time point examined in the current study (Niger et al. 2010). 
Dual stimulation with IL-1β and TNFα of bladder SMCs has also been demonstrated 
to increase Cx43 expression (Li et al. 2011), which was mediated by NF-κB and 
PKA. NF-κB binding sites have been detected in Cx43 promoter and been shown to 
be important in Cx43 regulation (Alonso et al. 2010). In the present study, 
IL-1β-mediated Cx43 increase in RACFs was also dependent on NF-κB. Additionally, 
NF-κB activation was reported in neonatal CMs stimulated with IL-1β inducing 
reduced Cx43 levels (Baum et al. 2012a). NF-κB activation and Cx43 upregulation 
were inhibited with docosahexaenoicacid (DHA, an Omega-3 fatty acid), 
suggesting NF-κB could be responsible for downregulating Cx43 (Baum et al. 
2012a). These conflicting regulatory actions of NF-κB on Cx43 highlight complex 
interactions.  
IL-1β was also found to induce the phosphorylation, and therefore activation, of 
p38 MAPK, JNK and ERK1/2 in HIG-82 cells within 10 min (Niger et al. 2010). The 
159 
 
IL-1 pathway was further dissected in this current study, using inhibitors of p38 
MAPK, JNK and MEK1, which to our knowledge has not been previously investigated 
in IL-1β mediated upregulation of Cx43 in CFs. Our data demonstrates that 
inhibition of MEK1 significantly blunts Cx43 upregulation by IL-1β. In addition, 
inhibition of p38 MAPK reduced IL-1β mediated Cx43 upregulation, however this 
did not reach significance. Consistent with these results, p38 MAPK and ERK1/2 
activation have been shown to promote Cx43 upregulation in various cell types 
(Jia et al. 2008;Polontchouk et al. 2002). Additionally, p38 MAPK and ERK1/2 
activation can not only mediate Cx43 expression but have also been shown to 
regulate phosphorylation of Cx43, and hence alter GJIC (Polontchouk et al. 2002). 
However, phosphorylation of Cx43 can either enhance or reduce GJIC depending 
on the site of phosphorylation (Solan and Lampe 2014). Interestingly, 
phosphorylation of ERK1/2 was associated with Ser279/Ser282 Cx43 
phosphorylation, resulting in a reduction in GJIC in an isolated rabbit heart 
preparation (Naitoh et al. 2006). On the contrary, IL-1β induced a dose dependent 
amplification of  GJIC in HIG-82 cells, which was inhibited by MEK1/2 inhibitors 
(Niger et al. 2010). Furthermore, MEK1/2 inhibition has also been shown to reduce 
cyclic mechanical stretch-induced Cx43 upregulation in rat neonatal CMs (Salameh 
et al. 2010). An increase in Cx43 by the anti-depressant drug, amitriptyline, has 
also been reported in rat primary cultured cortical astrocytes, which interestingly 
was prevented by p38 MAPK inhibition (Morioka et al. 2014). Together these 
studies support the role of p38 MAPK and MEK1/2 in Cx43 upregulation.  
A trend for potentiation of IL1β-mediated upregulation of Cx43 expression by JNK 
inhibition was shown in the current study. This is consistent with the reported 
downregulation of Cx43 in rat neonatal CMs following Ad overexpression of JNK 
(Petrich et al. 2002). Additionally, TNFα-induced downregulation of Cx43 in WT 
fibroblasts did not occur in JNK-/- fibroblasts, suggesting JNK acts to suppress Cx43 
expression (Tacheau et al. 2008). Experiments using the IL-1Ra demonstrated a 
dose dependent reduction in IL-1β-mediated Cx43 expression, confirming the 
well-established signalling of IL-1β through the IL-1R (Weber et al. 2010).  
Cx43 mRNA was shown to be upregulated as early as 1 h following IL-1β 
stimulation, suggesting a rapid induction of Cx43 gene transcription. However, no 
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change in miR-19b, -30c, -101a/b or -125b was detected between control and 
IL-1β treated RACFs, suggesting a lack of involvement in IL-1β-induced Cx43 
upregulation. However, this was only investigated in one experiment therefore 
further replication is required to make solid conclusions from this data.  
The additional cytokines/mediators investigated in the present study including 
Ang II and TNFα were not shown to significantly alter Cx43 mRNA expression. Ang II 
was found to promote an increase in Cx43 protein levels as early as 2 h stimulation 
of mouse aortas, which was maintained following 48 h of stimulation (Alonso et 
al. 2010). Additionally, neonatal CMs exhibited an augmentation in Cx43 protein 
and increased GJIC subsequent to Ang II stimulation at the same concentration 
and time point used in the current study (Polontchouk et al. 2002). Furthermore, 
Cx43 protein in rat neonatal CFs was rapidly increased following 3 h stimulation 
with Ang II (Adam et al. 2010). Unfortunately Cx43 mRNA levels were not 
examined in any of these studies, which makes it is difficult to make a direct 
comparison to the current results.  
TGFβ1 is an important mediator in the development of fibrosis, inducing MF 
transdifferentiation and the expression of many profibrotic proteins (Dobaczewski 
et al. 2011;Yan et al. 2011). TGFβ1 is known to promote the expression of a vast 
range of genes/proteins including CTGF (Chen et al. 2000;van Nieuwenhoven et 
al. 2013), αSMA and PAI-1 (Kawano et al. 2000;Li et al. 2008) in CFs. CTGF has 
been shown to be upregulated in human cardiac disease (Chen et al. 
2000;Koitabashi et al. 2007;Wu et al. 2014) and has been implicated in the 
promotion of cardiac fibrosis (reviewed in Daniels et al. 2009). In the present 
study, TGFβ1 was shown to upregulate CTGF, which was slightly reduced by 
combination treatment with IL-1β. A slight reduction in TGFβ1-mediated increase 
in CTGF protein was also observed in airway SMCs following IL-1β treatment (Xie 
et al. 2005). Conversely, in human CFs, TGFβ1 did not induce a significant 
increases in CTGF mRNA following 24 h stimulation (van Nieuwenhoven et al. 
2013). In the same study, IL-1α significantly reduced CTGF mRNA expression, 
which was inhibited by combination treatment with TGFβ1 (van Nieuwenhoven et 
al. 2013), similar to the results found in the present study with IL-1β. This 
illustrates very similar effects of IL-1α and IL-1β on CTGF expression. 
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RACFs used in this study were already shown to have a high expression of αSMA, 
suggesting conversion to MFs in culture. The levels of αSMA mRNA levels were 
significantly reduced by IL-1β treatment, which is in line with data from other 
studies completed in CFs (Bronnum et al. 2013;Saxena et al. 2013). TGFβ1 is well 
established to enhance αSMA expression in CFs (Bronnum et al. 2013;Yan et al. 
2011), however in the present study only a trend for upregulation of αSMA was 
found. This may be a consequence of already high αSMA levels in the RACFs 
utilised, which could also be the case for other TGFβ1 controlled genes examined 
in this study. Similarly, Saxena et al. (2013) reported no change in αSMA following 
24 h stimulation with TGFβ1 of CFs that had high basal levels of αSMA mRNA. In 
this study the increase in αSMA was only beginning to reach significance following 
72 h stimulation with TGFβ1, suggesting longer stimulations may be required to 
see a significant increase. Conversely, in lung and dermal fibroblasts an increase 
in αSMA was seen following 24 h stimulation with TGFβ1 (Mia et al. 2014). In 
agreement with other reports, co-stimulation of fibroblasts with IL-1β and TGFβ1 
resulted in a significant reduction in αSMA mRNA (Mia et al. 2014;Saxena et al. 
2013). Additionally, IL-1β inhibits TGFβ1-induced contraction of collagen pads by 
CFs (Saxena et al. 2013), supporting the ability of IL-1β to prevent fibroblast 
activation.  
The levels of PAI-1 mRNA were also examined in the present study, which has been 
previously been shown to be upregulated by TGFβ1 treatment in CFs (Li et al. 
2008). In the present study, there were no significant changes in PAI-1 mRNA over 
all conditions examined, although a trend for upregulation was seen in RACFs 
stimulated with TGFβ1.  
The transcriptional repressors snail and slug have been predominately investigated 
in the setting of epithelial–mesenchymal transition, the process of epithelial cells 
transdifferentiating to a cell with a mesenchymal phenotype (Lamouille et al. 
2014). TGFβ1-mediated increases in CTGF and collagen 1α1 mRNA were prevented 
in CFs that had snail knocked out (Biswas and Longmore 2016). These 
snail-depleted CFs also had reduced αSMA levels in comparison to control CFs, 
demonstrating the importance of snail in CF activation. Snail has previously been 
reported to be increased after TGFβ1 stimulation of CFs (Biswas and Longmore 
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2016), however in the present study only a small increase in snail was detected. 
A tendency for a reduction in snail expression was seen in cells stimulated with 
IL-1β. Conversely, others have found IL-1β to increase snail expression in squamous 
cell carcinoma cell lines (Lee et al. 2015;St John et al. 2009). The reasons for 
these differences are unknown, however if snail is important in fibroblast 
activation it may reflect the reported inhibitory effect of IL-1β on fibroblast 
activation (Bronnum et al. 2013;Mia et al. 2014;Saxena et al. 2013). IL-1β also 
induced a decrease in slug mRNA expression. It is important to note that these 
experiments only examined the effect of IL-1β and TGFβ1 on gene expression 
therefore further work is required to demonstrate the effects at the protein level.  
4.5 Summary 
IL-1β upregulates Cx43 at the gene and protein level in RACFs. The data suggest 
IL-1β acts at the IL-1R activating NF-κB, p38 MAPK and MEK1 as well as inhibiting 
JNK to promote increases in Cx43. Furthermore, IL-1β inhibits expression of the 
profibrotic marker, CTGF and the MF marker, αSMA, as well as reducing the 
expression of snail in RACFs. This suggests IL-1β may have anti-fibrotic actions on 
RACFs. Conversely, TGFβ1 significantly enhanced CTGF expression but had no 
significant effect on αSMA, PAI-1, snail and slug expression. Interestingly, TGFβ1 
inhibited IL-1β–induced downregulation of CTGF and snail and slightly reduced the 
reduction in αSMA expression. There was no effect of TGFβ1 on IL-1β-mediated 
decrease in slug expression. Together these data suggest opposing actions of IL-1β 
and TGFβ1 on CF activation.  
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Chapter 5 Co-culture investigation of cardiac 
myocyte: fibroblast interactions 
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5.1 Introduction 
As described in section 1.8 co-culture studies have illustrated many paracrine, 
mechanical and electrical interactions between CMs and CFs. Although neonatal 
CMs are useful to study the interactions between CMs and CFs, their clinical 
significance is limited due to many differences between neonatal and adult CMs. 
For instance, neonatal CMs have no to very little development of T-tubules (Chen 
et al. 1995a;Haddock et al. 1999), altered Ca2+ handing (Haddock et al. 
1999;Poindexter et al. 2001) and display spontaneous contractions (Qu et al. 
2001). These dissimilarities illustrate the importance of studying the effects of 
CFs on adult CMs. However, issues with adult CM culture makes this difficult. 
5.1.1 Culture effect on adult cardiac myocytes 
Adult CMs are a terminally differentiated cell type, however in culture they are 
well established to dedifferentiate (Fredj et al. 2005a;Fredj et al. 2005b). This 
results in a morphological change from rod shaped to neonatal-like (Poindexter et 
al. 2001). Some studies have utilised dedifferentiated CMs instead of CMs from a 
neonatal origin in anticipation that they would mimic a more mature phenotype. 
Indeed, in terms of Ca2+ handing, dedifferentiated CMs appeared to have an 
intermediate phenotype. For instance, like freshly isolated CMs, dedifferentiated 
adult CMs have Ca2+ transients which rely on the RyR, but also have an IP3 mediated 
component, which is typical of neonatal CMs (Poindexter et al. 2001). 
Additionally, Ca2+ and electrical activity in functional monolayers produced from 
long term culture (over 21 days) of guinea pig adult CMs were similar to that of 
the adult phenotype (Joshi-Mukherjee et al. 2013). Interestingly, in HF 
reactivation of foetal genes has been observed (Thum et al. 2007), which may 
suggest the initiation of CM dedifferentiation in disease. Additionally, in 
co-culture, CFs were reported to promote CM dedifferentiation, which may have 
an impact in the setting of disease (Dispersyn et al. 2001). 
In short term culture adult CMs develop rounded edges (Leach et al. 2005;Louch 
et al. 2004;Stimers and Dobretsov 1998), show decreased T-tubule density (Leach 
et al. 2005;Louch et al. 2004) and disorganised expression of Ca2+ handling proteins 
including the RyR and the pore forming subunit of the LTCC (Leach et al. 2005). 
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Although the rod shape of adult CMs is maintained for up to 72 h culture (Ellingsen 
et al. 1993;Louch et al. 2004), contractile and electrophysiological alterations 
have been reported. For instance rat adult CMs show a 30-50 % reduction in 
contractility over 6-24 h in culture, which was maintained from 24 to 72 h 
(Ellingsen et al. 1993). Additionally, the APD50 was markedly reduced by 60-70 % 
following 24 h (Ellingsen et al. 1993). Similarly, in swine adult CMs the APD50 was 
progressively reduced over 72 h in culture (Louch et al. 2004). In contrast APD90 
was gradually prolonged in culture indicating an AP shape change (Louch et al. 
2004). This may reflect reductions in the ICaL and IK1 therefore shortening the AP 
plateau and prolonging late repolarisation respectively. Indeed, IK1 was shown to 
be reduced at potentials between -20 and -60 mV in these cells (Louch et al. 
2004).  
Modifications of T-tubules, LTCCs and RyRs are likely to alter Ca2+ handling within 
the cell. Indeed, delayed SR release in swine adult CMs was demonstrated to 
become more evident after 24 and 72 h culture compared to freshly isolated cells 
(Louch et al. 2004). Additionally, the rise of the Ca2+ transient was significantly 
delayed at 24 and 72 h of culture and there was a trend for reduced Ca2+ transient 
amplitude (Louch et al. 2004). The reduction in the density of T-tubules in culture 
has been shown to differ between species. Mouse adult CMs showed no reduction 
in T-tubules over 72 h, conversely in rat adult CMs there was a progressive 
reduction over 72 h, which could not be prevented by chronic pacing (Pavlovic et 
al. 2010). Despite this, mouse adult CM did not respond to acute pacing 24 h 
following isolation while 85 % of rat adult CM still produced contraction following 
72 h (Pavlovic et al. 2010). This suggests rat CMs are more resistant to some 
effects of culture than murine cells.  
5.1.2 Adult cardiac myocyte: fibroblast co-culture models   
To date, there has been a limited number of studies investigating the functional 
effects of direct CM: CF interactions in adult cells. Typically co-culture models 
have involved the seeding of freshly isolated CMs on to preplated cultured 
fibroblasts (Chilton et al. 2007;Dispersyn et al. 2001). As well as calcein dye 
transfer between adult CMs and CFs (Chilton et al. 2007;Driesen et al. 2005), 
stimulation of adult rabbit CMs in co-culture resulted in a progressive increase in 
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[Ca2+]i of surrounding CFs, which was inhibited by the GJ uncoupler, heptanol, 
providing further evidence of heterocellular coupling (Chilton et al. 2007). Despite 
this no impact on APD90 was detected. A similar co-culture model has been utilised 
in the current study to provide information on the effects of co-culture on 
contraction and APs of rat adult CMs.  
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5.2 Aims 
• To assess the effects of untreated control and IL-1β treated RACFs on rat 
adult CM contraction and electrical activity. 
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5.3 Results 
This study utilised a cell culture model where freshly isolated CMs were seeded 
on to laminin coated dishes (control) or RACF monolayers and cultured overnight. 
Initially, the ability of calcein to transfer from pre-loaded CMs to the underlying 
RACFs was assessed. Following addition of CMs to the RACF monolayer, cells were 
imaged using confocal microscopy, typically between 0 and 1 h from CM addition, 
to locate the presence of calcein. Cells were then cultured overnight and imaged 
following approximately 20 h from initial CM addition. At 0-1 h, calcein was only 
detected in the overlaying CMs (top panel -Figure 5-1), however the following day, 
calcein could be detected in RACFs located below (middle and bottom panels - 
Figure 5-1), suggesting functional heterocellular GJ formation. As well as transfer 
of calcein, RACFs were shown to pull on the CMs suggesting mechanical 
interactions between the cells (red arrows - Figure 5-1).  
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Figure 5-1 Representative images showing the localisation of calcein in CMs and RACFs 
immediately after the addition of loaded CMs to the  RACF monolayer (0-1 h) and following 20 
h in culture. 
Freshly isolated CMs were loaded with 5 µM calcein for 30 min at 37 ⁰C and washed three times in 
PBS. 1×104 rod shaped CMs in 0.5 % FBS media were then added to a RACF monolayer in 35 mm 
glass bottomed petri dishes. The localisation of calcein was visualised immediately following CM 
addition (0-1 h) then again following 20 h (upper and middle panels respectively). The areas 
surrounded in the red box in the middle panel are expanded in the bottom panel showing calcein dye 
transfer into the underlying RACFs depicted by white arrows. Red arrows show examples of areas 
of the CM being pulled by the underlying RACFs. Images were taken on the Zeiss 510 LSM confocal 
microscope at x25 magnification. Scale bar represents 100 µm on the upper and middle panels and 
50 µm on the lower panel (n=2). 
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5.3.1 Effect of control or IL-1β treated RACFs on the contraction 
of cultured CMs 
Initially, cultured CMs were evaluated for the ability to contract in response to 
stimulus. Individual cells were selected at random and paced at 1 Hz and at 30 % 
above the voltage required to produce a contraction. A steady state of contraction 
was reached by pacing for 1 min prior to contraction measurement. A 
representative contraction trace (Figure 5-2Ai) along with an exemplar 
contraction trace which had a large volume of noise (Figure 5-2Aii) is shown. This 
noise was found to interfere with Dn90, CD10 and occasionally CD25, illustrated 
by large variation in these values (Figure 5-2B); therefore unfortunately these 
parameters could not be examined with accuracy in future analysis. Up90 (which 
is referred to as 10-90 % rise time in subsequent graphs), CD50, CD75 and CD90 
were 22.6 ± 0.7, 48.9 ± 7.8, 31.8 ± 5.3 and 18.5 ± 3.3 ms respectively (Figure 
5-2B).   
As functional contraction measurements could be recorded from cultured CMs, the 
effect of co-culturing CMs with RACFs was examined. CMs in culture alone 
(control) or in the presence of a RACF monolayer maintained their rod-like 
morphology (Figure 5-3A). Cultured CMs were found to require a greater voltage 
to induce contraction in the presence of RACFs (15.6 ± 1.1 vs. 21.3 ± 0.5 V, control 
vs. RACF monolayer; P<0.05; Figure 5-3B). Representative contraction traces from 
control CMs and CMs cultured with a RACF monolayer are shown (Figure 5-4Ai and 
ii respectively). No significant changes in the contraction parameters were 
detected between the groups (Figure 5-4B-E). However there was a consistent 
slight decrease in all these parameters in the presence of the RACF monolayer.  
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Figure 5-2 Contraction traces and contraction parameters that can be measured from cultured 
CMs. 
CMs were cultured for 24 h prior to pacing at 1 Hz and 30 % above the threshold voltage for each 
cell. (Ai) A representative contraction trace and an (Aii) example of a contraction trace where Dn90 
and CD10 values were unreliable due to peaks in the noise (arrows) which interfered with values. 
Scale bar represents 1 second. (B) Contraction parameters measured in cultured CMs from two 
hearts. Each point represents an individual cell and the mean is denoted by a line (n= 11 from two 
animals for all parameters except Dn90 and CD10 where n= 9). Up90; time from 10 % - 90 % 
contraction, Dn90; time from 10 % - 90 % relaxation, CD10; time from 10 % contraction - 90 % 
relaxation, CD25; time from 25 % contraction – 75 % relaxation, CD50; time from 50 % contraction 
- 50 % relaxation, CD75; time from 75 % contraction – 25 % relaxation, CD90; time from 90 % 
contraction – 10 % relaxation. 
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Figure 5-3 Representative images and stimulation threshold values of CMs cultured alone or 
with a RACF monolayer.  
(A) Images of representative CMs cultured for 24 h alone or with a RACF monolayer. (B) Cells were 
paced at 1 Hz and the voltage increased by 1V increments until the cell started to contract, taken as 
the stimulation threshold. Each point represents an individual cell and the mean is denoted by a line. 
n= 19 and n= 17 in control and RACF monolayer groups respectively from two animals. *P<0.05 vs. 
control (Student’s unpaired t-test).  
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Figure 5-4 Contraction measurements in CMs cultured alone or with a RACF monolayer. 
(A) Representative contraction traces from (i) CMs cultured alone or (ii) with a RACF monolayer. 
Scale bar represents 1 second. (B) 10-90 % rise time, (C) CD50, (D) CD75 and (E) CD90 values 
from CMs from two hearts. Each point represents an individual cell and the mean is denoted by a 
line. n= 11 and n= 15 in control and RACF monolayer groups respectively from two animals. No 
significant changes were detected using a Student’s unpaired t-test. CD50; time from 50 % 
contraction - 50 % relaxation, CD75; time from 75 % contraction - 25 % relaxation, CD90; time from 
90 % contraction - 10 % relaxation.  
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IL-1β concentration is increased in disease (Di et al. 2003) and it has been shown 
to augment Cx43 levels in RACFs (Chapter 4), therefore potentially enhancing 
coupling in co-culture and potentiating the effect of RACFs on CM function. 
Therefore the effect of IL-1β treated RACFs on the contraction of cultured CMs 
was examined. In this set of experiments RACFs were cultured in reduced serum 
for the longer time period of 48 h prior to CM addition. This was due to serum 
starvation 24 h before IL-1β stimulation for a further 24 h. There were no 
significant differences in voltage required to induce contraction between the 
groups (Figure 5-5). A representative contraction trace from control CMs and CMs 
in culture with untreated or IL-1β treated RACFs as well as with an image of the 
corresponding CM are shown (Figure 5-6A). There was no significant difference in 
the rise times for contraction between the groups (Figure 5-6B and Table 5.1). 
However, CD50, CD75 and CD90 were significantly reduced in CMs cultured with a 
RACF monolayer in comparison to control (all P<0.05). However, when CMs were 
cultured with RACFs which had been pre-treated with IL-1β, CD50, CD75 and CD90 
measurements were partially restored resulting in values not significant from 
control CMs alone or CMs cultured with a control RACF monolayer (Figure 5-6 and 
Table 5.1). 
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Figure 5-5 Stimulation threshold values of CMs cultured alone, with an RACF monolayer or 
with an IL-1β treated RACF monolayer. 
CMs were paced at 1 Hz and the voltage increased by 1V increments until the cell started to contract, 
taken as the stimulation threshold. Each point represents an individual cell and the mean is denoted 
by a line. n= 39 for all groups from three animals. No significant changes were detected using a one-
way ANOVA with Tukey’s multiple comparison test. 
 
  
C
on
tr
ol
R
A
C
F 
m
on
ol
ay
er
IL
-1
 R
A
C
F 
m
on
ol
ay
er
176 
 
 
Figure 5-6 Contraction measurements in CMs cultured alone, with an RACF monolayer or with 
an IL-1β treated RACF monolayer. 
(A) Representative traces and images of CMs cultured alone (top), with a RACF monolayer (middle) 
or with an IL-1β treated RACF monolayer (bottom). Scale bar represents 200 ms. (B) 10-90 % rise 
times, (C) CD50, (D) CD75 and (E) CD90 values from CMs from three hearts. Each point represents 
an individual cell and the mean is denoted by a line. n= 33, n= 29 and n= 25 for control, RACF 
monolayer and IL-1β RACF monolayer groups respectively from three animals. *P<0.05 vs. control 
(one-way ANOVA with Tukey’s multiple comparison test). CD50; time from 50 % contraction - 50 % 
relaxation, CD75; time from 75 % contraction - 25 % relaxation, CD90; time from 90 % contraction - 
10 % relaxation. 
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Table 5.1 Contraction parameter values of CMs in control, RACF monolayer and IL-1β RACF 
monolayer treatment groups.  
Values are represented as mean ± SEM. n= 33, n= 29 and n= 25 for control, RACF monolayer and 
IL-1β RACF monolayer groups respectively from three animals. *P<0.05 vs. control (one-way 
ANOVA with Tukey’s multiple comparison test. 
  
Contraction 
Parameter 
Control RACF monolayer IL-1β RACF 
monolayer 
10-90 % rise time 20.6 ± 0.5 ms 17.9 ± 0.9 ms 20.4 ± 0.7 ms 
CD50 56.7 ± 7.0 ms 36.1 ± 1.1 ms* 39.6 ± 2.6 ms 
CD75 29.8 ± 2.0 ms 22.7 ± 0.6 ms* 25.1 ± 1.4 ms 
CD90 17.5 ± 1.4 ms 12.7 ± 0.6 ms* 14.3 ± 0.9 ms 
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5.3.2 Effect of control or IL-1β treated RACFs on the action 
potential of cultured CMs 
The effect of culture on the AP 10-90 % rise time, APD20, APD50 and APD80 was 
determined by examining these parameters in freshly isolated and cultured CMs. 
Rise time, APD20 and APD50 values were very similar between freshly isolated and 
cultured CMs (Figure 5-7 and Table 5.2). There was also no significant change in 
APD80 between cultured CMs and freshly isolated CMs (45.5 ± 1.2 vs. 55.4 ± 4.4 ms, 
fresh vs. cultured CMs; Figure 5-7E and Table 5.2).  
Next the effect of an untreated or IL-1β treated RACF monolayer on AP parameters 
was examined. There were no significant changes in 10-90 % rise time, APD20, 
APD50 or APD80 between control CMs (CMs cultured alone) and CMs cultured with 
either a RACF monolayer or an IL-1β treated RACF monolayer (Figure 5-7 and Table 
5.2). However, there may be evidence for slight APD80 prolongation in the 
presence of a RACF monolayer (55.4 ± 4.4 vs. 71.0 ± 7.8 ms, control vs. RACF 
monolayer; Figure 5-8E and Table 5.2), which is marginally suppressed by IL-1β 
treatment of RACFs (71.0 ± 7.8 vs. 65.0 ± 5.5 ms, RACF monolayer vs. IL-1β RACF 
monolayer; Figure 5-8E and Table 5.2).   
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Figure 5-7 Action potential measurements in freshly isolated CMs and CMs cultured for 24 h. 
(A) A representative average action potential (AP) from a freshly isolated CM and a CM cultured for 
24 h. Scale bar represents 50 ms. (B) AP 10-90 % rise time, (C) duration at 20 % repolarisation 
(APD20), (D) duration at 50 % repolarisation (APD50) and (E) duration at 80 % repolarisation (APD80) 
in CMs from three hearts. Each point represents an individual cell and the mean from each heart is 
denoted by a line. CMs are separated into individual hearts due to the large number of cells per 
group. n= 85, and n= 122 for fresh and cultured groups respectively from three animals. No significant 
changes were detected using a Student’s unpaired t-test.  
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Figure 5-8 Action potential measurements in CMs cultured alone, with an RACF monolayer 
or with an IL-1β treated RACF monolayer. 
(A) A representative average action potential (AP) from a CM cultured alone, with an RACF 
monolayer or IL-1β treated RACF monolayer. Scale bar represents 50 ms. (B) AP 10-90 % rise time, 
(C) duration at 20 % repolarisation (APD20), (D) duration at 50 % repolarisation (APD50) and (E) 
duration at 80 % repolarisation (APD80) of CMs from three hearts. Each point represents an individual 
cell and the mean from each heart is denoted by a line. Values are separated into individual hearts 
due to the large number of cells. n= 122, n= 90 and n= 99 for control, RACF monolayer and IL-1β 
RACF monolayer groups respectively from three animals. No significant changes were detected 
using a one-way ANOVA with Tukey’s multiple comparison test. 
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Table 5.2 Action potential parameter values of fresh CMs and cultured CMs in control, RACF monolayer and IL-1β RACF monolayer treatment groups. 
 
 
 
 
 
 
 
 
 
Values are represented as mean ± SEM. n= 85, n= 122, n= 90 and n= 99 for fresh, cultured, RACF monolayer and IL-1β RACF monolayer groups respectively. No 
significant changes were detected using a one-way ANOVA with Tukey’s multiple comparison test. 
AP parameter Fresh Cultured (control) RACF monolayer IL-1β RACF monolayer 
10-90 % rise time 4.2 ± 0.3 ms 4.3 ± 0.4 ms 4.5 ± 0.4 ms 4.3 ± 0.2 ms 
APD20 9.3 ± 0.6 ms 9.5 ± 0.6 ms 10.3 ± 0.7 ms 10.0 ± 0.2 ms 
APD50 22.6 ± 1.1 ms 24.1 ± 1.6 ms 26.8 ± 2.3 ms 27.5 ± 1.8 ms 
APD80 45.5 ± 1.2 ms 55.4 ± 4.4 ms 71.0 ± 7.8 ms 65.0 ± 5.5 ms 
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5.3.3 Examination of RACF presence in control cultures 
In this study, CMs were seeded directly onto laminin coated petri dishes or 
monolayers of RACFs without any preplating of CMs. Preplating is commonly 
completed in other studies to remove CFs from cultures (Gaudesius et al. 
2003;Grand et al. 2014;Miragoli et al. 2006). Therefore, RACFs may be present in 
the control cultures in small numbers. Vimentin staining of control cultures fixed 
following the recording of APs was utilised to identify the presence of 
contaminating RACF. The staining revealed vimentin positive cells (top panel - 
Figure 5-9). However, the presence of vimentin-positive cells was negligible in 
comparison to RACF and IL-1β RACF monolayers (Figure 5-9).   
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Figure 5-9 Vimentin immunofluorescence in cultures of CMs seeded on laminin coated plates 
(control) or on a monolayer of untreated or IL-1β treated RACF. 
Cultures were fixed following action potential measurement and cells stained for vimentin (red). 
Nuclei were counterstained with DAPI (blue). White arrows depict vimentin staining in cells other 
than CMs in control cultures. All images were taken at x25 magnification on the Zeiss 510 LSM 
confocal microscope and normalised to IgG (bottom panel). Scale bar represents 100 µm (n=3).  
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5.4 Discussion 
An adult CM: CF co-culture model allowing direct and indirect cell interactions, 
as well as the measurement of contraction and APs from CMs was successfully 
established. In this model, calcein was shown to be transferred from CMs to RACFs, 
suggesting the formation of functional GJs between the cells. RACFs were shown 
to significantly reduce the CD of CMs but had no significant effect on APD80. 
Interestingly the effects of RACFs were reduced, albeit not quite to control values, 
when RACFs were treated with IL-1β.   
The formation of heterocellular GJs is supported by calcein dye transfer between 
adult cells following 20 h in culture, which is line with other reports (Chilton et 
al. 2007;Cho et al. 2007;Driesen et al. 2005). Calcein transfer between adult CMs 
and CFs has previously been reported to occur as early as 1-1.5 h (Cho et al. 
2007;Driesen et al. 2005). Only following 48 h co-culture was the transfer of the 
high MW tracer, dextran (10 kDa), from adult CFs to adult CMs observed, 
suggesting membrane fusion between the cells at this time point which is out with 
the time frame of current investigations (Driesen et al. 2005). Additionally, 
mechanical interactions between CMs and RACFs was observed, where regions of 
CM membranes were visualised to be being “pulled” by RACFs. This phenomenon 
this has been reported by others (Dispersyn et al. 2001;Driesen et al. 2005) and 
may be a contributing factor for the reduction in CD of CMs in co-culture due to 
restriction of normal CM contraction. Furthermore, greater expression of αSMA in 
CFs is likely to enhance the contractile force elicited on CMs. It is therefore 
reasonable to suggest that reduced αSMA in CFs as a result of IL-1β treatment 
(Chapter 4; Bronnum et al. 2013;Saxena et al. 2013) could contribute to less 
contractile force, consequently elevating restriction of CM contraction and effects 
on CD as reported in the current study. Indeed, IL-1β was shown to inhibit 
TGFβ-mediated contraction of collagen pads by CFs (Saxena et al. 2013), 
supporting this hypothesis.  
As well as direct cell-to-cell interactions, the model used in the current study 
allows for paracrine heterocellular interactions to occur which may also have 
effects on CM contraction. Indeed, spontaneous contractions of neonatal CMs was 
inhibited following treatment with FCM for 72 h, in comparison to control CM 
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cultures which displayed continued contractions (LaFramboise et al. 2007). 
Furthermore, as CM contraction is reliant on Ca2+, changes in contraction likely 
reflect alterations in Ca2+ handling. Although Ca2+ was not measured in the current 
study, Cartledge et al. (2015) found the Ca2+ transient decay to be faster in the 
adult CMs in a CM: CF co-culture transwell model in comparisons to CMs alone 
(Cartledge et al. 2015). This could explain the results of the present study due to 
quicker uptake/efflux of Ca2+ in the presence of CFs therefore leading to reduced 
CD. Interestingly this effect on the Ca2+ transient was ablated by TGFβ inhibition, 
demonstrating a role for TGFβ signalling between the cell types (Cartledge et al. 
2015).  
In the current study, although the CD was shortened there was no significant 
change in APD80 in CMs cultured with a RACF monolayer. Generally, shortening of 
the Ca2+ transient and CD would be expected to correlate with a shortening of 
APD, as shown by others (Weisser-Thomas et al. 2003). However, a trend for APD80 
prolongation in these co-cultured CMs was observed which may indicate that with 
further repeats a significant change could be observed. Paracrine factors, 
although not identified, from CFs have been reported to cause a prolongation of 
the APD in neonatal CMs (Pedrotty et al. 2009). Additionally, TGFβ1 released by 
CFs has been suggested to cause prolongation of the APD in rat adult CMs (Kaur et 
al. 2013). Conversely, FCM from healthy CFs had no effect on the APD of neonatal 
CMs, in fact FCM from CF-MI promoted the opposite effect of APD shortening 
(Vasquez et al. 2010). In a similar co-culture model to the one utilised in the 
current study with rabbit cells, there was no difference in APD90, despite evidence 
for coupling between the cells (Chilton et al. 2007).  
A CF-mediated increase in APD of neonatal CMs has also been postulated to be a 
consequence of electrical coupling through Cx43 (Askar et al. 2012). In the current 
study RACFs treated with IL-1β which had a greater expression of Cx43, (Chapter 
4), decreased the effects on CM contraction and APD compared to those in the 
presence of control untreated RACFs. This could potentially suggest a lack of 
involvement for Cx43 in the RACF-mediated effects. However, the functionality 
of GJs between CMs and IL-1β treated RACFs was not investigated in the present 
study, and is therefore an avenue for future work. Additionally, it is unlikely that 
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all CMs studied were coupled to RACFs; therefore differences in well coupled CMs 
could be diluted, contributing to the lack of APD80 significance. Therefore in 
further studies calcein could be used to detect adequately coupled cells and 
parameters measured. The previous study which reported the involvement of 
Cx43, also showed a delay in the AP upstroke in co-culture which was partly 
recovered by Cx43 knockdown (Askar et al. 2012). However, no change in AP 
upstroke was shown in the current study.  
As previously described, sharing of media between CMs and CFs promoted a faster 
Ca2+ transient decay than in CMs alone. Interestingly, this was slightly more 
apparent when CFs originated from a MI heart, therefore likely to be MFs 
(Cartledge et al. 2015). This could potentially explain why control RACFs induced 
greater effects than IL-1β treated RACFs, due to the reports that IL-1β inhibits the 
activation of CFs to the MF phenotype (Bronnum et al. 2013;Saxena et al. 2013). 
Indeed as shown in Chapter 4, IL-1β treated RACFs had significantly lower mRNA 
expression of the profibrotic MF markers, CTGF and αSMA, in comparison to control 
RACFs. Furthermore, other paracrine factors released by these different 
phenotypes of RACFs examined may explain the difference in result and requires 
further investigation.  
5.5 Summary 
Evidence for functional GJs between adult CMs and CFs has been provided in the 
current co-culture model. Here, RACFs were shown to shorten the CD and slightly 
enhance APD of adult CMs. Additionally, the effects of IL-1β on RACFs were shown 
to consistently elevate these effects. The reasons for these effects still require 
examination however could include restriction of contraction through mechanical 
interactions, paracrine interactions and potentially the involvement of 
heterocellular GJs.  
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Chapter 6 Establishing a model to investigate 
cardiac myocyte: fibroblast interactions via optical 
mapping in the intact heart 
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6.1 Introduction 
6.1.1 Intramyocardial cell injection models 
Direct intramyocardial cell injections have been investigated for both 
preventative and therapeutic use in experimental models of MI. Typically these 
studies have used genetically modified cells intended to provide a local release of 
therapeutic substances or to promote regeneration of the heart (Etzion et al. 
2002;Goncalves et al. 2010;Ruvinov et al. 2008). Fibroblasts have been identified 
as a valuable cell type for this area of research. For instance, the injection of 
1 × 106 CFs transduced with an Ad vector inducing the overexpression of the 
angiogenic factor, vascular endothelial growth factor (VEGF), 7 days prior to MI 
led to enhanced VEGF protein levels and capillary density 3 weeks later (Goncalves 
et al. 2010). Interestingly, this study found transgene expression to be maintained 
for least 45 days following injection versus only 7 days when the cell vector utilised 
was SMs, suggesting greater retention of CFs (Goncalves et al. 2010).  
Injection of cells directly into the myocardial scar has also been reported. The 
retention of 5 × 105 dermal fibroblasts within the MI scar of mice was assessed by 
van der Bogt et al. (2009). This study reported a decrease in viability of dermal 
fibroblasts originating from mice which ubiquitously express GFP and firefly 
luciferase reporter genes, over 28 days from injection measured by 
bioluminescence. Viability was found to be significantly reduced at 10 days 
following injection from viability assessed at day 2 (van der Bogt et al. 2009). 
Additionally, injection of 1 × 106 neonatal CFs transduced with a retrovirus to 
overexpress recombinant human erythropoietin in a final volume of 100 μL into 
the MI scar of Sprague-Dawley rats enhanced vascularisation in the scar (Ruvinov 
et al. 2008). Furthermore, an GFP signal was detected 7 days following injection 
of 1.5 × 106 CFs transduced with AdGFP (total volume of 150 μL in serum free 
DMEM) into the scar of Sprague-Dawley rats (Etzion et al. 2002). These cells were 
shown to form a viable graft 4 weeks after injection which was noted in some 
cases to be segregated from the host scar and viable myocardium (Etzion et al. 
2002).  
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The therapeutic use of fibroblast injection in the modulation of atrioventricular 
(AV) conduction in AF has also been reported. For instance the AH interval, a 
measure of AVN conduction time, was increased following injection of autologous 
dermal fibroblasts (ADFs) and more so when TGFβ1 was co-injected with ADFs into 
the canine AVN (Bunch et al. 2006). Similarly, the injection of ADFs into the AVN 
of the swine heart prolonged the P-R interval, hence slowing AV conduction 
(Tondato et al. 2015). These cells were shown to be retained at the site of 
injection for 28 days (Tondato et al. 2015). Ideally, both these studies showed no 
AV conduction block (Bunch et al. 2006;Tondato et al. 2015).  
Intramyocardial injection of fibroblasts has also been utilised to modulate the 
electrophysiology of CMs. Cho et al. (2007) generated a stable fibroblast cell line 
from guinea pig lung fibroblasts which expressed the pacemaker channel, 
hyperpolarization activated cyclic nucleotide gated potassium channel 1 (HCN1), 
and GFP using LV transduction. These cells where then injected into the apex of 
the guinea pig heart in 50 % polyethylene-glycol 1500 solution, a reagent used to 
promote cell fusion (Lentz and Lee 1999). This enabled the fibroblasts to fuse with 
host CMs resulting in pacemaker like properties in isolated CMs, such as 
spontaneous action potentials and a slow phase 4 (Cho et al. 2007). Additionally, 
coupling between injected NIH-3T3 fibroblasts stably expressing the voltage-gated 
potassium channel, Kv1.3, and host CMs has been reported by Yankelson et al. 
(2008). In this study, 6 × 106 fibroblasts were injected into the healthy left 
ventricle of the male Sprague-Dawley rats and electrophysiological effects 
assessed in vivo 7 days following injection (Yankelson et al. 2008). A significant 
prolongation of the ERP, which can be antiarrhythmic, was observed at the 
injection site which was not observed at a remote region of the heart. There was 
also a marginal increase in the ERP at the sites injected with WT NIH-3T3 
fibroblasts (Yankelson et al. 2008). 
Injection of embryonic CMs (eCMs), but not embryonic SMs, adult bone marrow 
cells or embryonic CFs into the murine ventricular scar were reported to reduce 
the insistence of induced VT (Roell et al. 2007). Cx43 expression in eCMs was found 
to be an important contributing factor to these effects illustrated by a 4-fold 
increase in CV within the infarct in animals injected with eCMs in comparison to 
sham hearts. There was also greater conduction slowing in the infarct in 
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comparison to the rest of the heart following perfusion of the GJ blocker, 
carbenoxolone. Additionally, SMs overexpressing Cx43 had a similar effect on 
reduced induced VT of eCMs, supporting the importance of Cx43 in injected cells 
(Roell et al. 2007).  
Vehicles used for cell transplantation have included DMEM (Goncalves et al. 2010), 
BSA (Christman et al. 2004) and PBS/saline (Ruvinov et al. 2008;van der Bogt et 
al. 2009). Furthermore, cells injected with fibrin biopolymer into the scar of 
Sprague-Dawley rats has been shown to increase the retention of SMs injected 
after 5 weeks (Christman et al. 2004). However, studies investigating coupling 
between injected and host cells may not benefit from a fibrin biopolymer vehicle 
which may prevent coupling between cells. Total fibroblast number and volumes 
injected into the rat heart have ranged from 1-6 × 106 and 100-300 μL respectively 
in previous studies (Etzion et al. 2002;Goncalves et al. 2010;Ruvinov et al. 
2008;Yankelson et al. 2008).  
6.1.2 Optical mapping  
OM is a technique commonly used in whole heart AP measurement. This allows 
tens of thousands of sites, and therefore action potentials to be recorded 
simultaneously (Burton and Cobbe 2001). Typically, photodiode arrays  and 
charge-coupled device (CCD) cameras have been used as photodetectors in cardiac 
OM due to their high spatial and temporal resolutions (Herron et al. 2012). 
However, CCDs/CMOS cameras are more advanced than photodiode arrays with 
regard to spatiotemporal resolution due to the larger number of pixels and rapid 
transfer to a computer (Herron et al. 2012). This is particularly useful in order to 
assess cardiac arrhythmias and changes in APs at the whole heart level. It involves 
the perfusion of a voltage-sensitive dye (VSD), which binds to the cell membrane 
and fluoresces light in direct proportion to membrane potential. Indeed, 
simultaneous optical and microelectrode recordings in the intact heart show a 
tight correlation (Efimov et al. 2004). In cardiac OM the VSDs typically used include 
the aminonaphthylethenylpyridinium (ANEP) dye, di-4-ANEPPs, and RH-237 (Mills 
et al. 2006;Omichi et al. 2004;Park et al. 2014;Wang et al. 2014a).  
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As predetermined areas are recorded over time during OM, movement can produce 
artefacts in recordings, one limitation to the technique (Burton and Cobbe 2001). 
This is typically overcome by the use of E-C uncouplers including the myosin 
inhibitors, 2,3-butanedione monoxime  (BDM) and blebbistatin, and/or mechanical 
restraint of the heart to produce accurate recordings (Burton and Cobbe 2001). 
However, BDM has been reported alter the APD (Baker et al. 2004;Liu et al. 1993), 
consequently restricting its use in cardiac OM. Conversely, blebbistatin has no 
effect on AP morphology (Fedorov et al. 2007), making it a more suitable reagent 
for electrophysiological measurements.    
Technological developments now allow multiparametric OM where more than one 
parameter, typically voltage and calcium, can be recorded simultaneously in the 
intact heart (Choi and Salama 2000;Chou et al. 2017;Myles et al. 2015). In the 
current study, this technique has been utilised to detect voltage changes and the 
eGFP signal in areas of the heart injected with AdeGFP or eGFP expressing RACFs.  
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6.2 Aims 
• To establish a model of intramyocardial injection of AdeGFP or RACFs 
transduced with an LVeGFP into the left ventricle of adult male Wistar rat 
hearts. 
• Perform ex vivo OM to determine any difference in APs within regions of 
the heart positive for eGFP in comparison to remote regions. 
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6.3 Results 
In preparation for cell injection into the rat left ventricular myocardium, RACFs 
were transduced with a LVeGFP at an MOI of 12 or 25, 48 h prior to injection. 
Initially an MOI of 12 was used due to efficient transduction of RACFs at this 
concentration (Figure 3-3). However due to some issues with lack of expression 
24 h following transduction, the concentration was doubled to an MOI of 25 to 
ensure that on the day of injection there was sufficient expression. To confirm 
that the treatment of cells prior to injection, including trypsin treatment, 
resuspension in PBS and storage on ice, did not result in cell death, residual cells 
were reintroduced back into culture and monitored until the day of sacrifice and 
OM. Low eGFP expression was detected 48 h following transduction (upper two 
images, Figure 6-1). Despite this, most cells displayed expression, suggesting 
efficient transduction which with time would develop full expression. Little to no 
toxicity was apparent in cells reintroduced into culture, demonstrating the cell 
treatment did not result in cell death. Additionally, these cells demonstrated high 
eGFP expression on the day of OM; approximately 7 days following implantation 
(Lower two images, Figure 6-1).  
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Figure 6-1 Representative images of pre-transduced RACFs with LVeGFP on the day of 
injection into the rat myocardium and of optical mapping. 
RACFs were transduced with LVeGFP at an MOI of 25 two days prior to implantation into the rat 
adult left ventricular myocardium. Cells were imaged for eGFP expression on the day of injection 
(two upper images) prior to trypsin treatment and resuspension in the appropriate volume of PBS. 
Cells were placed on ice and used for injection. Residual cells were then added to a 100 mm culture 
dish and cultured until the day of optical mapping (OM), approximately 7 days following implantation. 
Lower two images show eGFP expression from these recovered cells. Scale bar represents 100 μm. 
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6.3.1 eGFP detection in the myocardium 
Injection of Ad vectors had previously been optimised in house where 5 injections 
of 50 μL volume were performed around the apex of the heart (Zoccarato et al. 
2015). This protocol involved a total of 5 × 108 pfu in sterile PBS in 250 μL, which 
produced CMs expressing the transgene in the region of the injection, 7 days 
following surgery (Zoccarato et al. 2015). Due to this success a similar procedure 
was used in the current study, where 5 × 108 pfu AdeGFP was injected in a smaller 
total volume of 60 μL over two injections into the left ventricle (30 μL per 
injection). Additionally, in another group of animals a total of 1 × 106 RACF 
transduced with LVeGFP in PBS was injected over two 30 μL injections, which was 
at the lower range of fibroblast numbers used in previous studies (Etzion et al. 
2002;Goncalves et al. 2010;Ruvinov et al. 2008;Yankelson et al. 2008). The left 
ventricle was injected as the preparation set up required horizontal orientation 
of the heart and a myocardial surface that was as flat as possible for accurate AP 
recording.  
OM was performed on hearts injected with AdeGFP or RACFs transduced with 
LVeGFP, one week following surgery. In order to record APs over the epicardial 
surface, hearts were perfused with the VSD, RH-237. Voltage and eGFP signals 
were detected by cameras fitted with a long pass 715 nm or a single band 
520/28 nm filter, respectively. In RACF injected hearts, there were five successful 
eGFP detections, however one heart (H1) had to be discarded from analysis due 
to unclear APs (Figure 6-2). There were three hearts in the AdeGFP injected group 
which generally gave a larger eGFP signal in comparison to RACF injected hearts 
(Figure 6-3). Despite two injections, in most hearts only one bright spot was 
detected, although a second potential injection site could be observed in some 
hearts (Figure 6-2 - white arrow). For analysis, four areas were selected and 
labelled 1-4; the full field, the injection site (eGFP bright spot), a region which 
was close to the apex (apical remote region) and finally one close to the base of 
heart (basal remote region) respectively (Figure 6-2 and Figure 6-3). 
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Figure 6-2 Voltage signal, eGFP signal and analysis selection areas of hearts injected with 
eGFP positive RACFs. 
Hearts (H1-5) injected with eGFP positive RACFs were perfused with the voltage sensitive dye, 
RH-237, to give the voltage signal in shown in the first column detected by a camera fitted with a 
long pass 715 nm filter. The eGFP signal (middle column) was detected by a camera fitted with a 
520/28 nm single-band pass filter. eGFP bright spots, indicating the injection site, are depicted by 
red arrows and white arrow indicate the potential region of the second injection. The last column 
shows the selection areas used for analysis numbered 1-4, where 1 = full field, 2 = injection site, 3 = 
apical remote region and 4 = basal remote region. 
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Figure 6-3 Voltage signal, eGFP signal and analysis selection areas of hearts injected with 
AdeGFP.  
Hearts (H1-3) injected with AdeGFP were perfused with the voltage sensitive dye, RH-237, to give 
the voltage signal in shown in the first column detected by a camera fitted with a long pass 715 nm 
filter. The eGFP signal (middle column) was detected by a camera fitted with a 520/28 nm single-
band pass filter. eGFP bright spots, indicating the injection site, are depicted by red arrows. The last 
column shows the selection areas used for analysis numbered 1-4, where 1 = full field, 2 = injection 
site, 3 = apical remote region and 4 = basal remote region. 
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6.3.2 Dynamic pacing  
Hearts were paced at different CLs, beginning at 200 ms, close to the physiological 
rat heart rate (Damasceno et al. 2013). The CL was then progressively shortened 
to increase the heart rate until the heart could no longer be paced. An exemplar 
ECG trace and corresponding APs in both RACF and AdeGFP injected hearts are 
shown (Figure 6-4Ai and ii respectively). The representative APs are from within 
the injection site and in the apical or basal remote regions while the CL was 200ms 
(Figure 6-4Ai and ii).  
Data is presented in two ways, first to illustrate the relationship between the CL 
and either AP rise time (10-90 %) or APD80 (Figure 6-4) and secondly to clearly 
show the difference in these parameters at a set CL between the different regions 
within one heart (Figure 6-5 and Figure 6-6). In the latter graphs, CLs of 120 and 
200 ms were examined (Figure 6-5 and Figure 6-6). The rise time (10-90 %) of APs 
is unaltered by changes in the CL (Figure 6-4B – top graphs). Very little variation 
in rise time between the three sites or between different hearts was detected in 
the RACF group (Figure 6-4Bi – top graph and Figure 6-5A and C). Conversely, in 
the AdeGFP group a larger range of rise times were observed (Figure 6-4Bii – top 
graph). The basal remote regions appear to have the most delayed rise time 
(Figure 6-4Bii – top graph and Figure 6-5B and D). Although the mean line suggests 
that the rise time of APs within the injection site are more prolonged in 
comparison to the apical remote region (Figure 6-4Bii), this is only apparent for 
one of two hearts at CLs of 120 and 200 ms (Figure 6-5B and D).  
As the CL shortened, the APD80 was reduced in both RACF and AdeGFP injected 
hearts (Figure 6-4Bi and ii, lower graphs); a commonly observed relationship 
(Mahajan et al. 2008;Sabir et al. 2010). A large overlap between the APD80 values 
within the different regions, especially within the RACF injected hearts, was 
observed, suggesting no significant change between the regions (Figure 6-4Bi and 
ii, lower graphs). Rise time and APD80 values from CLs below 120 or 100 in RACF or 
AdeGFP groups, respectively are from one heart due to no pacing capture at these 
rates in the other hearts.  
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On further examination of APD80 in RACF injected hearts at CLs of 120 and 200 ms, 
the injection sites and apical remote regions had similar APD80 values. In 
comparison, the APD80 in basal remote regions tend to be shorter (Figure 6-6A and 
C). In AdeGFP injected hearts, there may be slight prolongation in the injection 
site which is more apparent at 200 ms versus 120 ms (Figure 6-6B and D). This was 
more pronounced in heart 1 than in 3.  
  
200 
 
 
Figure 6-4 Relationship between the action potential rise time and duration at different in cycle 
lengths during dynamic pacing in both RACF and AdeGFP injected hearts. 
Hearts were perfused with the voltage sensitive dye, RH237, to allow electrical activity to be 
recorded. (A) An exemplar ECG trace and action potential (AP) traces within the injection site (red), 
apical remote region (blue) and basal remote region (green) when paced at a cycle length (CL) of 
200 ms in both (i) RACF and (ii) AdeGFP injected hearts are shown. Scale bar represents 200 ms. 
(B) Graphs showing the 10-90 % rise time and AP duration at 80 % repolarisation (APD80) in (i) RACF 
(n=4) and (ii) AdeGFP (n=3) injected hearts. Each point represents a different heart and the line 
denotes the average.  
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Figure 6-5 Action potential rise time of hearts injected with RACF or AdeGFP when paced at 
a cycle length of 120 or 200 ms. 
(A-B) Action potential 10-90 % rise time while hearts were paced at a cycle length of 120 ms or (C-
D) 200 ms. (A-C) AP rise time from the injection site and apical and basal remote regions of RACF 
and (B-D) AdeGFP injected hearts are shown. Each symbol represents hearts 2-5 or 1 and 3 in 
RACF or AdeGFP groups respectively.  
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Figure 6-6 Action potential duration of hearts injected with RACF or AdeGFP when paced at 
a cycle length of 120 or 200 ms. 
(A-B) Action potential duration at 80 % repolarisation (APD80) while hearts were paced at a cycle 
length of 120ms or (C-D) 200 ms. (A-C) APD80 from the injection site and apical and basal remote 
regions of RACF and (B-D) AdeGFP injected hearts are shown. Each symbol represents hearts 2-5 
or 1 and 3 in RACF or AdeGFP groups respectively.  
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6.3.3 S1S2 pacing 
Hearts also underwent an extrastimulus pacing protocol known as S1S2, whereby 
hearts were paced at 200 ms (S1) prior to an extra impulse at a shorter CL (S2). 
The S2 was then progressively shortened until it did not produce an AP, and this 
was taken as the ERP. ERP was 64.3 ± 6.3 and 75.3 ± 5.8 ms in the RACF and 
AdeGFP injected hearts, respectively (Figure 6-7). There were no inductions of 
arrhythmias throughout the pacing protocol.  
The APs induced by S2 at a range of CLs were analysed and both the rise time and 
APD80 plotted as before. The same selection areas used in analysis of the dynamic 
pacing data were used for S1S2 analysis, with the addition of an area which was 
the same shape and size as the injection site (Figure 6-8). This was positioned at 
a region which had a similar activation time to the injection site, and referred to 
as remote region 3. As the AdeGFP injection site selection was larger than remote 
regions in two of the three hearts, a smaller region within the injection site was 
selected (labelled 2.5 in Figure 6-8). The rise time and APD80 of APs induced by S2 
in this smaller injection site closely mimicked the values in the original injection 
selection (Figure 6-9) and therefore to maintain consistency the original injection 
selection was used in analysis.  
An ECG trace and traces of APs within the selected regions showing an S1-S2 
interval of 90 ms from both an RACF and AdeGFP injected heart are shown (Figure 
6-10i and ii respectively). Similar to dynamic pacing (Figure 6-4); there was little 
difference in the mean rise time between the regions across the CLs examined in 
RACF injected hearts (Figure 6-10Bi – top graph). Additionally, in AdeGFP injected 
hearts a wide range of rise times were present (Figure 6-10Bii – top graph). The 
rise times in the other regions overlapped suggesting no consistent difference 
between the regions. This was also true for APD80 in both groups. Despite this, the 
mean APD80 (line) for the remote region 3, the most comparable region to the 
injection site, was shorter than that of the injection site in both RACF and AdeGFP 
groups (Figure 6-10Bi and ii –bottom graphs). 
  
204 
 
 
Figure 6-7 Effective refractory period of hearts injected with eGFP positive RACFs or AdeGFP. 
Hearts were paced at 200 ms prior to an extrastimulus impulse (S2) at increasingly shorter cycle 
lengths until an action potential did not fire, taken as the effective refractory period (ERP).  Each 
point represents a different heart and line denotes average.  
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Figure 6-8 Selection areas for eGFP positive RACF and AdeGFP injected hearts for S1S2 
pacing protocol. 
Four and three hearts were included in S1S2 analysis for eGFP positive RACF and AdeGFP injected 
hearts respectively. Black arrow indicates where the pacing electrode was and therefore pixels had 
to be removed from the selection. Selection areas are numbered 1-5 where, 1 = full field, 2 = injection 
site, 2.5 = smaller area in injection site, 3 = apical remote region, 4 = basal remote region, 5 = remote 
region 3.   
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Figure 6-9 Comparison of S2 action potential rise time and duration between the original 
injection selection and the smaller injection selection. 
Hearts were perfused with the voltage sensitive dye, RH-237, to allow electrical activity to be 
recorded. Hearts were paced at a cycle length of 200 ms prior to an extrastimulus (S2) at 
progressively shorter cycle lengths. (A) Average 10-90 % rise time and (B) action potential duration 
at 80 % repolarisation (APD80) from the injection site and a smaller region within the site following 
S2 in two AdeGFP injected hearts. Each point represents a different heart and the line denotes the 
average.  
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Figure 6-10 Relationship between the S2 action potential rise time and duration at different 
in cycle lengths in RACF and AdeGFP injected hearts. 
Hearts were perfused with the voltage sensitive dye, RH-237, to allow electrical activity to be 
recorded. (A) Hearts were paced at a cycle length of 200 ms prior to an extrastimulus (S2) at  
progressively shorter cycle lengths. An exemplar ECG trace and action potential (AP) traces within 
the injection site (red), apical remote region (blue), basal remote region (green) and remote region 3 
(pink) where the S1-S2 interval was 90 ms (black arrow). (Ai) RACF and (ii) AdeGFP injected hearts 
respectively. (B) Graphs showing the 10-90 % rise time and AP duration at 80 % repolarisation 
(APD80) of the S2 in (i) RACF and (ii) AdeGFP injected hearts. Each point represents a different heart 
and the line denotes the average.   
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To compare the characteristics of the S2 APs within the injection sites of each 
group, the rise time or APD80 over different CLs were plotted on the same graph 
(Figure 6-11). The injection site rise time was similar between the two groups, 
shown by overlapping  points and mean lines (Figure 6-11A). Although there was 
only 1 heart value at a CL of 70, 80, 160 and 180 ms in the AdeGFP group, APD80 
values following the S2 impulse within the range of 90-140 ms (where values from 
2-3 hearts are shown) were very similar (Figure 6-11B). In comparison, the RACF 
group had greater variation in APD80 values (Figure 6-11B). 
Interestingly, preliminary examination of the activation pattern demonstrated 
that in one heart from each group, the S2 impulse was slowed and activation was 
disrupted at the injection site (Figure 6-12). In both hearts this was most apparent 
at the shortest S1-S2 interval, therefore a common CL of 70 ms is presented. In 
the RACF injected heart activation following S1 was complete by 20 ms with the 
contour lines being relatively parallel from the site of activation over the 
epicardial surface. Additionally, no disruption was caused by the injection of cells. 
However following the S2 impulse there was slight activation slowing prior to the 
activation of the injection site and crowding of activation downstream of the 
injection site. This slowing of activation was more pronounced in the AdeGFP 
injected heart. Following the S1 impulse, the selected region was activated within 
12 ms. In contrast following the S2 impulse, full activation was complete in 20 ms, 
with the longest activation time occurring just downstream of the injection site. 
This may represent damage to the myocardium due to appearance of this in both 
groups. All other hearts examined did not present this pattern.  
  
209 
 
 
Figure 6-11 The S2 action potential rise time and duration in the injection site of RACF and 
AdeGFP injected hearts at different cycle lengths. 
Hearts were perfused with the voltage sensitive dye, RH237, to allow electrical activity to be 
recorded. Hearts were paced at a cycle length of 200 ms prior to an extrastimulus (S2) at 
progressively shorter cycle lengths. (A) 10-90 % rise time and (B) action potential duration at 80 % 
repolarisation (APD80) of APs in the injection site of both RACF and AdeGFP injected hearts. Each 
point represents a different heart (n=4 and n=3 for RACF and AdeGFP injected hearts respectively) 
and the line denotes the average. From cycle lengths of 90-140 ms, values from 2-3 AdeGFP hearts 
are shown, whereas only 1 heart value is shown in cycle lengths out with this range.  
 
Figure 6-12 Example AdeGFP and RACF injected hearts showing crowding of activation over 
the epicardial surface during an S2 impulse. 
Normal activation from the base to apex of the heart during S1 at a CL of 200 ms is observed  in both 
hearts. In RACF injected heart, the two upper contour plots, crowding of activation is seen at the 
injection site following S2 (CL = 70 ms). In the AdeGFP heart the (two lower images) activation much 
slower during S2 with distinct crowding of activation at the injection site. Injection sites are outlined 
in black. Red stars approximately indicate the origin of activation. Scale ranging from 0 – 20 ms is 
shown on the right. CL; cycle length.  
BA
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6.3.4 Preliminary detection of eGFP positive cells within the rat 
myocardium 
Following OM, all hearts were cut transversely into four segments and the section 
containing the injection site noted. Hearts were then fixed in 4 % PFA prior to 
tissue processing and embedded in paraffin wax. Preliminary staining of eGFP and 
the CM marker, cTnI, was completed on a heart injected with RACF which was cut 
longitudinally and not used for OM. eGFP positive cells which were negative for 
cTnI were detected in the left ventricular myocardium (Figure 6-13). Many other 
cells within that region were not eGFP or cTnI positive, suggesting the recruitment 
of other cell types to the area of injection; potentially inflammatory cells (Figure 
6-13). However to confirm this, further staining of inflammatory cell markers are 
required.  
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Figure 6-13 Preliminary immunofluorescence to identify eGFP positive RACFs within the rat left ventricular myocardium. 
 (A) A heart injected with eGFP positive RACFs was stained for DAPI (blue), eGFP (green) and cardiac troponin I (cTnI) (red). (B) Merged images of same heart at 
different section (n=1). All images were normalised to the appropriate IgG controls (exemplar IgG merge shown in A). Images shown in A and Bi where taken at x25 
magnification and the image in Bii taken at the higher magnification of x63. Scale bars represent 100 µm.  
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6.4 Discussion 
This study has successfully demonstrated that eGFP positive primary RACFs and 
AdeGFP-transduced CMs can be detected within the rat left ventricular 
myocardium, 7 days following injection. As this is a preliminary study, with only a 
small number of hearts, the effect on AP rise time and duration in the injection 
sites is far from confirmed. However, there may be a trend for slight prolongation 
of APD80 following the S2 impulse within the injection site in comparison to remote 
region 3 in both groups. Additionally, activation of one heart in each group was 
altered around the injection site at the shortest S1-S2 intervals. Larger group sizes 
along with more detailed histological analysis are required. 
Most studies suggest that injected fibroblasts are retained in the healthy 
myocardium or myocardial scar for at least 7 days following injection (Etzion et 
al. 2002;Yankelson et al. 2008). This is in agreement with the current study 
whereby a positive eGFP signal was detected ex vivo and eGFP positive cells 
observed in situ via IHC. However, on histological analysis of one heart which was 
injected with RACFs there was a large influx of eGFP negative cells, most likely to 
be of an inflammatory nature. Similarly, in rat hearts 7 days following injection 
of pre-labelled NIH-3T3 fibroblasts, there was an abundance of unlabelled cells in 
the region of injection (Yankelson et al. 2008). To confirm the presence of 
inflammatory cells, tissue sections could be stained for inflammatory cell markers 
such as CD68 and lymphocyte antigen (Ly) 6B.2 for macrophages and neutrophils, 
respectively (Peng et al. 2014). This inflammatory response is likely to be 
exacerbated by the use of non-autologous cells and could be dampened by 
immunosuppressant treatment, which has been used in other studies (Roell et al. 
2007;Yankelson et al. 2008). Although IHC was not performed on an AdeGFP 
injected heart for detection of eGFP expression in the current study, studies have 
reported a large inflammatory response following direct intramyocardial injection 
of Ad vectors (Huusko et al. 2010;Merentie et al. 2016;Toivonen et al. 2012).  
No consistent alteration in AP rise time or APD80 in the injection site versus the 
apical or basal region during dynamic pacing was detected. However, in 
comparison to remote region 3 utilised in S1S2 analysis there was a slight 
prolongation of APD80 in both RACF and AdeGFP injected areas. As this was 
detected in both groups, the prolongation is unlikely to be a consequence of 
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coupling between injected RACF and host CMs in the RACF injected hearts. It most 
likely reflects damage to the myocardium during injection and therefore 
examination of fibrosis is required. Despite this, immunostaining for Cx43 would 
allow examination of Cx43 expression at contact areas between eGFP positive 
RACFs and host CMs. Indeed, Yankelson et al. (2008) reported an increase in Cx43 
expression in grafted NIH-3T3 fibroblasts close to CMs and observed Cx43 
expression at heterocellular contact points (Yankelson et al. 2008).  
The S1S2 pacing protocol is a valuable tool for determining the arrhythmic 
potential of the heart as well as determining the ERP. In the present study, no 
inductions of arrhythmias were caused by the premature stimulus. Additionally, 
there was no difference in the ERP between RACF and AdeGFP injected hearts, or 
between the examined regions. In contrast, the ERP was slightly but significantly 
increased in vivo in the injection site 7 days following intramyocardial injection 
of WT NIH-3T3 fibroblasts in comparison to baseline (before cell injection) 
(Yankelson et al. 2008). Unfortunately an ERP for a remote region 7 days after 
injection was not reported for WT fibroblast injected hearts. Conversely as 
described in section 6.1.1, injection of Kv1.3 overexpressing NIH-3T3 fibroblasts 
produced a very large increase in ERP in the injection site in comparison to the 
remote region where there was no change from baseline (Yankelson et al. 2008). 
Throughout this study, hearts were paced from injection site which was identified 
by discolouration on the epicardial surface or in some cases by the detection of 
fluorescence from pre-labelled cells or following co-injection with a fluorescent 
tracer (Yankelson et al. 2008). This adaptation, pacing from the injection site, to 
future hearts in the current study would allow local ERP to be evaluated more 
precisely. In the present study, we directly measured APs over the epicardial 
surface, whereas Yankelson et al. (2008) used an indirect method by examination 
of electrograms.  
Although conduction block was not identified in any of the hearts examined, 
altered propagation of the premature stimulus, S2, was identified in one heart 
from each group. Typically, S2 propagates more slowly than S1 in both intact heart 
preparations and in neonatal CM monolayers (de et al. 2011;Stein et al. 2011). 
This was also observed in the current study in the two hearts shown in Figure 6-12. 
Crowding of activation close to or surrounding the injection site was also found in 
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both hearts. However, both the slowing and crowding of activation following S2 
was more pronounced in the AdeGFP injected heart, which could be a 
consequence of greater tissue damage in this heart, requiring further 
investigation. Following the addition of further heart numbers to each group, CV 
through the injection site would be an interesting parameter to examine.  
Limitations/issues to the current study include an absence of calcium 
measurement which is an important physiological measurement and lack of 
standardised pacing region, which was a result of electrode issues. Although, APD 
is typically greater closer to the activation site and shortens further from the 
activation site (Franz et al. 1987;Hanson et al. 2009;Yuan et al. 2001), this cannot 
be examined from the merged data in the current study due to differential pacing 
regions selected between hearts. While this not ideal, it may explain the variation 
between hearts. 
6.5 Summary 
Although this work is not complete, preliminary results show that RACFs are 
retained in the rat left ventricular myocardium for at least 7 days following 
implantation, which is in agreement with other reports (Etzion et al. 
2002;Yankelson et al. 2008). Furthermore, due to fluorescent labelling of cells 
prior to injection, APs from the injection site could be compared to other regions 
of the heart. Further hearts in each group and histological analysis post OM to 
determine the damage caused by injection, the inflammatory response and the 
coupling of injected RACF to host CMs is required to complete this study.  
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Chapter 7 General discussion 
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7.1 Overall summary 
CFs are a vital cell type in cardiac repair however persistent activation can result 
in maladaptive remodelling (Souders et al. 2009). Thus far, there have been a vast 
number of studies investigating CM: CF interactions in neonatal cell types with 
limited research on the effects of adult CFs on the function of adult CMs. 
Therefore, the primary aims of the work presented in this thesis were to establish 
the effects of RACFs on adult CM contraction and electrical activity in vitro, as 
well as to develop a model where potential heterocellular coupling could be 
evaluated in situ.  
Initially, the development of a LV vector which would enable the expression of 
Cx43 as well as a nuclear localised reporter protein under the control of an 
artificial αSMA promoter was investigated. Despite the apparent functionality of 
the designed insert (αSMA_eGFPNLS) shown by eGFP positive nuclei in RACFs 
following transfection, initial cloning into an LV plasmid vector was unsuccessful. 
This could be due to contaminating DNA interfering with the ligation process or an 
issue with the promoter as supported by successful ligation of eGFPNLS into an Ad 
plasmid, pVQ_CMV_K-NpA. Alternatively, a functional Ad vector overexpressing 
Cx43 was produced then characterised in HeLa cells and RACFs by western 
immunoblotting and ICC. 
As CFs have been reported to have a greater expression of Cx43 following MI 
(Vasquez et al. 2010;Zhang et al. 2010), potential mediators responsible for this 
were investigated. TGFβ1, IL-6 in combination with the sIL-6R, IL-1α and IL-1β 
were all shown to significantly enhance Cx43 mRNA levels. The latter two 
cytokines were found to induce the greatest augmentation in Cx43 levels and were 
therefore of particular interest in the current study, due to potentially greater 
ability to form GJs with CMs. IL-1α and IL-1β appear to have indistinguishable 
actions (Bujak and Frangogiannis 2009) therefore only IL-1β was investigated 
further. In the current study, IL-1β was shown to induce a morphological change 
in RACFs as well as an augmentation in Cx43 protein levels, which is in agreement 
with other reports in primary and cell-line rabbit synovial fibroblasts (Heino 
1986;Niger et al. 2010). Interestingly, this increase in Cx43 by IL-1β is the opposite 
of that seen in CMs (Baum et al. 2012a;Coppen et al. 2008), indicating differential 
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effects of IL-1β on Cx43 expression in different cell types. Further investigation 
into the IL-1 signalling pathway revealed the involvement of the IL-1R, NF-κB, p38 
MAPK and MEK1 in IL-1β-mediated increases in Cx43, all of which have been 
previously reported to be activated by IL-1β stimulation (Baum et al. 2012a;Niger 
et al. 2010;Weber et al. 2010;Yang et al. 2000). Additionally, JNK inhibition, also 
known to be activated by IL-1β (Niger et al. 2010), was found to enhance 
IL-1β-induced Cx43 up-regulation, suggesting JNK acts to inhibit IL-1β-mediated 
increases in Cx43. Moreover, the investigation into miRNAs either predicted (by 
target scan) or verified to target Cx43 (Danielson et al. 2013;Jin et al. 2013) as 
well as miRNAs known to be regulated by proinflammatory cytokines (Georgantas 
et al. 2014;Wang et al. 2014b), revealed no role for miR-1, -19b, -30c, -101, -125b 
or -133a in IL-1β-induced upregulation of Cx43.  
Furthermore, as IL-1β has been reported to inhibit TGFβ1-mediated fibroblast to 
MF differentiation (Bronnum et al. 2013;Mia et al. 2014;Saxena et al. 2013), the 
effects of IL-1β alone or in combination with TGFβ1 stimulation on the mRNA levels 
of known TGFβ1-regulated genes was investigated. Indeed, IL-1β was found to 
significantly reduce the expression of the MF markers, CTGF and αSMA, as well as 
significantly inhibit the TGFβ1-mediated increase in CTGF and trend for αSMA 
upregulation. This suggests that IL-1β-treated RACFs are less MF-like than control 
RACFs, and therefore important to consider in the co-culture model.   
To investigate the effects of control and IL-1β-treated adult RACFs on adult CM 
function, a CM: CF co-culture model was established. In this model, evidence for 
functional GJs between adult CM and CF was provided by calcein dye transfer, in 
agreement with other reports (Chilton et al. 2007;Driesen et al. 2005). 
Furthermore, CMs cultured for 24 h maintained contractile and electrical activity 
in response to stimulus, although there appeared to be a trend for prolongation 
of the APD80 in comparison to freshly isolated cells. Similarly this trend was 
reported in swine CMs following 24 h in culture, which reached significance at 72 h 
(Louch et al. 2004), supporting culture-mediated alterations in the electrical 
activity of CMs. Interestingly, the CD of cultured CMs was significantly reduced in 
the presence of a RACF monolayer. Despite this, RACFs induced a trend for APD80 
prolongation in comparison to CMs in culture alone. Furthermore, RACFs treated 
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with IL-1β which had previously been shown to have enhanced Cx43 levels as well 
as reduced mRNA levels of the MF markers, αSMA and CTGF, partly restored the 
effects of RACFs on CD. Together these results indicate that CFs can modify the 
function of CMs, however further studies are required to identity mechanisms 
involved.  
Next, a model to assess CM: CF interactions in situ was developed where RACFs 
transduced with LVeGFP were injected into the wall of the left ventricle. Injected 
cells were found to be retained in the myocardium 7 days following injection as 
detected by eGFP fluorescence on the surface of the intact heart and in IHC using 
an anti-eGFP antibody. Additionally, an AdeGFP was injected so that the area of 
injection could be clearly identified, following AdeGFP transduction of CMs in situ. 
APs were successfully recorded over the epicardial surface and areas of the 
myocardium injected with RACFs transduced with LVeGFP, or following direct 
gene delivery of AdeGFP, compared to other regions of the heart. Preliminary 
evidence for prolongation of APD80 following the S2 impulse in the injection sites 
in comparison to a site which was activated at approximately equivalent time and 
of identical shape (remote region 3) was detected. Additionally, in two hearts, 
one from each group, a change in the activation pattern following S2 impulse was 
observed close to the injection sites. However, as this prolongation and alteration 
in the pattern of activation was detected in both groups; it may reflect damage 
to the myocardium during injection.  
7.2 Future perspectives  
The co-culture model utilised within this thesis allows many interactions between 
the cells to occur, including those of a paracrine, mechanical and electrical 
nature, due to media sharing and direct contact allowing the formation of 
mechanical and GJs. Therefore, it is challenging to interpret what is responsible 
for the results observed, hence further studies are required to dissect potential 
mechanisms. To investigate paracrine interactions, the media from co-culture 
could be compared to that of cultured CMs or CFs by preforming cytometric bead 
array using flow cytometry (O'Carroll et al. 2015). This would allow up to 30 
different cytokines/growth factors to be evaluated simultaneously to identify 
potential candidates to investigate further. The transwell set up used by Cartledge 
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et al. (2015) revealed a bidirectional TGFβ interaction between adult CMs and CFs 
promoting a faster decay of the CM Ca2+ transient (Cartledge et al. 2015). This 
could therefore explain the current results of reduced CD in the presence of CFs 
due to the role of Ca2+ in CM contraction (Bers 2002), hence the levels of TGFβ 
should be evaluated.  
As IL-1β levels are enhanced in cardiac disease, the IL-1β-treated RACFs 
investigated in the current study could be thought to represent a population of 
CFs within the heart in pathophysiological settings. IL-1β may act to suppress CF 
activation allowing the inflammatory stage to occur prior to the profibrotic phase 
of cardiac repair (Saxena et al. 2013). Furthermore, control untreated RACFs are 
likely to be more MF-like than IL-1β treated RACFs, which is interesting due to 
their greater effect observed on CM function in comparison to IL-1β-treated RACF. 
Therefore, the role of the RACF phenotype could be further investigated in the 
CM co-culture model by treatment of RACFs with TGFβ1, a major driver of the MF 
phenotype (Bronnum et al. 2013;Mia et al. 2014;Saxena et al. 2013). Indeed, 
recently TGFβ1 has been shown to enhance the proarrhythmic nature of CFs on 
CMs in a neonatal cell culture model, by causing depolarisation of the RMP of CMs 
and promoting increased ectopic activity (Salvarani et al. 2017). These effects in 
neonatal preparations were attributed to direct heterocellular coupling (Salvarani 
et al. 2017). These observations, together with the results of the current study, 
support the rational that a greater MF phenotype has an enhanced influence on 
CM function.  
Although IL-1β promoted an increase in Cx43 expression at the cell surface, the 
ability of Cx43 to enhance GJIC either within RACF monolayers or between CMs 
and RACFs requires examination. GJ coupling in monolayers of RACFs could be 
assessed by scrape-loading RACFs with Lucifer yellow, a dye able to pass through 
functional GJs, and examining the distance travelled over a set time (Louault et 
al. 2008;Tarzemany et al. 2015). A pilot study to establish this assay in RACFs 
demonstrated issues with Lucifer yellow uptake/detection therefore requires 
further optimisation to investigate GJ coupling in these cells. Furthermore, 
calcein dye transfer (as investigated in this thesis) could be performed following 
IL-1β stimulation of RACFs. Additionally, RACFs could be transduced with the 
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AdCx43 produced in the current study to directly assess the effects of enhanced 
Cx43 expression in RACFs in comparison to control cells and cells transduced with 
a control Ad vector.  
The electrophysiological influence of CFs on CMs may also depend on the 
expression of different ion channels/pumps (Chilton et al. 2005;Li et al. 
2009;Salvarani et al. 2017). Interestingly, neonatal CFs treated with TGFβ1, which 
induced a depolarising effect on neonatal CMs, were shown to differ in ion 
channels/pumps and connexin transcripts in comparison to CFs treated with the 
TGFβR1 inhibitor (Salvarani et al. 2017). Amongst these transcripts, the expression 
of many K+ channel/subunits where up or down regulated as well as an increase 
in the sodium leak channel, which had previously not been reported to be present 
in CFs (Salvarani et al. 2017). This channel has been found to promote 
depolarisation of neurons therefore may contribute to TGFβ1-mediated CF 
depolarisation (Lu et al. 2007). Similarly, the RNA sequencing used in the previous 
mentioned study could be another interesting aspect to examine in control and 
IL-1β-treated cultures. Furthermore, measurement of Ca2+ transients in CMs would 
be beneficial to potentially explain the effect on CD of control and IL-1β treated 
RACFs, due to the well-established role of Ca2+ in contraction (Bers 2002).  
Restriction of contraction by mechanical pull of CMs by RACFs is another potential 
cause for the differential effects of control RACFs and IL-1β treated RACFs on CD 
due to reduced expression of the contractile protein, αSMA by IL-1β. However, it 
must be noted that only mRNA levels of αSMA were examined in the current study 
and others have reported no change in the protein level following 48 h stimulation 
with IL-1β, despite reduced levels of mRNA (Bronnum et al. 2013). Therefore, 
αSMA protein in the current study requires evaluation to support this hypothesis. 
Additionally, the role of αSMA in RACFs on CM CD effects could be examined with 
the use of actin targeting drugs (ATDs) such as Latrunculin B, Cytochalasin D or 
Jasplakinolide. These ATDs have previously been shown to successfully disrupt 
αSMA fibers in neonatal CFs but have no obvious effects on neonatal CMs (Rosker 
et al. 2011). Additionally, these drugs were shown to reduce the slowing of CV, 
ectopic activity and the depolarising effect of CFs in this neonatal model (Rosker 
et al. 2011). Therefore, this suggests that αSMA expression in CFs has a role in 
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electrophysiological effects on CMs; hence examination of the effect of ATDs on 
the trend for APD80 prolongation would also be interesting.  
This study has utilised CMs from healthy hearts, therefore it would be interesting 
to examine if RACFs can potentiate already dysfunctional CMs from diseased 
hearts (Li et al. 2004;Loennechen et al. 2002). Similarly, CFs from diseased hearts 
could be examined in co-culture, although caution is required due to reports that 
cells begin to lose their pathogenic phenotype in culture (Dawson et al. 2012). 
The effect of culture on the phenotype of RACFs is also a limitation to the current 
study. Additionally, rodent CMs differ to human cells, with respect to Ca2+ handling 
and AP shape. For instance, SERCA contribution to Ca2+ removal from the cytosol 
has been reported to be 90-92 % in rodent CMs (Bassani et al. 1994;Li et al. 1998) 
and 77 % in human CMs (Piacentino et al. 2003). Furthermore, there is little to no 
AP plateau in rodent CMs versus a defined plateau in human CMs (Li et al. 
2004;Varro et al. 1993). Therefore cells from a more comparable species such as 
rabbit or guinea-pig could be used as an alternative (Bers 2002;Varro et al. 1993).  
The extent of damage caused by direct intramyocardial injection could be 
assessed by picrosirius red staining of the collagen network (Xia et al. 2009), 
determination of the levels of apoptosis/necrosis of CMs and assessment of the 
degree of inflammatory response produced. Due to the difficultly of injecting a 
fast paced rat heart, any damage may be unavoidable and reflect baseline effects 
of surgery demonstrating the importance of the AdeGFP control. Ideally this 
control would be injection of the equivalent volume of PBS; however this would 
make identification of the injected site using OM challenging. Further analysis 
could involve examination of CV across the area of injection as well as alternans; 
parameters which can be assessed within the OPTIQ software utilised in the 
current study.   
The use of two-photon microscopy would give more detailed information on the 
effects, if any, of CM: CF coupling in situ and should be considered for future 
studies. Two-photon microscopy relies on two low energy long wavelength photons 
being absorbed simultaneously resulting in excitation of the fluorophore (Rubart 
2004). As two photons meet at a single plane within the tissue and are both 
required to produce fluorescence, no out of focus signal is produced (Rubart 
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2004). Ultimately this allows single cells deep within the intact heart to be 
monitored for functional parameters such as APs or Ca2+ transients (Ghouri et al. 
2015). This technique has previously been used following direct cell injection of 
eGFP labelled foetal CMs or SMs (Rubart et al. 2003;Rubart et al. 2004). Here, Ca2+ 
transients of donor and adjacent host CMs were assessed to determine the levels 
of coupling (Rubart et al. 2003;Rubart et al. 2004), therefore is ideal preparation 
for the current study. 
Although thus far, no differences have been identified between RACF and AdeGFP 
injected hearts, further studies could evaluate the effects of implantation of 
RACFs with different phenotypes. For instance, implantation of RACFs dual 
transduced with AdCx43 and LVeGFP would allow the direct effects of enhanced 
Cx43 levels in CFs, seen post-MI (Vasquez et al. 2010;Zhang et al. 2010), to be 
examined. Interestingly, it has been reported that injection of SMs overexpressing 
Cx43 into the scar of mice is anti-arrhythmic by reducing the vulnerability of the 
scar (Roell et al. 2007). However, taking into account the proarrhythmic effects 
of Cx43 expression in CFs in vitro, injection of CFs may produce differential effects 
and remains to be examined. Additionally, implantation of RACFs treated with 
different individual cytokines, potentially IL-1β or TGFβ1, would be interesting to 
examine. However, the phenotypes these treated RACFs in vivo may not be 
sustained over 7 days, therefore earlier time points may have to be examined.  
7.3 Conclusions 
In summary, the data from this thesis has provided further evidence for the ability 
of CFs to alter the function of CMs. Additionally, for the first time, the treatment 
of RACFs with IL-1β was shown to partially restore the effects of RACFs on CD. 
Furthermore, a technically challenging model that will be valuable in the future 
investigation of CM: CF heterocellular coupling in situ has been established.  
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Appendix 
 
Appendix figure 1 Immunoblots which constitute densitometry in figure 4-7. 
 
 
 
 
Appendix figure 2 Immunoblots which constitute densitometry in figure 4-9. 
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